0001213900-20-026881.txt : 20200916 0001213900-20-026881.hdr.sgml : 20200916 20200916125736 ACCESSION NUMBER: 0001213900-20-026881 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200916 DATE AS OF CHANGE: 20200916 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRAIN SCIENTIFIC INC. CENTRAL INDEX KEY: 0001662382 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 810876714 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 333-209325 FILM NUMBER: 201177988 BUSINESS ADDRESS: STREET 1: 125 WILBUR PLACE, SUITE 170 CITY: BOHEMIA STATE: NY ZIP: 11716 BUSINESS PHONE: (646) 388-3788 MAIL ADDRESS: STREET 1: 125 WILBUR PLACE, SUITE 170 CITY: BOHEMIA STATE: NY ZIP: 11716 FORMER COMPANY: FORMER CONFORMED NAME: All Soft Gels Inc DATE OF NAME CHANGE: 20151229 10-Q/A 1 f10q0320a1_brainscien.htm AMENDMENT NO. 1 TO FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

Amendment No. 1

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from _____ to _____

Commission file number: 333-209325

BRAIN SCIENTIFIC INC.

(Name of Registrant in Its Charter)

Nevada		81-0876714
State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

125 Wilbur Place, Suite 170

Bohemia, NY 11716

(Address of principal executive offices)

(917) 388-1578
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit). Yes ☒ No ☐

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act).

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 19,383,794 shares of Common Stock, $0.001 par value, at May 18, 2020.

EXPLANATORY NOTE

As disclosed in Item 4.02 of Brain Scientific Inc.’s (the “Company”) current report on Form 8-K filed with the U.S Securities and Exchange Commission (“SEC”) on August 18, 2020, on August 12, 2020 the Company, under the authority of its board of directors, following discussion with Sadler, Gibb & Associates, LLC, the Company’s independent registered public accounting firm, concluded that the Company’s previously filed financial statements for the three months ended March 31, 2020, can no longer be relied upon.

The Company is filing this Amendment No. 1 (“Form 10-Q/A”) to the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, which was filed with the SEC on May 19, 2020 (the “Original Filing”), to reflect restatements of the Consolidated Balance Sheet at March 31, 2020, the Consolidated Statement of Operations, Consolidated Statement of Changes in Shareholders’ Equity (Deficit), and Consolidated Statement of Cash Flows for the three months ended March 31, 2020, and the related notes thereto.

The following sections in the Original Filing are amended and restated in this Form 10-Q/A, solely as a result of, and to reflect, the restatement:

Part I - Item 1 - Financial Statements

Part I - Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations

In addition, pursuant to the rules of the SEC, Part II, Item 6 of the Original Filing has been amended to include the currently-dated certifications from our principal executive officer and principal financial officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. The certifications of the principal executive officer and principal financial officer are included in this Form 10-Q/A as Exhibits 31.1, 31.2, 32.1 and 32.2.

For the convenience of the reader, this Form 10-Q/A sets forth the information in the Original Filing in its entirety, as such information is modified and superseded where necessary to reflect the restatement. This Form 10-Q/A should be read in conjunction with our filings with the SEC subsequent to the date of the Original Filing, in each case as those filings may have been, or with respect to the Original Filing will be, superseded or amended.

Except as described above, no other changes have been made to the Original Filing. This Form 10-Q/A speaks as of the date of the Original Filing and does not reflect events that may have occurred after the date of the Original Filing, or modify or update any disclosures that may have been affected by subsequent events.

BRAIN SCIENTIFIC INC.

Index

Part I – Financial Information

Item 1 – Financial Statements	1
Condensed Consolidated Balance Sheets as of March 31, 2020 (restated) (unaudited) and December 31, 2019	1
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2020 (restated) and 2019 (unaudited)	2
Condensed Consolidated Statements of Stockholders’ Deficit for the Three Months Ended as of March 31, 2020 (restated) and March 31, 2019 (unaudited)	3
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 (restated) and 2019 (unaudited)	4
Notes to Unaudited Condensed Consolidated Financial Statements	5
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3 – Quantitative and Qualitative Disclosures About Market Risk	25
Item 4 – Controls and Procedures	25

Part II – Other Information

Item 1 – Legal Proceedings	26
Item 1A- Risk Factors	26
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 3 – Defaults Upon Senior Securities	26
Item 4 – Mine Safety Disclosures	26
Item 5 – Other Information	26
Item 6 – Exhibits	27

Signatures	28

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Brain Scientific Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2020			December 31, 2019
	(Restated)
	(Unaudited)

ASSETS
CURRENT ASSETS:
Cash	$	27,947		$	261,436
Accounts receivable		6,706			5,555
Inventory		371			-
Prepaid expenses and other current assets		10,329			21,637
Prepaid expenses and other current assets - related party		700			700
TOTAL CURRENT ASSETS		46,053			289,328

Property and equipment, net		1,333			1,674

TOTAL ASSETS	$	47,386		$	291,002

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	495,091		$	298,578
Accounts payable and accrued expenses - related party		8,737			9,263
Notes payable		70,000			50,000
Convertible notes payable, net		406,482			499,232
Derivative liabilities		571,843			-
Finance lease - short term		4,595			6,377
Loans payable - related party		322,967			323,084
TOTAL CURRENT LIABILITIES:		1,879,715			1,186,534

TOTAL LIABILITIES		1,879,715			1,186,534

Commitments and contingencies		-			-

STOCKHOLDERS’ DEFICIT

Preferred stock, $0.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively		-			-
Common stock, $0.001 par value; 200,000,000 shares authorized, 19,383,794 and 19,380,460 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively		19,384			19,381
Additional paid in capital		2,772,711			2,756,798
Accumulated deficit		(4,623,737	)		(3,672,077	)
Accumulated other comprehensive income		(687	)		366
TOTAL STOCKHOLDERS’ DEFICIT		(1,832,329	)		(895,532	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	47,386		$	291,002

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Brain Scientific Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

	Three Months Ended March 31,
	2020			2019
	(Restated)

REVENUE	$	133,845		$	2,250

COST OF GOODS SOLD		104,982			-

GROSS PROFIT		28,863			2,250

SELLING, GENERAL AND ADMINISTRATIVE
Research and development		96,390			22,290
Professional fees		123,608			111,073
Sales and marketing expenses		40,584			47,792
Occupancy expenses		11,638			22,060
General and administrative expenses		208,635			201,241
TOTAL SELLING, GENERAL AND ADMINISTRATIVE		480,855			404,456

LOSS FROM OPERATIONS		(451,992	)		(402,206	)

OTHER INCOME (EXPENSE):
Interest expense		(453,616	)		(8,053	)
Other income		1,290			-
Change in fair market value of derivative liabilities		(47,219	)		-
Foreign currency transaction loss		(123	)		-
TOTAL OTHER EXPENSE		(499,668	)		(8,053	)

LOSS BEFORE INCOME TAXES		(951,660	)		(410,259	)

PROVISION FOR INCOME TAXES		-			-

NET LOSS		(951,660	)		(410,259	)

OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustment		(1,053	)		-
TOTAL COMPREHENSIVE LOSS	$	(952,713	)	$	(410,259	)

NET LOSS PER COMMON SHARE
Basic and diluted	$	(0.05	)	$	(0.02	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic and diluted		19,380,460			19,205,624

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Brain Scientific Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

										Accumulated
					Additional					Other
	Common Stock				Paid-in		Accumulated			Comprehensive
	Shares		Amount		Capital		Deficit			Income			Total

Balance at December 31, 2019		19,380,460	$	19,381	$	2,756,798	$	(3,672,077	)	$	366		$	(895,532	)
Fair value of stock options vested		-		-		5,914		-			-			5,914
Issuance of common stock for services		3,334		3		9,999		-			-			10,002
Foreign currency translation adjustment		-		-		-		-			(1,053	)		(1,053	)
Net loss		-		-		-		(951,660	)					(951,660	)
Balances at March 31, 2020		19,383,794	$	19,384	$	2,772,711	$	(4,623,737	)	$	(687	)	$	(1,832,329	)

										Accumulated
					Additional					Other
	Common Stock				Paid-in		Accumulated			Comprehensive
	Shares		Amount		Capital		Deficit			Income		Total

Balance at December 31, 2018		19,205,624	$	19,206	$	2,595,034	$	(2,668,212	)	$	-	$	(53,972	)
Fair value of stock options vested		-		-		4,334		-			-		4,334
Issuance of common stock for services		13,334		13		548		-			-		561
Net loss		-		-		-		(410,259	)				(410,259	)
Balances at March 31, 2019		19,218,958	$	19,219	$	2,599,916	$	(3,078,471	)	$	-	$	(459,336	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Brain Scientific Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended March 31,
	2020			2019
	(Restated)

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(951,660	)	$	(410,259	)
Change in net loss to net cash used in operating activities:
Depreciation and amortization expense		341			299
Amortization of debt discount and non-cash interest expense		431,874			3,117
Change in fair value of derivative liabilities		47,219			-
Fair value of stock options vested		5,914			4,334
Common stock issued for services		10,002			561
Changes in operating assets and liabilities:
Accounts receivable		(1,151	)		-
Inventory		(371	)		-
Other liabilities		(1,782	)		(1,411	)
Prepaid expenses and other current assets		11,308			(5,707	)
Accounts payable and accrued expenses		196,513			17,163
Accounts payable - related party		(526	)		(31,900	)
NET CASH USED IN OPERATING ACTIVITIES	$	(252,319	)	$	(423,803	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	$	-		$	(1,005	)
NET CASH USED IN INVESTING ACTIVITIES	$	-		$	(1,005	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable	$	-		$	230,000
Proceeds from note payable		20,000			-
Proceeds from related party loans		-			75,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	$	20,000		$	305,000

Effect of exchange rate changes on cash		(1,170	)		-

NET CHANGE IN CASH		(233,489	)		(119,808	)
CASH AT BEGINNING OF THE PERIOD		261,436			163,563
CASH AT END OF THE PERIOD	$	27,947		$	43,755

Supplemental Disclosure of Cash Flow Information

Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

Supplemental Disclosure of Non-Cash Investing and Financing Activities

Financing fees payable to a related party related to the issuance of convertible debentures	$	-		$	18,400
Debt discount and derivative liability associated with convertible notes payable	$	176,274		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS

Brain Scientific Inc. (the “Company”), was incorporated under the laws of the state of Nevada on November 18, 2013 under the name All Soft Gels Inc. The Company on September 21, 2018 acquired MemoryMD, Inc. (“MemoryMD”), a privately held Delaware corporation formed in February 2015. Upon completion of the acquisition, MemoryMD is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of MemoryMD, the surviving entity and accounting acquirer. MemoryMD is a cloud computing, data analytics and medical device technology company in the NeuroTech and brain monitoring industries seeking to commercialize its EEG devices and caps. The Company is headquartered in New York, New York.

Reverse Merger and Corporate Restructure

On September 21, 2018, the Company entered into a merger agreement (the “Merger Agreement”) with MemoryMD and AFGG Acquisition Corp. to acquire MemoryMD (the “Acquisition”). The transactions contemplated by the Merger Agreement were consummated on September 21, 2018 and, pursuant to the terms of the Merger Agreement, all outstanding shares of MemoryMD were exchanged for shares of the Company’s common stock. Accordingly, the Company acquired 100% of MemoryMD in exchange for the issuance of shares of the Company’s common stock and MemoryMD became the Company’s wholly owned subsidiary. The Company issued an additional 4,083,252 shares of its common stock upon the automatic conversion at the closing of an aggregate of $1,507,000 principal amount plus accrued interest of outstanding convertible promissory notes issued by MemoryMD, and it further issued an additional 1,604,378 shares of its common stock upon the automatic conversion immediately subsequent to the closing of an aggregate of $640,000 principal amount plus accrued interest of outstanding convertible promissory notes issued by MemoryMD. Furthermore, as of the closing, Mr. Amer Samad, the sole director and executive officer until the consummation of the Acquisition, committed to tender for cancellation 6,495,000 shares of the Company’s common stock as part of the conditions to closing, of which 6,375,000 have been cancelled at December 31, 2018 and 120,000 are expected to be cancelled as soon as practicable. Total shares issued as a result of the Acquisition was 13,421,752.

The Acquisition has been accounted for as a reverse recapitalization of Brain Scientific by MemoryMD, but in substance as a capital transaction, rather than a business combination since Brain Scientific had nominal or no operations and assets prior to and as of the closing of the Acquisition. The transaction is deemed a reverse recapitalization and the accounting is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded. For accounting purposes, MemoryMD is treated as the surviving entity and accounting acquirer although Brain Scientific was the legal acquirer. Accordingly, the Company’s historical financial statements are those of MemoryMD.

All references to common stock, share and per share amounts have been retroactively restated to reflect the reverse recapitalization as if the transaction had taken place as of the beginning of the earliest period presented.

Assignment and Assumption Agreement

As of immediately prior to the closing of the Acquisition, the Company entered into an Assignment and Assumption Agreement with Chromium 24 LLC, pursuant to which Chromium 24 LLC assumed all of the Company’s remaining assets and liabilities through the closing of the Acquisition. Accordingly, as of the closing of the Acquisition, Brain Scientific had no assets or liabilities other than the shares of MemoryMD acquired in the Acquisition.

Name Change and Increase in Authorized Shares

On September 18, 2018, the Company filed an amendment to its certificate of incorporation with the Nevada Secretary of State to change its name to Brain Scientific Inc. On September 18, 2018, FINRA approved of the name change as well as a ticker symbol change, which was effective as of September 19, 2018. In addition, the Company increased its authorized shares of common stock from 50,000,000 to 200,000,000 and created and authorized 10,000,000 shares of undesignated preferred stock.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

Unaudited Interim Financial Information

The Company has prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These consolidated financial statements are unaudited and, in the Company’s opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of its balance sheets, operating results, and cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for 2020. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been omitted in accordance with the rules and regulations of the SEC. These consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with GAAP.

Principles of Consolidation

The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810").

The consolidated financial statements include the accounts of the Company and its subsidiaries, MemoryMD and MemoryMD - Russia. The operations of the newly formed 100% wholly owned subsidiary, MemoryMD – Russia, are included beginning April 1, 2019. All significant consolidated transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and equipment and assumptions used in the valuation of options and warrants.

Cash and Cash Equivalents

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At March 31, 2020 and December 31, 2019, the Company had no cash equivalents.

The Company’s cash is held with financial institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these financial institutions. As of March 31, 2020 and December 31, 2019, the Company had $0 and $11,436, respectively, in excess over the FDIC insurance limit.

Inventory

Inventory consists of finished goods that are valued at lower of cost or market using the weighted average method. As of March 31, 2020 and December 31, 2019, the Company had inventory totaling $371 and $0, respectively.

Property, Equipment and Depreciation

Property and equipment are recorded at cost, less depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for repair and maintenance are charged to operations as incurred. Property and equipment consisted of computer equipment, with an estimated useful life of three years. Depreciation expense was $341 and $299 for the three months ended March 31, 2020 and 2019, respectively.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

Convertible Notes Payable

The Company has issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be at a discount to the common stock at the time of conversion. For certain notes, the conversion features of these notes are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred.

Derivative Instruments

The Company evaluates its convertible notes and warrants to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.

The Company utilizes the Monte Carlo Method that values the liability of the debt conversion feature derivative financial instruments and derivative warrants based on a probability of a down round event. The reason the Company selected the lattice binomial model is that in many cases there may be multiple embedded features or the features of the bifurcated derivatives may be so complex that a Black-Scholes valuation does not consider all of the terms of the instrument. Therefore, the fair value may not be appropriately captured by simple models.

From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.

Revenue Recognition

On January 1, 2018, the Company adopted ASC Topic 606 Revenue from Contracts with Customers. This guidance requires an entity to recognize revenue by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Once the steps are met, revenue is recognized, generally upon receiving a letter of acceptance from the customer. There has been no material effect on the Company’s financial statements as a result of adopting Topic 606.

The Company recognizes revenue from the sale of NeuroCaps, Universal as well as revenue from the sale of goods purchased through manufacturers of medical devices. All revenue for the three months ended March 31, 2020 is from the sale of medical devices purchased from Neurotech, a related party.

Research and Development Costs

The Company expenses all research and development costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging, and proprietary products and technology. Research and development costs recognized in the statement of operations for the three months ended March 31, 2020 and 2019 were $96,390 and $22,290, respectively.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

Sales and Marketing

Advertising and marketing costs are expensed as incurred. Advertising and marketing costs recognized in the statement of operations for the three months ended March 31, 2020 and 2019 were $40,584 and $47,792, respectively.

Stock-based Compensation

The Company measures and recognizes compensation expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.

Basic and Diluted Net Loss Per Common Share

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. In the three months ended March 31, 2020 2,302,250 anti-dilutive securities were excluded from the computation.

Fair Value of Financial Instruments

The Company’s financial instruments are measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.

Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows:

●

Level 1 - Quoted prices in active markets for identical assets or liabilities.

●

Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

●

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs.

The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets, convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

The Company did not have any other Level 1 or Level 2 assets or liabilities as of March 31, 2020 and the Company did not have any other Level 1, Level 2 or Level 3 assets or liabilities as of December 31, 2019.

Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of March 31, 2020.

Liabilities	Amounts at Fair Value		Level 1		Level 2		Level 3
Derivative liability – conversion feature	$	308,641	$	-	$	-	$	308,641
Derivative liability - warrants		263,202		-		-		263,202
Total	$	571,843	$	-	$	-	$	571,843

Income Taxes

The Company accounts for income taxes using the asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods.

The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of March 31, 2020 and December 31, 2019, the Company had no unrecognized uncertain income tax positions.

On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for years beginning after December 31, 2017. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118") was issued and allows a company to recognize provisional amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment.

Recent Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption.

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “Measurement of Credit Losses on Financial Instruments,” which requires measurement and recognition of expected credit losses at the point a loss is probable to occur, rather than expected to occur, which will generally result in earlier recognition of allowances for credit losses. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted ASU 2016-13 in the first quarter of 2020 and the adoption did not have a material impact on its condensed consolidated financial statements.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

NOTE 3 – GOING CONCERN

The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern for a period of one year from the issuance of these financial statements. For the three months ended March 31, 2020, the Company had $133,845 in revenues, a net loss of $951,660 and had net cash used in operations of $252,319. Additionally, as of March 31, 2020, the Company had working capital deficit, stockholders’ deficit and accumulated deficit of $1,833,662, $1,832,329 and $4,623,737 respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of the issuance of these financial statements.

The financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.

Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications and ultimately achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investments or achieve an adequate sales level.

NOTE 4 – CONVERTIBLE NOTES PAYABLE

In January 2019, the Company commenced an offering of up to $500,000 pursuant to which the Company will issue convertible notes to investors. On January 18, 2019, February 5, 2019 and July 23, 2019, the Company issued three such convertible notes payable to three investors for $100,000, $130,000 and $150,000, respectively. The notes bear interest at a fixed rate of 10% per annum, computed based on a 360-day year and mature on the earlier of one year from the date of issuance or the consummation of an equity or equity-linked round of financing of the Company in excess of $1,000,000 (“Qualified Financing”) or other event pursuant to which conversion shares are to be issued pursuant to the terms of the note. On February 28, 2020, the Company and the holder of the January 18, 2019 convertible note agreed to extend the maturity date of the January 18, 2019 convertible note to January 18, 2021. Also on February 28, 2020, the Company and the holder of the February 5, 2019 convertible note agreed to extend the maturity date of the February 5, 2019 convertible note to February 5, 2021.

The notes are convertible into common stock of the Company following events on the following terms: with no action on the part of the note holder upon the consummation of a Qualified Financing, the debt will be converted to new round stock based on the product of the outstanding principal and accrued interest multiplied by 1.35, then divided by the accrual per share price of the new round common stock. If a change of control occurs or if the Company completes a firmly underwritten public offering of its common stock prior to the Qualified Financing the notes would, at the election of the holders of a majority of the outstanding principal of the notes, be either payable on demand as of the closing of such change of control or Initial Public Offering (‘IPO”) or convertible into shares of common stock immediately prior to such change of control transaction or IPO transaction at a price per share equal to the lesser of the per share value of the common stock as determined by the Company’s Board of Directors or the per share consideration to be received by the holders of the common stock in such change of control or IPO transaction. Based on the terms of the conversion, the holders may receive a discount, and the notes are considered to have a contingent beneficial conversion feature. If conversion of the debt occurs, the Company will recognize an expense related to the intrinsic value. The Company recorded $37,541of accrued interest and has a total outstanding principal balance of $380,000 as of March 31, 2020.

In the event that the Company consummates a financing prior to the Maturity Date, other than a Qualified Financing, and the economic terms thereof are more favorable to the investors in such financing than the terms of the note, the note shall automatically be amended to reflect such more favorable economic terms.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

December 31, 2019 Securities Purchase Agreement

On December 31, 2019, the Company entered into a Securities Purchase Agreement and issued and sold to a third party (the “Investor”) a Convertible Note in the original principal amount of $275,000 (the “Note”), and a warrant to purchase 100,000 shares of the Company’s common stock (the “Warrant”). The aggregate purchase price received by the Company was $250,000 after an original issue discount of $25,000. A one-time interest charge of 8% was applied on December 31, 2019 and will be payable, along with the Principal, on July 31, 2020 (the “Maturity Date”), as may be extended at the option of the Investor.

The unpaid outstanding principal amount and accrued and unpaid interest under the Note shall be convertible into shares of the Company’s common stock at any time at the option of the Investor. The conversion price shall be equal to 80% multiplied by the price per share paid by the investors in the next capital raising transaction consummated by the Company in the amount of $1,000,000 or more (the “Qualified Financing”), subject to adjustments as provided in the Note. In the event the Investor elects to convert the Note prior to a Qualified Financing, the conversion price shall be the effective exercise price per share from time to time pursuant to the Warrant. At any time prior to the Maturity Date, upon 10 business days’ notice to the Investor, the Company shall have the right to pre-pay the entire remaining principal amount of the Note subject to the pre-payment terms contained in the Note. The note is valued at face value and not considered a derivative since the Qualified Financing is at the control of the Company. The Company recorded $9,429 of accrued interest and has a total outstanding principal balance of $275,000 as of March 31, 2020.

The Note contains a price-based anti-dilution provision, pursuant to which the conversion price of the Note shall be reduced upon the occurrence of certain dilutive issuances of Company securities as set forth in the Note. The conversion of the Note is also subject to a beneficial ownership limitation of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such conversion. In the event the Company, prior to the Maturity Date, issues any Security (as defined in the Note) with any term more favorable to the holder of such Security or with a term in favor of the holder of such Security that was not similarly provided to the Investor, then at the Investor’s option such term shall become a part of the Note. The Company also agreed to provide piggy-back registration rights to the Investor pursuant to which the Company shall include all shares issuable upon conversion of the Note on the next registration statement the Company files with the Securities and Exchange Commission.

The Note contains events of default which, among other things, entitle the Investor to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the Note. Upon the occurrence of any event of default, the outstanding balance shall immediately and automatically increase to 130% of the outstanding balance immediately prior to the event of default, and the conversion price of the Note shall be redefined to equal 65% of the lowest trade accruing during the 10 consecutive Trading Days (as defined in the Note) immediately preceding the applicable Conversion Date (as defined in the Note). Nickolay Kukekov, a director of the Company, and a third party, each has personally guaranteed the repayment of the Note.

The Warrant has an exercise price of $1.25 per share (the “Exercise Price”), subject to adjustments as provided in the Warrant, and has a term of five years. The Warrant contains a price-based anti-dilution provision, pursuant to which the exercise price of the Warrant shall be reduced upon the occurrence of certain dilutive issuances of securities as set forth in the Warrant, with a corresponding increase in the number of shares underlying the Warrant if the dilutive event occurs during the first three years of the Warrant, and a cashless exercise provision. The exercise of the Warrant is subject to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. The Company calculated the Warrants at fair value of $130,768 using the Monte Carlo model, which was recognized as a discount to the Note and is being amortized as interest expense over the remaining term of the notes.

In the year ended December 31, 2019, the Company recorded a total debt discount of $155,768 related to the above convertible notes. On March 18, 2020, the Company recorded an additional debt discount of $176,274 related to the above convertible notes. Amortization of the debt discount is recorded as interest expense and a total of $83,523 was amortized during the three months ended March 31, 2020.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

Derivative Accounting for the Convertible Notes Payable

The Company evaluated the terms and conditions of the Note under the guidance of ASC 815. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted, and all additional convertible debentures and warrants are included in the value of the derivative liabilities. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion options and warrants and shares to be issued were recorded as derivative liabilities on the issuance date and revalued at each reporting period.

Certain of the Company’s embedded conversion features on debt and outstanding warrants are treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to settle these outstanding contracts, or due to other rights connected with these contracts, such as registration rights. In the case of insufficient authorized share capital available to fully settle outstanding contracts, the Company utilizes the issuance date sequencing method to reclassify outstanding contracts as derivative instruments. These instruments do not trade in an active securities market.

Derivative Liabilities

The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2020:

	Amount
Balance on December 31, 2019	$	-
Issuances to debt discount		176,274
Issuances to interest expense		348,350
Change in fair value of derivative liabilities		39,916
Change in fair value of warrant liabilities		7,303
Balance on March 31, 2020	$	571,843

The fair value of the derivative conversion features and warrant liabilities as of March 31, 2020 were calculated using a Monte-Carlo option model valued with the following assumptions:

	March 31, 2020
Dividend yield		0	%
Expected volatility		108% - 130.3	%
Risk free interest rate		0.21% - 0.51	%
Contractual terms (in years)		0.08 – 4.50
Conversion/Exercise price	$	0.80 - $1.25

NOTE 5 – PROMISSORY NOTES

October 23, 2019 Note

On October 23, 2019, an investor of the Company subscribed for a promissory note (the “October Note”) and loaned to the Company $50,000.

The October Note bears interest at a fixed rate of 14% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date. The principal amount and any accrued and unpaid interest due under the October Note is payable on October 21, 2020. The Company recorded $1,359 of accrued interest and has a total outstanding principal balance of $50,000 as of March 31, 2020.

The October Note contains customary events of default, which, if uncured, entitle the lender to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the October Note.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

February 21, 2020 Note

On February 21, 2020, a third party loaned the Company $20,000, evidenced by a non-convertible promissory note (the “February Note”). The February Note bears interest at a fixed rate of 12% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date. The principal amount and any accrued and unpaid interest due under the February Note is payable on July 1, 2020. The Company recorded $260 of accrued interest and has a total outstanding principal balance of $20,000 as of March 31, 2020.

The February Note contains customary events of default, which, if uncured, entitle the lender to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the February Note.

NOTE 6 – OTHER LIABILITIES

In 2016, the Company recorded a liability in connection with the sale of two Electroencephalograms (“EEG”) machines as it provided a guarantee to the customer’s financing company (See Note 2). In June 2017, the customer defaulted on its payments and an additional $19,107 was booked as a liability and recognized as a loss on the sale of the assets for interest and some taxes related to the transaction. As of March 31, 2020 and December 31, 2019, total liability to the financing company reflected in Other Liabilities is $4,595 and $6,377, respectively.

Future minimum commitments related to the EEG liability consisted of the following at March 31, 2020:

Years ended December 31,	Amount (USD)
Remainder 2020		4,595
Total	$	4,595

NOTE 7 – RELATED PARTY TRANSACTIONS

During the year ended December 31, 2018, an entity controlled by Mr. Vadim Sakharov, former CEO of the Company and current director and executive officer, provided a $50,000 non-interest-bearing, no-term loan to the Company. An additional $5,530 of non-interest bearing no-term proceeds were loaned to the Company during the year ended December 31, 2019. As of March 31, 2020, and December 31, 2019, the balance was $55,530 and $55,530, respectively.

During the three months ended March 31, 2020 and 2019, the Company had expenses related to research and development costs of $10,200 and $0, respectively, to an entity controlled by Mr. Sakharov.

During the year ended December 31, 2019, an affiliate of Boris Goldstein, the Company’s Chairman of the Board, provided an aggregate total of $50,000, in non-interest-bearing, no-term loans to the Company. As of March 31, 2020 and December 31, 2019, the balance was $50,000 and $50,000, respectively.

On September 1, 2018, the Company entered into a sublease agreement with a company controlled by the Company’s Chairman, whereby the Company makes payments to the related party for shared office space. This lease was terminated on March 31, 2019. For the three months ended March 31, 2020 and 2019, the Company has made approximately $0 and $4,900, respectively, in rent payments to the related party.

During the year ended December 31, 2019, an affiliate of Nickolay Kukekov, a director of the Company, provided an aggregate total of $217,000 in non-interest-bearing, no-term loans to the Company. As of March 31, 2020 and December 31, 2019, the balance was $217,000 and $217,000, respectively.

During the three months ended March 31, 2020 and 2019, the Company purchased an aggregate of $101,613 and $0 of medical devices for resale and distribution from Neurotech, a company that Mr. Sakharov is a shareholder and executive manager.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

NOTE 8 – STOCKHOLDERS’ DEFICIT

Preferred Stock

The Company has authorized 10,000,000 shares of undesignated preferred stock with a $0.001 par value. As of March 31, 2020, no preferred shares have been issued and these shares are considered blank check preferred shares with no terms, limitations, or rights associated with them.

Common Stock

The Company has authorized 200,000,000 shares of common stock with a $0.001 par value per share. The holders of common stock are entitled to one vote for each share of common stock held at the time of vote. As of March 31, 2020, the Company had 19,383,794 shares outstanding or deemed outstanding.

Shares Issued for Services

On August 8, 2018, the Company entered into a one-year agreement with an advisor for consulting services, as extended for an additional one-year period. The Company extended this agreement through August 9, 2020. Pursuant to the agreement, as amended, the Company has the right to pay $5,000 or issue the advisor a maximum of 6,667 shares of common stock on a quarterly basis. The Company elected to issue 1,667 shares for the services provided during the three months ended March 31, 2020 at a value of $3.00 per share or $5,001.

On August 28, 2018, the Company entered into a one-year agreement with an advisor for consulting services, as extended for an additional one-year period. The Company has extended this agreement through August 28, 2020. Pursuant to the agreement, as amended, the Company has the right to pay $5,000 or issue the advisor a maximum of 6,667 shares of common stock on a quarterly basis. The Company elected to issue 1,667 shares for the services provided during the three months ended March 31, 2020 at a value of $3.00 per share or $5,001.

Warrants

The following table summarized the warrant activity for the three months ended March 31, 2020:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Warrants	Shares		Price		Term		Value
Balance Outstanding, December 31, 2019		502,250	$	0.57		3.98	$	-
Granted		-		-		-		-
Forfeited		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Balance Outstanding, March 31, 2020		502,250	$	0.57		3.73	$	-

Exercisable, March 31, 2020		502,250	$	0.57		3.73	$	-

Options

On January 14, 2019, the Board of Directors approved the issuance of options to purchase an aggregate of 800,000 and 200,000 shares of common stock to Boris Goldstein and Vadim Sakharov, respectively. The options have an exercise price of $0.75 per share which will vest over a 24-month period as follows: 25% (or 200,000 and 50,000, respectively) shall vest six months after the grant date with the remaining options will vest on a monthly basis at a rate of 1/24^th per month. The options will expire on January 14, 2029. The aggregate fair value of $17,111 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life 10 years, (ii) volatility of 77%, (iii) risk free rate of 2.71% (iv) dividend rate of zero, (v) stock price of $0.042, and (vi) exercise price of $0.75. The expense will be amortized over the vesting period and a total of $10,432 was recorded during the year ended December 31, 2019. A total of $1,595 was recorded during the three months ended March 31, 2020.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

On January 30, 2020, the Board of Directors approved the issuance of options to purchase an aggregate of 800,000 of common stock to Boris Goldstein. The options have an exercise price of $0.75 per share which will vest over a 24-month period on a monthly basis at a rate of 1/24^th per month. The options will expire on January 30, 2030. The aggregate fair value of $51,757 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life 10 years, (ii) volatility of 76%, (iii) risk free rate of 1.57% (iv) dividend rate of zero, (v) stock price of $0.12, and (vi) exercise price of $0.75. The expense will be amortized over the vesting period. A total of $4,319 was recorded during the three months ended March 31, 2020.

The following table summarized the option activity for the three months ended March 31, 2020:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Options	Shares		Price		Term		Value
Balance Outstanding, December 31, 2019		1,000,000	$	0.75		9.05	$	-
Granted		800,000		0.75		10		-
Forfeited		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Balance Outstanding, March 31, 2020		1,800,000	$	0.75		9.26	$	-

Exercisable, March 31, 2020		818,750	$	0.75		8.92	$	-

For future periods, the remaining value of the stock options totaling approximately $52,523 will be amortized into the statement of operations consistent with the period for which the services will be rendered.

NOTE 9 – COMMITMENTS AND CONTINGENCIES

Operating Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize most leases on their balance sheets as a right-of-use asset with a corresponding lease liability. Lessor accounting under the standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the standard effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update:

●

The option to not reassess prior conclusions related to the identification, classification and accounting for initial direct costs for leases that commenced prior to January 1, 2019.

●

Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less.

●

The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment.

●

The package of practical expedients applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases.

As a result of the above, the adoption of ASC 842 did not have a material effect on the consolidated financial statements. The Company will review for the existence of embedded leases in future agreements.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

The Company has inventoried all leases where the Company is a lessee as of the initial date of application and has examined other contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance. The Company’s lease population comprises lease for corporate office space and a warehouse that are year-to-year basis with monthly rent ranging from approximately $150 to $3,200 and qualify under the practical expedient of short-term leases. The Company does not have exclusive rights of control to any assets in the customer and vendor contracts reviews and does not have any financing leases as of the date of adoption of ASC 842.

Beginning January 1, 2020, the Company entered into a 12-month lease agreement ending December 31, 2020, with a third party in Russia. The Company is paying rent at a rate of 17,900 Rubles ($227) per month.

Beginning June 1, 2019, the Company entered into a 10-month lease agreement ending March 31, 2020 with a third party in Russia. The Company is paying rent at a rate of 12,000 Rubles ($152) per month.

Additionally, the Company also rents a warehouse. Beginning December 1, 2018, the Company entered into a 6-month warehouse rental agreement for $2,980 per month. The lease was renewed on June 1, 2019 for an additional year ending May 31, 2020, for $3,171 per month.

Total rent expense for the three months ended March 31, 2020 and 2019 was $11,638 and $22,060 respectively.

Equity Incentive Plan

As of September 21, 2018, the Company’s board of directors adopted, and stockholders approved the 2018 Equity Incentive Plan (“the 2018 Plan”). The 2018 Plan has a 10-year term, which terminates on the day prior to the 10^th anniversary of its adoption by the Board. Under the 2018 Plan, the Company may grant equity-based incentive awards, including options, restricted stock, and other stock-based awards, to any directors, employees, advisers, and consultants that provide services to the Company. The vesting period, term and exercise price will be determined at the time of the grant. An aggregate of up to 3,500,000 of the Company’s common stock are reserved for issuance under the 2018 Plan. As of March 31, 2020 the Company has granted 1,800,000 options and has 1,800,000 options outstanding under the 2018 Plan (see Note 8).

NOTE 10 - RESTATEMENT

The Company, while undergoing the review of its consolidated financial statements for the six months ended June 30, 2020, commenced an evaluation of its accounting in connection with the Note (as defined in Note 4) for derivative accounting in accordance with ASC 815. Management originally deemed these agreements to be fixed in nature and a derivative would not need be recognized. On August 12, 2020, under the authority of the board of directors, the Company determined that these agreements and underlying warrants should have been recorded as a derivative with changes in the fair value of the derivate to be recorded in the condensed consolidated statement of operations and comprehensive loss (see Note 4). Accordingly, the Company has restated the condensed consolidated interim financial statements and included the required disclosures for the three months ended March 31, 2020.

The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported Condensed Consolidated Balance Sheet at March 31, 2020:

	March 31, 2020
	As Reported			Adjustment			As Restated
Convertible notes payable, net	$	565,781		$	(159,299	)	$	406,482
Derivative liabilities	$	-		$	571,843		$	571,843
Current liabilities	$	1,467,171		$	412,544		$	1,879,715
Total liabilities	$	1,467,171		$	412,544		$	1,879,715
Accumulated deficit	$	(4,211,193	)	$	(412,544	)	$	(4,623,737	)
Total stockholders’ deficit	$	1,419,785		$	(412,544	)	$	(1,832,329	)

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported Condensed Consolidated Statement of Operations and Comprehensive Loss for the three months ended March 31, 2020:

	March 31, 2020
	As Reported			Adjustment			As Restated
Interest expense	$	(88,291	)	$	(365,325	)	$	(453,616	)
Change in fair market value of derivative liabilities	$	-		$	(47,219	)	$	(47,219	)
Net Loss	$	(539,116	)	$	(412,544	)	$	(951,660	)
Total comprehensive loss	$	(540,169	)	$	(412,544	)	$	(952,713	)
Net loss per common share, basic and diluted	$	(0.03	)	$	(0.02	)	$	(0.05	)

NOTE 11 – SUBSEQUENT EVENTS

In accordance with ASC 855 “Subsequent Events,” Company management reviewed all material events through the date this report was issued, and the following subsequent events took place.

The Effects of COVID-19

The World Health Organization (WHO) declared the coronavirus outbreak a pandemic on January 30, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside, as well as our employees, suppliers and customers. While the disruption is currently expected to be temporary, there is considerable uncertainty around the duration of the closings and shelter-in-place orders and the ultimate impact of governmental initiatives. However, the financial impact and duration cannot be reasonably estimated at this time.

Convertible Grid Notes

On April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Caleca Note”) to Thomas J. Caleca (“Caleca”), an existing stockholder of the Company, pursuant to which Caleca agreed to advance to the Company the aggregate principal amount of $125,000 (the “Caleca Aggregate Advance”). The Company also issued to Caleca a common stock purchase warrant (the “Caleca Warrant”), granting Caleca the right to purchase up to 750,000 shares of the Company’s common stock at a per share exercise price of $0.80 (subject to adjustment as set forth in the Caleca Warrant).

Also on April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Brown Note”, and together with the Caleca Note, the “Grid Notes”) to Andrew Brown (“Brown”, and together with Caleca, the “Grid Investors”), an existing stockholder of the Company, pursuant to which Brown agreed to advance to the Company the aggregate principal amount of $125,000 (the “Brown Aggregate Advance”, and together with the Caleca Aggregate Advance, the “Aggregate Advance”). The Company also issued to Brown a common stock purchase warrant (the “Brown Warrant”, and together with the Caleca Warrant, the “2020 Warrants”), granting Brown the right to purchase up to 750,000 shares of the Company’s common stock at a per share exercise price of $0.80 (subject to adjustment as set forth in the Brown Warrant). The 2020 Warrants are exercisable at any time commencing on the eighteen-month anniversary of the issuance of the 2020 Warrants (as may be accelerated pursuant to the terms of the 2020 Warrants) and expiring on the five-year anniversary of the issuance of the 2020 Warrants.

BRAIN SCIENTIFIC INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2020

(unaudited)

On April 22, 2020, the Grid Investors each made their first cash advance of $25,000 pursuant to the terms of the Grid Notes, for an aggregate cash advance to the Company of $50,000 (the “First Advance”). The Grid Investors shall make additional cash advances to the Company pursuant to the terms of their Grid Notes.

The Grid Notes bear interest on the unpaid balances at a fixed simple rate of twelve percent (12%) per annum (subject to a rate increase if the Company commits an Event of Default (as defined in the Grid Notes)), computed based on a 360-day year of twelve 30-day months, commencing on the date of the respective advance and payable quarterly. The principal amount of the Aggregate Advance, or so much thereof as has been advanced to the Company by the Grid Investors from time to time pursuant to the Grid Notes, will be payable on April 21, 2021 (the “Maturity Date”), unless sooner converted into shares of the Company’s common stock pursuant to the terms of the Grid Notes.

The unpaid outstanding principal amount and accrued and unpaid interest under the Grid Notes shall be convertible at any time prior to the Maturity Date at the election of the Grid Investors into such number of shares of the Company’s common stock obtained by dividing the amount so converted by $1.00 (the “Conversion Price”). At the Maturity Date, all of the remaining unpaid outstanding principal amount and accrued and unpaid interest (the “Outstanding Balance”) under the Grid Notes shall automatically convert into such number of shares of the Company’s common stock obtained by dividing the Outstanding Balance by the Conversion Price. The Grid Notes may not be prepaid by the Company in whole or in part without the prior written consent of the respective Grid Investor.

The Grid Notes contain customary events of default, which, if uncured, entitle the Grid Investors to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, their Grid Notes.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

The following discussion should be read in conjunction with our unaudited financial statements and related notes included in Item 1, “Financial Statements,” of this Quarterly Report on Form 10-Q. Certain information contained in this MD&A includes “forward-looking statements.” Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition and results of operations, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our existing and proposed business, including many assumptions regarding future events. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors, including those risks described in detail in the section entitled “Risk Factors” of this Quarterly Report on Form 10-Q.

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology.

In light of these risks and uncertainties, and especially given the nature of our existing and proposed business, there can be no assurance that the forward-looking statements contained in this section and elsewhere in this Quarterly Report on Form 10-Q will in fact occur. Potential investors should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

Overview

We are a neurodiagnostic and predictive technology platform company seeking to provide a centralized platform for data acquisition and analysis of EEG data that combines cutting-edge medical device technologies with cloud-based telehealth services. Both our NeuroCap, a pre-gelled disposable EEG headset, and NeuroEEG, a 16 channel, portable, cloud-enabled data acquisition platform for EEG activity, received FDA clearance to market in 2018.

On September 21, 2018, we entered into a merger agreement (the “Merger Agreement”) with MemoryMD, Inc. and AFGG Acquisition Corp. to acquire MemoryMD, Inc. (the “Acquisition”). The transactions contemplated by the Merger Agreement were consummated on September 21, 2018 and, pursuant to the terms of the Merger Agreement, all outstanding shares of MemoryMD were exchanged for shares of our common stock. Accordingly, we acquired 100% of Memory MD, Inc. in exchange for the issuance of shares of our common stock and MemoryMD, Inc. became our wholly-owned subsidiary. We issued an additional 4,083,252 shares of our common stock upon the automatic conversion at the closing of an aggregate of $1,507,000 principal amount plus accrued interest of outstanding convertible promissory notes issued by MemoryMD Inc., and we further issued an additional 1,604,378 shares of our common stock upon the automatic conversion immediately subsequent to the closing of an aggregate of $640,000 principal amount plus accrued interest of outstanding convertible promissory notes issued by MemoryMD Inc.

As of immediately prior to the closing of the Acquisition, we entered into an Assignment and Assumption Agreement with Chromium 24 LLC, pursuant to which Chromium 24 LLC assumed all of our remaining assets and liabilities through the closing of the Acquisition. Accordingly, as of the closing of the Acquisition, we had no assets or liabilities.

Our sole business since the Acquisition is the business of MemoryMD. Our management’s discussion and analysis below is based on the financial results of MemoryMD.

We have very limited resources. To date, our primary activities have been limited to, and our limited resources have been dedicated to, performing business and financial planning, raising capital, recruiting personnel, negotiating with business partners and the licensors of our intellectual property and conducting development activities, although we have acted as a distributor of third-party medical devices in Russia (including those purchased from a company affiliated with one of our officers and directors) which has generated revenue for us. Our first products, the NeuroCap and NeuroEEG, are ready for commercialization and sale and we have commenced some non-recurring, initial sales. Our other products are still being tested or are still under development.

We have incurred losses since inception of MemoryMD in 2015 and had an accumulated deficit of $4,623,737 as of March 31, 2020, primarily as a result of expenses incurred in connection with our research and development programs and from general and administrative expenses associated with our operations. We expect to continue to incur significant expenses and increasing operating and net losses for the foreseeable future.

Historically, our primary source of cash has been proceeds from the sale of convertible promissory notes and other borrowings. To fund our operations, for the three months ended March 31, 2020, we issued one promissory note for gross proceeds of $20,000. For the year ended December 31, 2019, we issued convertible promissory notes for aggregate gross proceeds of $630,000. In addition, during the fiscal year ended December 31, 2019, we borrowed an aggregate of $273,084 from related parties. Additionally, in April 2020, existing stockholders of the Company agreed to advance to the Company an aggregate amount of $250,000 pursuant to the terms of Convertible Grid Promissory Notes (the “Grid Notes”). As of May 12, 2020, a total aggregate amount of $50,000 has been advanced pursuant to the terms of the Grid Notes.

We need to obtain substantial additional funding in connection with our continuing operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. However, we may be unable to raise additional funds when needed on favorable terms or at all. Our failure to raise such capital as and when needed would have a negative impact on our financial condition and our ability to develop and commercialize our products and future products and our ability to pursue our business strategy. See “–Liquidity and Capital Requirements” below.

Financial Overview

Revenue

For the three months ended March 31, 2020, we have generated approximately $134,000 of revenue through our acting as a distributor of third-party medical devices in Russia (including those purchased from a company affiliated with one of our officers and directors), while we continue to commercialize our products. While we intend to continue generating revenues through the sale of third party medical devices, we do not intend for it to be our primary source of revenue in the long-term. We do not expect to generate recurring, material revenue from our products unless or until we successfully commercialize our products. If we fail to successfully commercialize our developed products or fail to complete the development of any other product candidate we may pursue in the future, in a timely manner, or fail to obtain regulatory approval, we may not be able to solely rely on generating substantial and material revenue from the distribution of third-party medical devices.

General and Administrative

General and administrative expenses consist primarily of personnel-related costs for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees relating to corporate matters, intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development and financial matters, and product costs. We anticipate that our general and administrative expenses will significantly increase in the future to support our continued research and development activities, commercialization of our products, if approved, and the increased costs of operating as a public company. These increases will include increased costs related to the hiring of additional personnel and fees for legal and professional services, as well as other public company related costs.

Research and Development

Research and development expenses consist of expenses incurred in performing research and development activities in developing our products. Research and development expenses include compensation and benefits for research and development employees, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, costs related to regulatory operations, fees paid to consultants, and other outside expenses. Research and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed.

We expect our research and development expenses to remain substantially the same for the next six to nine months as we continue to develop and commercialize our products. As we develop our cloud-based computing system, we expect our research and development expenses to significantly increase.

Interest Expense

Interest expense primarily consists of amortized note issuance costs and interest costs related to the convertible notes we issued in 2019. The convertible notes bear interest at fixed rate ranging from 8%-10% per annum.

Results of Operations

Comparison of the Three Months Ended March 31, 2020 and 2019

The following table sets forth the results of operations of the Company for the three months ended March 31, 2020 and March 31, 2019.

	Three Months Ended March 31,				Period to Period
	2020		2019		Change

Revenues	$	133,845	$	2,250	$	131,595
General and administrative	$	208,635	$	201,241	$	7,394
Research and development	$	96,390	$	22,290	$	74,100
Professional fees	$	123,608	$	111,073	$	12,535
Interest expense	$	453,616	$	8,053	$	445,563
Other income	$	1,290	$	-	$	1,290

Three Months Ended March 31, 2020 and 2019

Revenues

Revenue for the three months ended March 31, 2020 was $133,845 compared to $2,250 for the three months ended March 31, 2019. In the three months ended March 31, 2020, we generated our revenue through acting as a distributor of third-party medical devices in Russia (including those purchased from a company affiliated with one of our offices and directors). In the three months ended March 31, 2019, our revenue was related to data analysis of the EEG software.

General and administrative expenses

General and administrative expenses were $208,635 for the three months ended March 31, 2020, compared to $201,241 for the three months ended March 31, 2019. General and administrative costs were in-line quarter over quarter.

Research and development expenses

Research and development expenses were $96,390 for the three months ended March 31, 2020, compared to $22,290 for the three months ended March 31, 2019. The increase was primarily due to an increase in development activities surrounding the development of a new, modified version of the NeuroCap.

Professional fees

Professional fees were $123,608 for the three months ended March 31, 2020, compared to $111,073 for the three months ended March 31, 2019. The increase was primarily due to an increase in accounting fees in the current year.

Interest expense

Interest expense, for the three months ended March 31, 2020 was $453,616, of which, approximately $84,000 is related to the amortization of debt discount related to the Company’s convertible promissory notes. The additional $386,000 is related to interest expense related to the Company’s convertible notes and promissory notes of which approximately $350,000 is non-cash. Interest expense, for the three months ended March 31, 2019 was $8,053, consisting of interest expense of $4,216 and amortization of debt issuance costs of $3,117 related to the Company’s convertible promissory notes totaling $230,000, as well as interest expense related to a lease of $720.

Other income

Other income for the three months ended March 31, 2020 was $1,290 compared to $0 in the three months ended March 31, 2019. This is primarily related to the write-off of $1,167 of accrued interest.

Liquidity and Capital Resources

While we have generated revenue in 2019 and 2020, we anticipate that we will continue to incur losses for the foreseeable future. Furthermore, substantially all of such revenue was generated through acting as a distributor of third-party medical devices in Russia, and we did not have any material sales of our products. We anticipate that our expenses will increase substantially as we develop our products and pursue pre-clinical testing and clinical trials, seek any further regulatory approvals, contract to manufacture any products, establish our own sales, marketing and distribution infrastructure to commercialize our Products, hire additional staff, add operational, financial and management systems and operate as a public company.

Historically, our primary source of cash has been proceeds from the sale of convertible promissory notes and related party loans. Through July 23, 2019, we sold an aggregate principal amount of approximately $2.95 million in multiple tranches of convertible promissory notes, of which $380,000 remains outstanding and unconverted. In addition, on December 31, 2019, we issued and sold to a third party a convertible note in the original principal amount of $275,000, and a warrant to purchase 100,000 shares of our common stock, pursuant to which we received $250,000 after an original issue discount of $25,000. We have also from time to time issued shares of our common stock to individuals and entities as payment for services rendered to us in lieu of cash.

All of our then-outstanding convertible promissory notes, in the aggregate principal amount plus interest through September 21, 2018 of $2,275,050, converted into aggregate of 5,687,630 shares of our common stock upon or immediately after the closing of the Acquisition.

In connection with the private placement of the convertible promissory notes, we paid the placement agent a cash fee of $117,880, in addition to equity compensation in the form of common stock purchase warrants.

We have no current source of revenue to sustain our present activities other than as acting as a distributor of medical devices in Russia (including those purchased from a company affiliated with one of our offices and directors), which is not our primary business goal, and we do not expect to generate material revenue, from our products until, and unless, the FDA or other regulatory authorities approve our products under development and we successfully commercialize our products. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through our distributorship revenue, a combination of equity (preferred stock or common stock) and debt financings as well as collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third-party partners, we may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or through collaborations, strategic alliances or licensing arrangements when needed, we may be required to delay, limit, reduce or terminate our Product development, future commercialization efforts, or grant rights to develop and market our cortical strip, grid electrode and depth electrode technology that we would otherwise prefer to develop and market ourselves.

Our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the years ended December 31, 2019 and 2018, noting the existence of substantial doubt about our ability to continue as a going concern. This uncertainty arose from management’s review of our results of operations and financial condition and its conclusion that, based on our operating plans, we did not have sufficient existing working capital to sustain operations for a period of twelve months from the date of the issuance of these financial statements.

We believe our existing cash and cash equivalents, without raising additional funds or generating revenues, will be sufficient to fund our operating expenses only to approximately July 2020.

In January 2019, we commenced a convertible note offering for up to $500,000, of which we have raised $380,000 through July 23, 2019. In December 2019, we also raised an aggregate gross amount of $275,000, less a $25,000 original issue discount, from an investor pursuant to a securities purchase agreement. In April 2020, existing stockholders of the Company agreed to advance to the Company an aggregate amount of $250,000 pursuant to the terms of Convertible Grid Promissory Notes (the “Grid Notes”). As of May 12, 2020, a total aggregate amount of $100,000 has been advanced pursuant to the terms of the Grid Notes. We may obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute on our business plan.

The development of our products is subject to numerous uncertainties, and we have based these estimates on assumptions that may prove to be substantially different than we currently anticipate and could use our cash resources sooner than we expect. Additionally, the process of developing medical devices is costly, and the timing of progress in pre-clinical tests and clinical trials is uncertain. Our ability to successfully transition to profitability will be dependent upon achieving a level of product sales adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

Net cash used in operating activities

Net cash used in operating activities was $252,319 for the three months ended March 31, 2020 compared to $423,803 for the three months ended March 31, 2019. This fluctuation is primarily due to an increase in net loss of approximately $541,000 offset by an increase of approximately $429,000 in amortization of debt discount and non-cash interest expense related to the 2019 issuance of a convertible debenture and in accounts payable and changes in accrued expenses third party and related party of approximately $210,000.

Net cash used in investing activities

Net cash used in investing activities was $0 for the three months ended March 31, 2020, compared to $1,005 for the three months ended March 31, 2019. The decrease is due to no new purchases of fixed assets in the three months ended March 31, 2020 as compared to March 31, 2019.

Net cash provided by financing activities

Net cash provided by financing activities was $20,000 for the three months ended March 31, 2020, which consisted of the proceeds from the issuance of a third-party promissory note.

Net cash provided by financing activities was $305,000 for the three months ended March 31, 2019, which primarily consisted of the sale of the Company’s convertible promissory notes for aggregate gross proceeds of $230,000 as well as proceeds from a related party loan of $75,000.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our financial statements prospectively from the date of the change in estimate.

While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this Report, we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments.

Use of Estimates: The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation.

Fair Value of Financial Instruments: Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:

●

Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

●

Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.

●

Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and borrowings. The fair value of current financial assets and current financial liabilities approximates their carrying value because of the short-term maturity of these financial instruments.

Income Taxes. The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes, ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock Based Compensation. The Company accounts for the grant of restricted stock awards in accordance with ASC 718, “Compensation-Stock Compensation.” ASC 718 requires companies to recognize in the statement of operations the grant-date fair value of equity based compensation. The expense is recognized over the period during which the employee is required to provide service in exchange for the compensation. Any remaining unrecognized balance will be recognized ratably over the life of the vesting period and is a reduction of stockholders’ equity.

The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 “Equity-Based Payments to Non-Employees.”

Recent Accounting Pronouncements

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable for smaller reporting companies.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). As required by Rule 13a-15(b) under the Exchange Act, management of the Company, under the direction of our Board of Directors and Chief Financial Officer, reviewed and performed an evaluation of the effectiveness of design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of March 31, 2020. Based on that review and evaluation, the Board of Directors and Chief Financial Officer, along with the management of the Company, have determined that as of March 31, 2020, the disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and were not effective to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. Specifically, we have identified the following material weakness in our disclosure controls: (i) insufficient written policies and procedures to ensure timely filing of reports that the Company files or submits under the Exchange Act, and (ii) a lack of full-time executive management, including a lack of a full-time chief executive officer and chief financial officer, and other members of management who would otherwise oversee the Company’s disclosure controls and procedures.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting, identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business.

We are not currently a party in any legal proceeding or governmental regulatory proceeding nor are we currently aware of any pending or potential legal proceeding or governmental regulatory proceeding proposed to be initiated against us that would have a material adverse effect on us or our business.

Item 1A. Risk Factors.

Not required for a Smaller Reporting Company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

All unregistered issuances of equity securities during the period covered by this quarterly report have been previously disclosed on our Current Reports on Form 8-K. Please see Item 5- Other Information regarding unregistered issuances of equity securities during the period subsequent to the period covered by this quarterly report.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits

The exhibits listed below are hereby furnished to the SEC as part of this report:

10.1		Non-Convertible Promissory Note (Incorporated by reference to the Registrant’s Current Report on Form 8-K filed on February 27, 2020)
10.2		Allonge to Convertible Promissory Note dated February 28, 2020 ($130,000) (Incorporated by reference to the Registrant’s Current Report on Form 8-K filed on March 5, 2020)
10.3		Allonge to Convertible Promissory Note dated February 28, 2020 ($100,000) (Incorporated by reference to the Registrant’s Current Report on Form 8-K filed on March 5, 2020)
10.4		Boris Goldstein Employment Agreement (Incorporated by reference to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed on March 31, 2020)
10.5		Vadim Sakharov Employment Agreement (Incorporated by reference to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed on March 31, 2020)
10.6		Convertible Grid Promissory Note, dated April 21, 2020, issued to Thomas J. Caleca (Incorporated by reference to the Registrant’s Current Report on Form 8-K filed on April 27, 2020)
10.7		Common Stock Purchase Warrant, dated April 21, 2020, issued to Thomas J. Caleca (Incorporated by reference to the Registrant’s Current Report on Form 8-K filed on April 27, 2020)
10.8		Convertible Grid Promissory Note, dated April 21, 2020, issued to Andrew Brown (Incorporated by reference to the Registrant’s Current Report on Form 8-K filed on April 27, 2020)
10.9		Common Stock Purchase Warrant, dated April 21, 2020, issued to Andrew Brown (Incorporated by reference to the Registrant’s Current Report on Form 8-K filed on April 27, 2020)
31.1		Certification of Boris Goldstein, Chairman of the Board
31.2		Certification of Mark Corrao, Chief Financial Officer
32.1		Certification of Boris Goldstein, Chairman of the Board, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Mark Corrao, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.1		XBRL Instance.
101.SCH		XBRL Taxonomy Extension Schema.
101.CAL		XBRL Taxonomy Extension Calculation.
101.DEF		XBRL Taxonomy Extension Definition.
101.LAB		XBRL Taxonomy Extension Labels.
101.PRE		XBRL Taxonomy Extension Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 16^th day of September, 2020.

	BRAIN SCIENTIFIC INC.

	By:	/s/ Boris Goldstein
	Name:	Boris Goldstein
	Title:	Chairman of the Board
		(Interim Principal Executive Officer)

	By:	/s/ Mark Corrao
	Name:	Mark Corrao
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 f10q0320a1ex31-1_brain.htm CERTIFICATION

Exhibit 31.1

Certifications of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Boris Goldstein, certify that:

I have reviewed this quarterly report on Form 10-Q/A of Brain Scientific Inc.;

Based upon my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based upon my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrants’ board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: September 16, 2020

/s/ Boris Goldstein
Chairman, Secretary and Executive Vice President (Principal Executive Officer)

EX-31.2 3 f10q0320a1ex31-2_brain.htm CERTIFICATION

Exhibit 31.2

Certifications of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Mark Corrao, certify that:

I have reviewed this quarterly report on Form 10-Q/A of Brain Scientific Inc.;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Dated: September 16, 2020

/s/ Mark Corrao
Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 f10q0320a1ex32-1_brain.htm CERTIFICATION

Exhibit 32.1

Certification of Principal Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

I, Boris Goldstein, Chairman of the Board, Secretary and Executive Vice President of Brain Scientific Inc., hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the quarterly report on Form 10-Q/A for the period ending March 31, 2020 of Brain Scientific Inc. (the “Form 10-Q/A”) fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q/A fairly presents, in all material respects, the financial condition and results of operations of Brain Scientific Inc.

Dated: September 16, 2020	/s/ Boris Goldstein
	Boris Goldstein
	Chairman, Secretary and Executive Vice President
	(Principal Executive Officer)

EX-32.2 5 f10q0320a1ex32-2_brain.htm CERTIFICATION

Exhibit 32.2

Certification of Principal Financial Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

I, Mark Corrao, Chief Financial Officer of Brain Scientific Inc., hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the quarterly report on Form 10-Q/A for the period ending September 30, 2020 of Brain Scientific Inc. (the “Form 10-Q/A”) fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q/A fairly presents, in all material respects, the financial condition and results of operations of Brain Scientific Inc.

Dated: September 16, 2020	/s/ Mark Corrao
	Mark Corrao
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.INS 6 brsf-20200331.xml XBRL INSTANCE FILE 0001662382 2020-01-01 2020-03-31 0001662382 2020-05-18 0001662382 2020-03-31 0001662382 2019-12-31 0001662382 2019-01-01 2019-03-31 0001662382 us-gaap:CommonStockMember 2019-12-31 0001662382 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001662382 us-gaap:RetainedEarningsMember 2019-12-31 0001662382 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001662382 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001662382 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001662382 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001662382 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001662382 us-gaap:CommonStockMember 2020-03-31 0001662382 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001662382 us-gaap:RetainedEarningsMember 2020-03-31 0001662382 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001662382 us-gaap:CommonStockMember 2018-12-31 0001662382 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001662382 us-gaap:RetainedEarningsMember 2018-12-31 0001662382 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001662382 2018-12-31 0001662382 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001662382 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001662382 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001662382 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001662382 us-gaap:CommonStockMember 2019-03-31 0001662382 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001662382 us-gaap:RetainedEarningsMember 2019-03-31 0001662382 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001662382 2019-03-31 0001662382 brsf:MemoryMDMember 2018-09-21 0001662382 brsf:MemoryMDMember brsf:AutomaticConversionAtClosingMember brsf:PrincipalAndAccruedInterestOfPromissoryNoteIssuedByMemoryMDMember 2018-09-20 2018-09-21 0001662382 brsf:MemoryMDMember brsf:AutomaticConversionImmediatelySubsequentToClosingMember brsf:PrincipalAndAccruedInterestOfPromissoryNoteIssuedByMemoryMDMember 2018-09-20 2018-09-21 0001662382 2018-09-21 0001662382 2018-09-20 2018-09-21 0001662382 srt:MinimumMember 2018-09-18 0001662382 srt:MaximumMember 2018-09-18 0001662382 2018-09-18 0001662382 brsf:MemoryMDMember 2020-01-01 2020-03-31 0001662382 srt:MinimumMember 2017-12-01 2017-12-22 0001662382 srt:MaximumMember 2017-12-01 2017-12-22 0001662382 us-gaap:FairValueInputsLevel1Member 2020-01-01 2020-03-31 0001662382 us-gaap:FairValueInputsLevel2Member 2020-01-01 2020-03-31 0001662382 us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-03-31 0001662382 us-gaap:FairValueInputsLevel1Member 2020-03-31 0001662382 us-gaap:FairValueInputsLevel2Member 2020-03-31 0001662382 us-gaap:FairValueInputsLevel3Member 2020-03-31 0001662382 us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2019-01-01 2019-01-31 0001662382 us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2019-01-01 2019-01-18 0001662382 us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2019-02-02 2019-02-02 0001662382 us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2019-07-10 2019-07-23 0001662382 us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-03-31 0001662382 us-gaap:ConvertibleNotesPayableMember brsf:SecuritiesPurchaseAgreementMember 2019-01-01 2019-12-31 0001662382 us-gaap:ConvertibleNotesPayableMember brsf:SecuritiesPurchaseAgreementMember 2019-12-31 0001662382 us-gaap:ConvertibleNotesPayableMember brsf:SecuritiesPurchaseAgreementMember 2020-12-31 0001662382 us-gaap:ConvertibleNotesPayableMember brsf:SecuritiesPurchaseAgreementMember 2020-01-01 2020-12-31 0001662382 us-gaap:DebtInstrumentRedemptionPeriodOneMember 2020-01-01 2020-03-31 0001662382 us-gaap:ConvertibleNotesPayableMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2019-01-01 2019-12-31 0001662382 us-gaap:ConvertibleNotesPayableMember brsf:SecuritiesPurchaseAgreementMember 2020-03-01 2020-03-18 0001662382 srt:MinimumMember 2020-01-01 2020-03-31 0001662382 srt:MaximumMember 2020-01-01 2020-03-31 0001662382 srt:MinimumMember 2020-03-31 0001662382 srt:MaximumMember 2020-03-31 0001662382 2019-10-23 0001662382 brsf:PromissoryNotesMember 2020-02-21 0001662382 brsf:PromissoryNotesMember 2020-01-01 2020-03-31 0001662382 brsf:PromissoryNotesMember 2020-03-31 0001662382 2016-01-01 2016-12-31 0001662382 2017-07-01 2017-07-31 0001662382 srt:ChiefExecutiveOfficerMember 2018-12-31 0001662382 srt:ChiefExecutiveOfficerMember 2019-12-31 0001662382 srt:ChiefExecutiveOfficerMember 2020-03-31 0001662382 brsf:MrSakharovShareholderAndExecutiveManagerrMember 2020-01-01 2020-03-31 0001662382 brsf:MrSakharovShareholderAndExecutiveManagerrMember 2019-01-01 2019-03-31 0001662382 srt:AffiliatedEntityMember 2019-12-31 0001662382 srt:AffiliatedEntityMember 2020-03-31 0001662382 srt:WarehouseMember srt:BoardOfDirectorsChairmanMember 2020-01-01 2020-03-31 0001662382 srt:WarehouseMember srt:BoardOfDirectorsChairmanMember 2019-01-01 2019-03-31 0001662382 brsf:AffiliateOneMember 2019-12-31 0001662382 brsf:AffiliateOneMember 2020-03-31 0001662382 brsf:AdvisorMember brsf:IssuePriceOneMember brsf:OneYearAgreementMember 2018-08-01 2018-08-08 0001662382 brsf:AdvisorMember brsf:IssuePriceOneMember brsf:OneYearAgreementMember 2020-03-31 0001662382 brsf:AdvisorMember brsf:FourMonthAgreementMember 2018-08-01 2018-08-28 0001662382 brsf:AdvisorMember brsf:FourMonthAgreementMember 2018-08-28 0001662382 brsf:AdvisorMember brsf:FourMonthAgreementMember 2020-01-01 2020-03-31 0001662382 2018-08-01 2018-08-28 0001662382 srt:BoardOfDirectorsChairmanMember us-gaap:StockOptionMember 2019-01-01 2019-01-14 0001662382 brsf:MrVadimSakharovMember 2019-01-01 2019-01-14 0001662382 srt:BoardOfDirectorsChairmanMember us-gaap:StockOptionMember 2019-01-14 0001662382 srt:BoardOfDirectorsChairmanMember us-gaap:StockOptionMember 2019-01-01 2019-12-31 0001662382 srt:BoardOfDirectorsChairmanMember us-gaap:StockOptionMember 2020-01-01 2020-03-31 0001662382 brsf:BorisGoldsteinMember us-gaap:StockOptionMember brsf:EmploymentAgreementMember 2020-01-01 2020-01-30 0001662382 brsf:BorisGoldsteinMember us-gaap:StockOptionMember brsf:EmploymentAgreementMember 2020-01-30 0001662382 2020-01-01 2020-01-30 0001662382 brsf:JesseWCrowneMember us-gaap:StockOptionMember brsf:EmploymentAgreementMember 2020-01-01 2020-01-30 0001662382 brsf:BorisGoldsteinMember us-gaap:StockOptionMember brsf:EmploymentAgreementMember 2020-01-01 2020-03-31 0001662382 us-gaap:StockOptionMember 2020-01-01 2020-03-31 0001662382 us-gaap:WarrantMember 2019-12-31 0001662382 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001662382 us-gaap:WarrantMember 2020-03-31 0001662382 us-gaap:StockOptionMember 2019-12-31 0001662382 us-gaap:StockOptionMember 2020-03-31 0001662382 brsf:TwelveMonthYearAgreementMember brsf:ThirdPartyMember 2020-01-01 2020-01-02 0001662382 brsf:TenMonthYearAgreementMember brsf:ThirdPartyMember 2019-06-01 2019-06-01 0001662382 brsf:TwelveMonthYearAgreementMember brsf:ThirdPartyMember 2019-06-01 2019-06-01 0001662382 brsf:SixMonthWareHousMember 2018-11-29 2018-12-01 0001662382 2018-11-29 2018-12-01 0001662382 brsf:EquityIncentivePlan2018Member 2018-09-17 2018-09-21 0001662382 brsf:EquityIncentivePlan2018Member 2018-09-21 0001662382 brsf:EquityIncentivePlan2018Member 2020-01-01 2020-03-31 0001662382 brsf:EquityIncentivePlan2018Member 2020-03-31 0001662382 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0001662382 brsf:AdjustmentMember 2020-03-31 0001662382 brsf:AsRestatedMember 2020-03-31 0001662382 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-01-01 2020-03-31 0001662382 brsf:AdjustmentMember 2020-01-01 2020-03-31 0001662382 brsf:AsRestatedMember 2020-01-01 2020-03-31 0001662382 brsf:ConvertibleGridNotesMember us-gaap:SubsequentEventMember 2020-04-02 2020-04-21 0001662382 brsf:ConvertibleGridNotesMember us-gaap:SubsequentEventMember 2020-04-21 0001662382 brsf:convertiblePromissoryNotesMember 2020-04-22 0001662382 brsf:GridInvestorsMember us-gaap:SubsequentEventMember 2020-04-22 0001662382 brsf:ConvertibleGridNotesMember 2020-04-22 0001662382 brsf:ConvertibleGridNotesMember 2020-01-01 2020-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:RUB 10-Q/A 2020-03-31 333-209325 BRAIN SCIENTIFIC INC. NV Yes Yes Non-accelerated Filer true true false As disclosed in Item 4.02 of Brain Scientific Inc.’s (the Company) current report on Form 8-K filed with the U.S Securities and Exchange Commission (“SEC”) on August 18, 2020, on August 12, 2020 the Company, under the authority of its board of directors, following discussion with Sadler, Gibb & Associates, LLC, the Company’s independent registered public accounting firm, concluded that the Company’s previously filed financial statements for the three months ended March 31, 2020, can no longer be relied upon.The Company is filing this Amendment No. 1 (“Form 10-Q/A”) to the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, which was filed with the SEC on May 19, 2020 (the “Original Filing”), to reflect restatements of the Consolidated Balance Sheet at March 31, 2020, the Consolidated Statement of Operations, Consolidated Statement of Changes in Shareholders’ Equity (Deficit), and Consolidated Statement of Cash Flows for the three months ended March 31, 2020, and the related notes thereto.The following sections in the Original Filing are amended and restated in this Form 10-Q/A, solely as a result of, and to reflect, the restatement:Part I - Item 1 - Financial StatementsPart I - Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of OperationsIn addition, pursuant to the rules of the SEC, Part II, Item 6 of the Original Filing has been amended to include the currently-dated certifications from our principal executive officer and principal financial officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. The certifications of the principal executive officer and principal financial officer are included in this Form 10-Q/A as Exhibits 31.1, 31.2, 32.1 and 32.2.For the convenience of the reader, this Form 10-Q/A sets forth the information in the Original Filing in its entirety, as such information is modified and superseded where necessary to reflect the restatement. This Form 10-Q/A should be read in conjunction with our filings with the SEC subsequent to the date of the Original Filing, in each case as those filings may have been, or with respect to the Original Filing will be, superseded or amended.Except as described above, no other changes have been made to the Original Filing. This Form 10-Q/A speaks as of the date of the Original Filing and does not reflect events that may have occurred after the date of the Original Filing, or modify or update any disclosures that may have been affected by subsequent events. true --12-31 Q1 2020 0001662382 true 19383794

27947

261436

6706

5555

371

10329

21637

700

46053

289328

1333

1674

47386

291002

495091

298578

8737

9263

70000

50000

406482

499232

571843

4595

6377

322967

323084

1879715

1186534

1879715

1186534

19384

19381

2772711

2756798

-4623737

-3672077

-687

366

-1832329

-895532

47386

291002

0.001

10000000

0.001

200000000

19383794

19380460

19383794

19380460

133845

2250

104982

28863

2250

96390

22290

123608

111073

40584

47792

11638

22060

208635

201241

480855

404456

-451992

-402206

453616

8053

1290

47219

-123

-499668

-8053

-951660

-410259

-951660

-410259

-1053

-952713

-410259

-0.05

-0.02

19380460

19205624

19380460

19381

2756798

-3672077

366

5914

3334

9999

10002

-1053

-951660

19383794

19384

2772711

-4623737

-687

19205624

19206

2595034

-2668212

-53972

4334

13334

548

561

-410259

19218958

19219

2599916

-3078471

-459336

341

299

431874

3117

47219

5914

4334

10002

561

1151

371

-1782

-1411

-11308

5707

-196513 -17163

-526

-31900

-252319

-423803

1005

-1005

230000

20000

75000

20000

305000

-1170

-233489

-119808

163563

43755

18400

176274

NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Brain Scientific Inc. (the “Company”), was incorporated under the laws of the state of Nevada on November 18, 2013 under the name All Soft Gels Inc. The Company on September 21, 2018 acquired MemoryMD, Inc. (“MemoryMD”), a privately held Delaware corporation formed in February 2015. Upon completion of the acquisition, MemoryMD is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of MemoryMD, the surviving entity and accounting acquirer. MemoryMD is a cloud computing, data analytics and medical device technology company in the NeuroTech and brain monitoring industries seeking to commercialize its EEG devices and caps. The Company is headquartered in New York, New York. Reverse Merger and Corporate Restructure On September 21, 2018, the Company entered into a merger agreement (the “Merger Agreement”) with MemoryMD and AFGG Acquisition Corp. to acquire MemoryMD (the “Acquisition”). The transactions contemplated by the Merger Agreement were consummated on September 21, 2018 and, pursuant to the terms of the Merger Agreement, all outstanding shares of MemoryMD were exchanged for shares of the Company’s common stock. Accordingly, the Company acquired 100% of MemoryMD in exchange for the issuance of shares of the Company’s common stock and MemoryMD became the Company’s wholly owned subsidiary. The Company issued an additional 4,083,252 shares of its common stock upon the automatic conversion at the closing of an aggregate of $1,507,000 principal amount plus accrued interest of outstanding convertible promissory notes issued by MemoryMD, and it further issued an additional 1,604,378 shares of its common stock upon the automatic conversion immediately subsequent to the closing of an aggregate of $640,000 principal amount plus accrued interest of outstanding convertible promissory notes issued by MemoryMD. Furthermore, as of the closing, Mr. Amer Samad, the sole director and executive officer until the consummation of the Acquisition, committed to tender for cancellation 6,495,000 shares of the Company’s common stock as part of the conditions to closing, of which 6,375,000 have been cancelled at December 31, 2018 and 120,000 are expected to be cancelled as soon as practicable. Total shares issued as a result of the Acquisition was 13,421,752. The Acquisition has been accounted for as a reverse recapitalization of Brain Scientific by MemoryMD, but in substance as a capital transaction, rather than a business combination since Brain Scientific had nominal or no operations and assets prior to and as of the closing of the Acquisition. The transaction is deemed a reverse recapitalization and the accounting is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded. For accounting purposes, MemoryMD is treated as the surviving entity and accounting acquirer although Brain Scientific was the legal acquirer. Accordingly, the Company’s historical financial statements are those of MemoryMD. All references to common stock, share and per share amounts have been retroactively restated to reflect the reverse recapitalization as if the transaction had taken place as of the beginning of the earliest period presented. Assignment and Assumption Agreement As of immediately prior to the closing of the Acquisition, the Company entered into an Assignment and Assumption Agreement with Chromium 24 LLC, pursuant to which Chromium 24 LLC assumed all of the Company’s remaining assets and liabilities through the closing of the Acquisition. Accordingly, as of the closing of the Acquisition, Brain Scientific had no assets or liabilities other than the shares of MemoryMD acquired in the Acquisition. Name Change and Increase in Authorized Shares On September 18, 2018, the Company filed an amendment to its certificate of incorporation with the Nevada Secretary of State to change its name to Brain Scientific Inc. On September 18, 2018, FINRA approved of the name change as well as a ticker symbol change, which was effective as of September 19, 2018. In addition, the Company increased its authorized shares of common stock from 50,000,000 to 200,000,000 and created and authorized 10,000,000 shares of undesignated preferred stock. Unaudited Interim Financial Information The Company has prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These consolidated financial statements are unaudited and, in the Company’s opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of its balance sheets, operating results, and cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for 2020. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been omitted in accordance with the rules and regulations of the SEC. These consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes.

1.00

4083252

1507000

1604378

640000

6495000

6375000

120000

13421752

50000000

200000000

10000000

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with GAAP. Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810"). The consolidated financial statements include the accounts of the Company and its subsidiaries, MemoryMD and MemoryMD - Russia. The operations of the newly formed 100% wholly owned subsidiary, MemoryMD – Russia, are included beginning April 1, 2019. All significant consolidated transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and equipment and assumptions used in the valuation of options and warrants. Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At March 31, 2020 and December 31, 2019, the Company had no cash equivalents. The Company’s cash is held with financial institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these financial institutions. As of March 31, 2020 and December 31, 2019, the Company had $0 and $11,436, respectively, in excess over the FDIC insurance limit. Inventory Inventory consists of finished goods that are valued at lower of cost or market using the weighted average method.  As of March 31, 2020 and December 31, 2019, the Company had inventory totaling $371 and $0, respectively. Property, Equipment and Depreciation Property and equipment are recorded at cost, less depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for repair and maintenance are charged to operations as incurred. Property and equipment consisted of computer equipment, with an estimated useful life of three years. Depreciation expense was $341 and $299 for the three months ended March 31, 2020 and 2019, respectively. Convertible Notes Payable The Company has issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be at a discount to the common stock at the time of conversion. For certain notes, the conversion features of these notes are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred. Derivative Instruments The Company evaluates its convertible notes and warrants to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The Company utilizes the Monte Carlo Method that values the liability of the debt conversion feature derivative financial instruments and derivative warrants based on a probability of a down round event. The reason the Company selected the lattice binomial model is that in many cases there may be multiple embedded features or the features of the bifurcated derivatives may be so complex that a Black-Scholes valuation does not consider all of the terms of the instrument. Therefore, the fair value may not be appropriately captured by simple models.  From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled. Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606 Revenue from Contracts with Customers. This guidance requires an entity to recognize revenue by applying the following steps:  (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Once the steps are met, revenue is recognized, generally upon receiving a letter of acceptance from the customer. There has been no material effect on the Company’s financial statements as a result of adopting Topic 606. The Company recognizes revenue from the sale of NeuroCaps, Universal as well as revenue from the sale of goods purchased through manufacturers of medical devices. All revenue for the three months ended March 31, 2020 is from the sale of medical devices purchased from Neurotech, a related party. Research and Development Costs The Company expenses all research and development costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging, and proprietary products and technology. Research and development costs recognized in the statement of operations for the three months ended March 31, 2020 and 2019 were $96,390 and $22,290, respectively. Sales and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs recognized in the statement of operations for the three months ended March 31, 2020 and 2019 were $40,584 and $47,792, respectively. Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. In the three months ended March 31, 2020 2,302,250 anti-dilutive securities were excluded from the computation. Fair Value of Financial Instruments The Company’s financial instruments are measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 1 - Quoted prices in active markets for identical assets or liabilities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs.</td></tr> </table> The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets, convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items. The Company did not have any other Level 1 or Level 2 assets or liabilities as of March 31, 2020 and the Company did not have any other Level 1, Level 2 or Level 3 assets or liabilities as of December 31, 2019. Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of March 31, 2020. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amounts at Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Derivative liability – conversion feature</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">308,641</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">         -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">308,641</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Derivative liability - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">263,202</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">263,202</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">571,843</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">571,843</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of March 31, 2020 and December 31, 2019, the Company had no unrecognized uncertain income tax positions. On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for years beginning after December 31, 2017. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118") was issued and allows a company to recognize provisional amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment. Recent Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “Measurement of Credit Losses on Financial Instruments,” which requires measurement and recognition of expected credit losses at the point a loss is probable to occur, rather than expected to occur, which will generally result in earlier recognition of allowances for credit losses. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted ASU 2016-13 in the first quarter of 2020 and the adoption did not have a material impact on its condensed consolidated financial statements.

Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with GAAP.

Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810"). The consolidated financial statements include the accounts of the Company and its subsidiaries, MemoryMD and MemoryMD - Russia. The operations of the newly formed 100% wholly owned subsidiary, MemoryMD – Russia, are included beginning April 1, 2019. All significant consolidated transactions and balances have been eliminated in consolidation.

1.00

Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and equipment and assumptions used in the valuation of options and warrants.

Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At March 31, 2020 and December 31, 2019, the Company had no cash equivalents. The Company’s cash is held with financial institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these financial institutions. As of March 31, 2020 and December 31, 2019, the Company had $0 and $11,436, respectively, in excess over the FDIC insurance limit.

250000

11436

Inventory Inventory consists of finished goods that are valued at lower of cost or market using the weighted average method.  As of March 31, 2020 and December 31, 2019, the Company had inventory totaling $371 and $0, respectively.

371

Property, Equipment and Depreciation Property and equipment are recorded at cost, less depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for repair and maintenance are charged to operations as incurred. Property and equipment consisted of computer equipment, with an estimated useful life of three years. Depreciation expense was $341 and $299 for the three months ended March 31, 2020 and 2019, respectively.

341

299

Convertible Notes Payable The Company has issued convertible notes, which contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares at a fixed price which may be at a discount to the common stock at the time of conversion. For certain notes, the conversion features of these notes are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred.

Derivative Instruments The Company evaluates its convertible notes and warrants to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The Company utilizes the Monte Carlo Method that values the liability of the debt conversion feature derivative financial instruments and derivative warrants based on a probability of a down round event. The reason the Company selected the lattice binomial model is that in many cases there may be multiple embedded features or the features of the bifurcated derivatives may be so complex that a Black-Scholes valuation does not consider all of the terms of the instrument. Therefore, the fair value may not be appropriately captured by simple models.  From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.

Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606 Revenue from Contracts with Customers. This guidance requires an entity to recognize revenue by applying the following steps:  (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Once the steps are met, revenue is recognized, generally upon receiving a letter of acceptance from the customer. There has been no material effect on the Company’s financial statements as a result of adopting Topic 606. The Company recognizes revenue from the sale of NeuroCaps, Universal as well as revenue from the sale of goods purchased through manufacturers of medical devices. All revenue for the three months ended March 31, 2020 is from the sale of medical devices purchased from Neurotech, a related party.

Research and Development Costs The Company expenses all research and development costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging, and proprietary products and technology. Research and development costs recognized in the statement of operations for the three months ended March 31, 2020 and 2019 were $96,390 and $22,290, respectively.

Sales and Marketing Advertising and marketing costs are expensed as incurred. Advertising and marketing costs recognized in the statement of operations for the three months ended March 31, 2020 and 2019 were $40,584 and $47,792, respectively.

40584

47792

Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.

Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. In the three months ended March 31, 2020 2,302,250 anti-dilutive securities were excluded from the computation.

2302250

Fair Value of Financial Instruments The Company’s financial instruments are measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 1 - Quoted prices in active markets for identical assets or liabilities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs.</td></tr> </table> The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets, convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items. The Company did not have any other Level 1 or Level 2 assets or liabilities as of March 31, 2020 and the Company did not have any other Level 1, Level 2 or Level 3 assets or liabilities as of December 31, 2019. Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of March 31, 2020. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amounts at Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Derivative liability – conversion feature</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">308,641</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">         -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">308,641</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Derivative liability - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">263,202</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">263,202</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">571,843</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">571,843</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of March 31, 2020 and December 31, 2019, the Company had no unrecognized uncertain income tax positions. On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for years beginning after December 31, 2017. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118") was issued and allows a company to recognize provisional amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment.

0.50

0.34

0.21

Recent Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “Measurement of Credit Losses on Financial Instruments,” which requires measurement and recognition of expected credit losses at the point a loss is probable to occur, rather than expected to occur, which will generally result in earlier recognition of allowances for credit losses. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted ASU 2016-13 in the first quarter of 2020 and the adoption did not have a material impact on its condensed consolidated financial statements.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amounts at Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Derivative liability – conversion feature</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">308,641</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">         -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">308,641</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Derivative liability - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">263,202</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">263,202</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">571,843</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">571,843</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

308641 308641

263202

571843

NOTE 3 – GOING CONCERN The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern for a period of one year from the issuance of these financial statements. For the three months ended March 31, 2020, the Company had $133,845 in revenues, a net loss of $951,660 and had net cash used in operations of $252,319. Additionally, as of March 31, 2020, the Company had working capital deficit, stockholders’ deficit and accumulated deficit of $1,833,662, $1,832,329 and $4,623,737 respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of the issuance of these financial statements. The financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications and ultimately achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investments or achieve an adequate sales level. 1833662

NOTE 4 – CONVERTIBLE NOTES PAYABLE In January 2019, the Company commenced an offering of up to $500,000 pursuant to which the Company will issue convertible notes to investors. On January 18, 2019, February 5, 2019 and July 23, 2019, the Company issued three such convertible notes payable to three investors for $100,000, $130,000 and $150,000, respectively. The notes bear interest at a fixed rate of 10% per annum, computed based on a 360-day year and mature on the earlier of one year from the date of issuance or the consummation of an equity or equity-linked round of financing of the Company in excess of $1,000,000 (“Qualified Financing”) or other event pursuant to which conversion shares are to be issued pursuant to the terms of the note. On February 28, 2020, the Company and the holder of the January 18, 2019 convertible note agreed to extend the maturity date of the January 18, 2019 convertible note to January 18, 2021. Also on February 28, 2020, the Company and the holder of the February 5, 2019 convertible note agreed to extend the maturity date of the February 5, 2019 convertible note to February 5, 2021. The notes are convertible into common stock of the Company following events on the following terms: with no action on the part of the note holder upon the consummation of a Qualified Financing, the debt will be converted to new round stock based on the product of the outstanding principal and accrued interest multiplied by 1.35, then divided by the accrual per share price of the new round common stock. If a change of control occurs or if the Company completes a firmly underwritten public offering of its common stock prior to the Qualified Financing the notes would, at the election of the holders of a majority of the outstanding principal of the notes, be either payable on demand as of the closing of such change of control or Initial Public Offering (‘IPO”) or convertible into shares of common stock immediately prior to such change of control transaction or IPO transaction at a price per share equal to the lesser of the per share value of the common stock as determined by the Company’s Board of Directors or the per share consideration to be received by the holders of the common stock in such change of control or IPO transaction. Based on the terms of the conversion, the holders may receive a discount, and the notes are considered to have a contingent beneficial conversion feature. If conversion of the debt occurs, the Company will recognize an expense related to the intrinsic value. The Company recorded $37,541of accrued interest and has a total outstanding principal balance of $380,000 as of March 31, 2020. In the event that the Company consummates a financing prior to the Maturity Date, other than a Qualified Financing, and the economic terms thereof are more favorable to the investors in such financing than the terms of the note, the note shall automatically be amended to reflect such more favorable economic terms. December 31, 2019 Securities Purchase Agreement On December 31, 2019, the Company entered into a Securities Purchase Agreement and issued and sold to a third party (the “Investor”) a Convertible Note in the original principal amount of $275,000 (the “Note”), and a warrant to purchase 100,000 shares of the Company’s common stock (the “Warrant”). The aggregate purchase price received by the Company was $250,000 after an original issue discount of $25,000. A one-time interest charge of 8% was applied on December 31, 2019 and will be payable, along with the Principal, on July 31, 2020 (the “Maturity Date”), as may be extended at the option of the Investor. The unpaid outstanding principal amount and accrued and unpaid interest under the Note shall be convertible into shares of the Company’s common stock at any time at the option of the Investor. The conversion price shall be equal to 80% multiplied by the price per share paid by the investors in the next capital raising transaction consummated by the Company in the amount of $1,000,000 or more (the “Qualified Financing”), subject to adjustments as provided in the Note. In the event the Investor elects to convert the Note prior to a Qualified Financing, the conversion price shall be the effective exercise price per share from time to time pursuant to the Warrant. At any time prior to the Maturity Date, upon 10 business days’ notice to the Investor, the Company shall have the right to pre-pay the entire remaining principal amount of the Note subject to the pre-payment terms contained in the Note. The note is valued at face value and not considered a derivative since the Qualified Financing is at the control of the Company. The Company recorded $9,429 of accrued interest and has a total outstanding principal balance of $275,000 as of March 31, 2020. The Note contains a price-based anti-dilution provision, pursuant to which the conversion price of the Note shall be reduced upon the occurrence of certain dilutive issuances of Company securities as set forth in the Note. The conversion of the Note is also subject to a beneficial ownership limitation of 4.99% of the number of shares of common stock outstanding immediately after giving effect to such conversion. In the event the Company, prior to the Maturity Date, issues any Security (as defined in the Note) with any term more favorable to the holder of such Security or with a term in favor of the holder of such Security that was not similarly provided to the Investor, then at the Investor’s option such term shall become a part of the Note. The Company also agreed to provide piggy-back registration rights to the Investor pursuant to which the Company shall include all shares issuable upon conversion of the Note on the next registration statement the Company files with the Securities and Exchange Commission. The Note contains events of default which, among other things, entitle the Investor to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the Note. Upon the occurrence of any event of default, the outstanding balance shall immediately and automatically increase to 130% of the outstanding balance immediately prior to the event of default, and the conversion price of the Note shall be redefined to equal 65% of the lowest trade accruing during the 10 consecutive Trading Days (as defined in the Note) immediately preceding the applicable Conversion Date (as defined in the Note). Nickolay Kukekov, a director of the Company, and a third party, each has personally guaranteed the repayment of the Note. The Warrant has an exercise price of $1.25 per share (the “Exercise Price”), subject to adjustments as provided in the Warrant, and has a term of five years. The Warrant contains a price-based anti-dilution provision, pursuant to which the exercise price of the Warrant shall be reduced upon the occurrence of certain dilutive issuances of securities as set forth in the Warrant, with a corresponding increase in the number of shares underlying the Warrant if the dilutive event occurs during the first three years of the Warrant, and a cashless exercise provision. The exercise of the Warrant is subject to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. The Company calculated the Warrants at fair value of $130,768 using the Monte Carlo model, which was recognized as a discount to the Note and is being amortized as interest expense over the remaining term of the notes. In the year ended December 31, 2019, the Company recorded a total debt discount of $155,768 related to the above convertible notes. On March 18, 2020, the Company recorded an additional debt discount of $176,274 related to the above convertible notes. Amortization of the debt discount is recorded as interest expense and a total of $83,523 was amortized during the three months ended March 31, 2020. Derivative Accounting for the Convertible Notes Payable The Company evaluated the terms and conditions of the Note under the guidance of ASC 815. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted, and all additional convertible debentures and warrants are included in the value of the derivative liabilities. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion options and warrants and shares to be issued were recorded as derivative liabilities on the issuance date and revalued at each reporting period. Certain of the Company’s embedded conversion features on debt and outstanding warrants are treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to settle these outstanding contracts, or due to other rights connected with these contracts, such as registration rights. In the case of insufficient authorized share capital available to fully settle outstanding contracts, the Company utilizes the issuance date sequencing method to reclassify outstanding contracts as derivative instruments. These instruments do not trade in an active securities market. Derivative Liabilities The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2020: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance on December 31, 2019</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 88%; text-align: justify">Issuances to debt discount</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">176,274</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Issuances to interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">348,350</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Change in fair value of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,916</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrant liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,303</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Balance on March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">571,843</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The fair value of the derivative conversion features and warrant liabilities as of March 31, 2020 were calculated using a Monte-Carlo option model valued with the following assumptions: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 87%; text-align: justify">Dividend yield</td> <td style="width: 1%"> </td> <td style="width: 1%"></td> <td style="width: 10%; text-align: right">0</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">108% - 130.3</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Risk free interest rate</td> <td> </td> <td> </td> <td style="white-space: nowrap; text-align: right">0.21% - 0.51</td> <td>%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Contractual terms (in years)</td> <td> </td> <td> </td> <td style="text-align: right">0.08 – 4.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Conversion/Exercise price</td> <td> </td> <td>$</td> <td style="text-align: right">0.80 - $1.25</td> <td> </td></tr> </table>

500000

100000

130000

150000

The notes bear interest at a fixed rate of 10% per annum, computed based on a 360-day year and mature on the earlier of one year from the date of issuance or the consummation of an equity or equity-linked round of financing of the Company in excess of $1,000,000 (“Qualified Financing”) or other event pursuant to which conversion shares are to be issued pursuant to the terms of the note. 380000 275000

100000

250000

25000 0.08 The unpaid outstanding principal amount and accrued and unpaid interest under the Note shall be convertible into shares of the Company’s common stock at any time at the option of the Investor. The conversion price shall be equal to 80% multiplied by the price per share paid by the investors in the next capital raising transaction consummated by the Company in the amount of $1,000,000 or more (the “Qualified Financing”), subject to adjustments as provided in the Note. In the event the Investor elects to convert the Note prior to a Qualified Financing, the conversion price shall be the effective exercise price per share from time to time pursuant to the Warrant. At any time prior to the Maturity Date, upon 10 business days’ notice to the Investor, the Company shall have the right to pre-pay the entire remaining principal amount of the Note subject to the pre-payment terms contained in the Note. The note is valued at face value and not considered a derivative since the Qualified Financing is at the control of the Company. The Company recorded $9,429 of accrued interest and has a total outstanding principal balance of $275,000 as of March 31, 2020.

0.0499

1.30

0.65

1.25

0.0999

130768

155768

176274

83523

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance on December 31, 2019</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 88%; text-align: justify">Issuances to debt discount</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">176,274</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Issuances to interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">348,350</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Change in fair value of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,916</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrant liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,303</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Balance on March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">571,843</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

176274 348350 39916 7303

571843

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 87%; text-align: justify">Dividend yield</td> <td style="width: 1%"> </td> <td style="width: 1%"></td> <td style="width: 10%; text-align: right">0</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">108% - 130.3</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Risk free interest rate</td> <td> </td> <td> </td> <td style="white-space: nowrap; text-align: right">0.21% - 0.51</td> <td>%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Contractual terms (in years)</td> <td> </td> <td> </td> <td style="text-align: right">0.08 – 4.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Conversion/Exercise price</td> <td> </td> <td>$</td> <td style="text-align: right">0.80 - $1.25</td> <td> </td></tr> </table>

0.00

1.08

1.303

0.0021

0.0051

P29D

P4Y6M

0.80

1.25

NOTE 5 – PROMISSORY NOTES October 23, 2019 Note On October 23, 2019, an investor of the Company subscribed for a promissory note (the “October Note”) and loaned to the Company $50,000. The October Note bears interest at a fixed rate of 14% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date. The principal amount and any accrued and unpaid interest due under the October Note is payable on October 21, 2020. The Company recorded $1,359 of accrued interest and has a total outstanding principal balance of $50,000 as of March 31, 2020. The October Note contains customary events of default, which, if uncured, entitle the lender to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the October Note.  February 21, 2020 Note On February 21, 2020, a third party loaned the Company $20,000, evidenced by a non-convertible promissory note (the “February Note”). The February Note bears interest at a fixed rate of 12% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date. The principal amount and any accrued and unpaid interest due under the February Note is payable on July 1, 2020. The Company recorded $260 of accrued interest and has a total outstanding principal balance of $20,000 as of March 31, 2020. The February Note contains customary events of default, which, if uncured, entitle the lender to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, the February Note. 50000 The October Note bears interest at a fixed rate of 14% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date.

1359

50000 20000 The February Note bears interest at a fixed rate of 12% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date.

260

20000

NOTE 6 – OTHER LIABILITIES In 2016, the Company recorded a liability in connection with the sale of two Electroencephalograms (“EEG”) machines as it provided a guarantee to the customer’s financing company (See Note 2). In June 2017, the customer defaulted on its payments and an additional $19,107 was booked as a liability and recognized as a loss on the sale of the assets for interest and some taxes related to the transaction. As of March 31, 2020 and December 31, 2019, total liability to the financing company reflected in Other Liabilities is $4,595 and $6,377, respectively. Future minimum commitments related to the EEG liability consisted of the following at March 31, 2020: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Years ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount (USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 88%; font-weight: bold">Remainder 2020</td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,595</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,595</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

19107

4595

6377

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Years ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount (USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 88%; font-weight: bold">Remainder 2020</td><td style="padding-bottom: 1.5pt; width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,595</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,595</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

4595

NOTE 7 – RELATED PARTY TRANSACTIONS During the year ended December 31, 2018, an entity controlled by Mr. Vadim Sakharov, former CEO of the Company and current director and executive officer, provided a $50,000 non-interest-bearing, no-term loan to the Company. An additional $5,530 of non-interest bearing no-term proceeds were loaned to the Company during the year ended December 31, 2019. As of March 31, 2020, and December 31, 2019, the balance was $55,530 and $55,530, respectively. During the three months ended March 31, 2020 and 2019, the Company had expenses related to research and development costs of $10,200 and $0, respectively, to an entity controlled by Mr. Sakharov. During the year ended December 31, 2019, an affiliate of Boris Goldstein, the Company’s Chairman of the Board, provided an aggregate total of $50,000, in non-interest-bearing, no-term loans to the Company. As of March 31, 2020 and December 31, 2019, the balance was $50,000 and $50,000, respectively. On September 1, 2018, the Company entered into a sublease agreement with a company controlled by the Company’s Chairman, whereby the Company makes payments to the related party for shared office space. This lease was terminated on March 31, 2019. For the three months ended March 31, 2020 and 2019, the Company has made approximately $0 and $4,900, respectively, in rent payments to the related party. During the year ended December 31, 2019, an affiliate of Nickolay Kukekov, a director of the Company, provided an aggregate total of $217,000 in non-interest-bearing, no-term loans to the Company. As of March 31, 2020 and December 31, 2019, the balance was $217,000 and $217,000, respectively. During the three months ended March 31, 2020 and 2019, the Company purchased an aggregate of $101,613 and $0 of medical devices for resale and distribution from Neurotech, a company that Mr. Sakharov is a shareholder and executive manager.

50000

5530

55530

10200 0

50000

0 4900

217000

101613 0

NOTE 8 – STOCKHOLDERS’ DEFICIT Preferred Stock The Company has authorized 10,000,000 shares of undesignated preferred stock with a $0.001 par value. As of March 31, 2020, no preferred shares have been issued and these shares are considered blank check preferred shares with no terms, limitations, or rights associated with them. Common Stock The Company has authorized 200,000,000 shares of common stock with a $0.001 par value per share. The holders of common stock are entitled to one vote for each share of common stock held at the time of vote. As of March 31, 2020, the Company had 19,383,794 shares outstanding or deemed outstanding. Shares Issued for Services On August 8, 2018, the Company entered into a one-year agreement with an advisor for consulting services, as extended for an additional one-year period. The Company extended this agreement through August 9, 2020. Pursuant to the agreement, as amended, the Company has the right to pay $5,000 or issue the advisor a maximum of 6,667 shares of common stock on a quarterly basis. The Company elected to issue 1,667 shares for the services provided during the three months ended March 31, 2020 at a value of $3.00 per share or $5,001. On August 28, 2018, the Company entered into a one-year agreement with an advisor for consulting services, as extended for an additional one-year period. The Company has extended this agreement through August 28, 2020. Pursuant to the agreement, as amended, the Company has the right to pay $5,000 or issue the advisor a maximum of 6,667 shares of common stock on a quarterly basis. The Company elected to issue 1,667 shares for the services provided during the three months ended March 31, 2020 at a value of $3.00 per share or $5,001. Warrants The following table summarized the warrant activity for the three months ended March 31, 2020: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Balance Outstanding, December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">502,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.57</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.98</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">         -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Balance Outstanding, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">502,250</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.57</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3.73</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Exercisable, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">502,250</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.57</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3.73</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Options On January 14, 2019, the Board of Directors approved the issuance of options to purchase an aggregate of 800,000 and 200,000 shares of common stock to Boris Goldstein and Vadim Sakharov, respectively. The options have an exercise price of $0.75 per share which will vest over a 24-month period as follows: 25% (or 200,000 and 50,000, respectively) shall vest six months after the grant date with the remaining options will vest on a monthly basis at a rate of 1/24th per month. The options will expire on January 14, 2029. The aggregate fair value of $17,111 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life 10 years, (ii) volatility of 77%, (iii) risk free rate of 2.71% (iv) dividend rate of zero, (v) stock price of $0.042, and (vi) exercise price of $0.75. The expense will be amortized over the vesting period and a total of $10,432 was recorded during the year ended December 31, 2019. A total of $1,595 was recorded during the three months ended March 31, 2020. On January 30, 2020, the Board of Directors approved the issuance of options to purchase an aggregate of 800,000 of common stock to Boris Goldstein. The options have an exercise price of $0.75 per share which will vest over a 24-month period on a monthly basis at a rate of 1/24th per month. The options will expire on January 30, 2030. The aggregate fair value of $51,757 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life 10 years, (ii) volatility of 76%, (iii) risk free rate of 1.57% (iv) dividend rate of zero, (v) stock price of $0.12, and (vi) exercise price of $0.75. The expense will be amortized over the vesting period. A total of $4,319 was recorded during the three months ended March 31, 2020. The following table summarized the option activity for the three months ended March 31, 2020: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Balance Outstanding, December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.75</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9.05</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">          -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Balance Outstanding, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,800,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.75</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9.26</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Exercisable, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">818,750</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.75</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8.92</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> For future periods, the remaining value of the stock options totaling approximately $52,523 will be amortized into the statement of operations consistent with the period for which the services will be rendered.

19383794

5000

6667

1667

3.00

5001

6667

1667

3.00

5001

800000

200000

The options have an exercise price of $0.75 per share which will vest over a 24-month period as follows: 25% (or 200,000 and 50,000, respectively) shall vest six months after the grant date with the remaining options will vest on a monthly basis at a rate of 1/24th per month.

0.75

P24M

2029-01-14

17111

P10Y

0.77

0.0271

0.00

0.042

0.75

10432

1595

800000

0.75

2030-01-30

51757

P10Y

0.76

0.0157

0.12

0.75

4319

52523

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Balance Outstanding, December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">502,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.57</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.98</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">         -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Balance Outstanding, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">502,250</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.57</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3.73</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Exercisable, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">502,250</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.57</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3.73</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

502250

0.57

P3Y357D

502250

0.57

P3Y266D 502250 0.57 P3Y266D

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Options</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Term</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Balance Outstanding, December 31, 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.75</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9.05</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">          -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Balance Outstanding, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,800,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.75</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9.26</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Exercisable, March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">818,750</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.75</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8.92</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

1000000

0.75

P9Y18D

800000

0.75

P10Y

1800000

P9Y94D

818750

0.75

P8Y335D

NOTE 9 – COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize most leases on their balance sheets as a right-of-use asset with a corresponding lease liability. Lessor accounting under the standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the standard effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">The option to not reassess prior conclusions related to the identification, classification and accounting for initial direct costs for leases that commenced prior to January 1, 2019.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">The package of practical expedients applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases.</td></tr> </table> As a result of the above, the adoption of ASC 842 did not have a material effect on the consolidated financial statements. The Company will review for the existence of embedded leases in future agreements. The Company has inventoried all leases where the Company is a lessee as of the initial date of application and has examined other contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance. The Company’s lease population comprises lease for corporate office space and a warehouse that are year-to-year basis with monthly rent ranging from approximately $150 to $3,200 and qualify under the practical expedient of short-term leases. The Company does not have exclusive rights of control to any assets in the customer and vendor contracts reviews and does not have any financing leases as of the date of adoption of ASC 842. Beginning January 1, 2020, the Company entered into a 12-month lease agreement ending December 31, 2020, with a third party in Russia. The Company is paying rent at a rate of 17,900 Rubles ($227) per month. Beginning June 1, 2019, the Company entered into a 10-month lease agreement ending March 31, 2020 with a third party in Russia. The Company is paying rent at a rate of 12,000 Rubles ($152) per month. Additionally, the Company also rents a warehouse. Beginning December 1, 2018, the Company entered into a 6-month warehouse rental agreement for $2,980 per month. The lease was renewed on June 1, 2019 for an additional year ending May 31, 2020, for $3,171 per month. Total rent expense for the three months ended March 31, 2020 and 2019 was $11,638 and $22,060 respectively. Equity Incentive Plan As of September 21, 2018, the Company’s board of directors adopted, and stockholders approved the 2018 Equity Incentive Plan (“the 2018 Plan”). The 2018 Plan has a 10-year term, which terminates on the day prior to the 10th anniversary of its adoption by the Board. Under the 2018 Plan, the Company may grant equity-based incentive awards, including options, restricted stock, and other stock-based awards, to any directors, employees, advisers, and consultants that provide services to the Company. The vesting period, term and exercise price will be determined at the time of the grant. An aggregate of up to 3,500,000 of the Company’s common stock are reserved for issuance under the 2018 Plan. As of March 31, 2020 the Company has granted 1,800,000 options and has 1,800,000 options outstanding under the 2018 Plan (see Note 8).

150 3200 17900 -227 12000 -152 2980

The lease was renewed on June 1, 2019 for an additional year ending May 31, 2020, for $3,171 per month.

11638

22060

The 2018 Plan has a 10-year term, which terminates on the day prior to the 10th anniversary of its adoption by the Board.

3500000

1800000

NOTE 10 - RESTATEMENT The Company, while undergoing the review of its consolidated financial statements for the six months ended June 30, 2020, commenced an evaluation of its accounting in connection with the Note (as defined in Note 4) for derivative accounting in accordance with ASC 815. Management originally deemed these agreements to be fixed in nature and a derivative would not need be recognized. On August 12, 2020, under the authority of the board of directors, the Company determined that these agreements and underlying warrants should have been recorded as a derivative with changes in the fair value of the derivate to be recorded in the condensed consolidated statement of operations and comprehensive loss (see Note 4). Accordingly, the Company has restated the condensed consolidated interim financial statements and included the required disclosures for the three months ended March 31, 2020. The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported Condensed Consolidated Balance Sheet at March 31, 2020:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Adjustment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Restated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Convertible notes payable, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">565,781</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(159,299</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">406,482</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Derivative liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">571,843</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">571,843</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467,171</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">412,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,879,715</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467,171</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">412,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,879,715</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated deficit</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,211,193</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(412,544</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,623,737</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total stockholders’ deficit</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,419,785</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(412,544</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,832,329</td><td style="text-align: left">)</td></tr> </table> The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported Condensed Consolidated Statement of Operations and Comprehensive Loss for the three months ended March 31, 2020: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Adjustment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Restated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Interest expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(88,291</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(365,325</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(453,616</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Change in fair market value of derivative liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(47,219</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(47,219</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(539,116</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(412,544</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(951,660</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total comprehensive loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(540,169</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(412,544</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(952,713</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net loss per common share, basic and diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.02</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Adjustment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Restated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Convertible notes payable, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">565,781</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(159,299</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">406,482</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Derivative liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">571,843</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">571,843</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467,171</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">412,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,879,715</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467,171</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">412,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,879,715</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated deficit</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,211,193</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(412,544</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,623,737</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total stockholders’ deficit</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,419,785</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(412,544</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,832,329</td><td style="text-align: left">)</td></tr> </table>

565781

-159299

406482

571843

1467171

412544

1879715

1467171

412544

1879715

-4211193

-412544

-4623737

1419785

-412544

-1832329

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Reported</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Adjustment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As Restated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Interest expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(88,291</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(365,325</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(453,616</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Change in fair market value of derivative liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(47,219</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(47,219</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(539,116</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(412,544</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(951,660</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total comprehensive loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(540,169</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(412,544</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(952,713</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net loss per common share, basic and diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.02</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td></tr> </table>

88291

365325

453616

-47219 -47219

-539116

-412544

-951660

-540169

-412544

-952713

-0.03

-0.02

-0.05

NOTE 11 – SUBSEQUENT EVENTS In accordance with ASC 855 “Subsequent Events,” Company management reviewed all material events through the date this report was issued, and the following subsequent events took place. The Effects of COVID-19 The World Health Organization (WHO) declared the coronavirus outbreak a pandemic on January 30, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside, as well as our employees, suppliers and customers. While the disruption is currently expected to be temporary, there is considerable uncertainty around the duration of the closings and shelter-in-place orders and the ultimate impact of governmental initiatives. However, the financial impact and duration cannot be reasonably estimated at this time. Convertible Grid Notes On April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Caleca Note”) to Thomas J. Caleca (“Caleca”), an existing stockholder of the Company, pursuant to which Caleca agreed to advance to the Company the aggregate principal amount of $125,000 (the “Caleca Aggregate Advance”). The Company also issued to Caleca a common stock purchase warrant (the “Caleca Warrant”), granting Caleca the right to purchase up to 750,000 shares of the Company’s common stock at a per share exercise price of $0.80 (subject to adjustment as set forth in the Caleca Warrant).  Also on April 21, 2020, the Company issued a Convertible Grid Promissory Note (the “Brown Note”, and together with the Caleca Note, the “Grid Notes”) to Andrew Brown (“Brown”, and together with Caleca, the “Grid Investors”), an existing stockholder of the Company, pursuant to which Brown agreed to advance to the Company the aggregate principal amount of $125,000 (the “Brown Aggregate Advance”, and together with the Caleca Aggregate Advance, the “Aggregate Advance”). The Company also issued to Brown a common stock purchase warrant (the “Brown Warrant”, and together with the Caleca Warrant, the “2020 Warrants”), granting Brown the right to purchase up to 750,000 shares of the Company’s common stock at a per share exercise price of $0.80 (subject to adjustment as set forth in the Brown Warrant). The 2020 Warrants are exercisable at any time commencing on the eighteen-month anniversary of the issuance of the 2020 Warrants (as may be accelerated pursuant to the terms of the 2020 Warrants) and expiring on the five-year anniversary of the issuance of the 2020 Warrants.  On April 22, 2020, the Grid Investors each made their first cash advance of $25,000 pursuant to the terms of the Grid Notes, for an aggregate cash advance to the Company of $50,000 (the “First Advance”). The Grid Investors shall make additional cash advances to the Company pursuant to the terms of their Grid Notes. The Grid Notes bear interest on the unpaid balances at a fixed simple rate of twelve percent (12%) per annum (subject to a rate increase if the Company commits an Event of Default (as defined in the Grid Notes)), computed based on a 360-day year of twelve 30-day months, commencing on the date of the respective advance and payable quarterly. The principal amount of the Aggregate Advance, or so much thereof as has been advanced to the Company by the Grid Investors from time to time pursuant to the Grid Notes, will be payable on April 21, 2021 (the “Maturity Date”), unless sooner converted into shares of the Company’s common stock pursuant to the terms of the Grid Notes. The unpaid outstanding principal amount and accrued and unpaid interest under the Grid Notes shall be convertible at any time prior to the Maturity Date at the election of the Grid Investors into such number of shares of the Company’s common stock obtained by dividing the amount so converted by $1.00 (the “Conversion Price”). At the Maturity Date, all of the remaining unpaid outstanding principal amount and accrued and unpaid interest (the “Outstanding Balance”) under the Grid Notes shall automatically convert into such number of shares of the Company’s common stock obtained by dividing the Outstanding Balance by the Conversion Price. The Grid Notes may not be prepaid by the Company in whole or in part without the prior written consent of the respective Grid Investor. The Grid Notes contain customary events of default, which, if uncured, entitle the Grid Investors to accelerate the due date of the unpaid principal amount of, and all accrued and unpaid interest on, their Grid Notes.

an existing stockholder of the Company, pursuant to which Caleca agreed to advance to the Company the aggregate principal amount of $125,000 (the “Caleca Aggregate Advance”). The Company also issued to Caleca a common stock purchase warrant (the “Caleca Warrant”), granting Caleca the right to purchase up to 750,000 shares of the Company’s common stock at a per share exercise price of $0.80 (subject to adjustment as set forth in the Caleca Warrant).

125000

750000

0.80 25000 50000

0.12

EX-101.SCH 7 brsf-20200331.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Stockholders’ Deficit link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Organization and Nature of Operations link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Convertible Notes Payable link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Promissory Notes link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Other Liabilities link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Restatement link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Convertible Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Other Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Restatement (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Organization and Nature of Operations (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Convertible Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Convertible Notes Payable (Details) - Schedule of change in fair value including net transfers link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Convertible Notes Payable (Details) - Schedule of fair value of conversion features and warrant liabilities link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Promissory Notes (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Other Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Other Liabilities (Details) - Schedule of future minimum commitments link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Stockholders' Deficit (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Stockholders' Deficit (Details) - Schedule of warrant activity link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Stockholders' Deficit (Details) - Schedule of option activity link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Restatement (Details) - Schedule of previously reported condensed consolidated balance sheet link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Restatement (Details) - Schedule of previously condensed consolidated statement of operations and comprehensive loss link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 brsf-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 brsf-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 brsf-20200331_lab.xml XBRL LABEL FILE Statement of Financial Position [Abstract] TOTAL CURRENT ASSETS TOTAL ASSETS TOTAL CURRENT LIABILITIES: Current liabilities TOTAL LIABILITIES Total liabilities TOTAL STOCKHOLDERS’ DEFICIT Balance Balance Total stockholders’ deficit Stockholders' deficit TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Income Statement [Abstract] GROSS PROFIT TOTAL SELLING, GENERAL AND ADMINISTRATIVE LOSS FROM OPERATIONS TOTAL OTHER EXPENSE LOSS BEFORE INCOME TAXES NET LOSS Net loss Net Loss TOTAL COMPREHENSIVE LOSS Total comprehensive loss Statement of Stockholders' Equity [Abstract] Balance (in Shares) Balance (in Shares) Equity Components [Axis] Statement of Cash Flows [Abstract] NET CASH USED IN OPERATING ACTIVITIES Net cash used in operation activity NET CASH USED IN INVESTING ACTIVITIES NET CASH PROVIDED BY FINANCING ACTIVITIES NET CHANGE IN CASH CASH AT BEGINNING OF THE PERIOD CASH AT END OF THE PERIOD Cash Accounting Policies [Abstract] Schedule of financial liabilities measured at fair value [Abstract] Fair Value Hierarchy and NAV [Axis] Going Concern [Abstract] Debt Disclosure [Abstract] Schedule of change in fair value including net transfers [Abstract] Balance on December 31, 2019 Balance on March 31, 2020 Schedule of fair value of conversion features and warrant liabilities [Abstract] Statistical Measurement [Axis] Promissory Notes [Abstract] Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract] Schedule of future minimum commitments [Abstract] Total Related Party Transactions [Abstract] Disclosure Text Block Supplement [Abstract] Schedule of warrant activity [Abstract] Warrant outstanding at beginning Warrant outstanding at ending Warrant purchase shares (in Shares) Warrant outstanding at beginning Warrant outstanding at ending Warrant exercise price per share (in Dollars per share) Warrant outstanding at beginning Schedule of option activity [Abstract] Option outstanding at beginning (in Shares) Option outstanding at ending (in Shares) Number of option outstanding (in Shares) Option outstanding at beginning (in Dollars) Award Type [Axis] Commitments and Contingencies Disclosure [Abstract] Restatementof Previously Issued Condensed Consolidated Interim Financial Statements [Abstract] Schedule of previously reported condensed consolidated balance sheet [Abstract] Revision of Prior Period [Axis] Schedule of previously condensed consolidated statement of operations and comprehensive loss [Abstract] Subsequent Events [Abstract] Document Type Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Amendment Description Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Small Business ASSETS CURRENT ASSETS: Accounts receivable Inventory Prepaid expenses and other current assets Prepaid expenses and other current assets - related party Property and equipment, net LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES: Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Notes payable Convertible notes payable, net Derivative liabilities Finance lease - short term Loans payable - related party Commitments and contingencies STOCKHOLDERS’ DEFICIT Preferred stock, $0.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, authorized (in Shares) Preferred stock, shares issued Preferred stock, shares outstanding Common stock, $0.001 par value; 200,000,000 shares authorized, 19,383,794 and 19,380,460 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, authorized (in Shares) Common stock, shares issued Common stock, shares outstanding Additional paid in capital Accumulated deficit Accumulated other comprehensive income REVENUE Revenues COST OF GOODS SOLD SELLING, GENERAL AND ADMINISTRATIVE Research and development Research and development expense Professional fees Sales and marketing expenses Occupancy expenses General and administrative expenses OTHER INCOME (EXPENSE): Other income Foreign currency transaction loss PROVISION FOR INCOME TAXES OTHER COMPREHENSIVE LOSS Foreign currency translation adjustment NET LOSS PER COMMON SHARE Basic and diluted (in Dollars per share) Net loss per common share, basic and diluted (in Dollars per share) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic and diluted (in Shares) Fair value of stock options vested Issuance of common stock for services Value of share issued for services Issuance of common stock for services (in Shares) Number of share issued for services (in Shares) Foreign currency translation adjustment Net loss CASH FLOWS FROM OPERATING ACTIVITIES: Change in net loss to net cash used in operating activities: Depreciation and amortization expense Amortization of debt discount and non-cash interest expense Change in fair value of derivative liabilities Fair value of stock options vested Common stock issued for services Changes in operating assets and liabilities: Other liabilities Accounts payable - related party CASH FLOWS FROM INVESTING ACTIVITIES: CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from convertible notes payable Proceeds from note payable Proceeds from convertible debt Proceeds from related party loans Effect of exchange rate changes on cash Supplemental Disclosure of Cash Flow Information Cash paid for interest Cash paid for taxes Supplemental Disclosure of Non-Cash Investing and Financing Activities Financing fees payable to a related party related to the issuance of convertible debentures Debt discount and derivative liability associated with convertible notes payable Interest expense Interest expense Change in fair market value of derivative liabilities Change in fair market value of derivative liabilities Accounts receivable Inventory Prepaid expenses and other current assets Accounts payable and accrued expenses Purchase of property and equipment Common stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income ORGANIZATION AND NATURE OF OPERATIONS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Schedule of financial liabilities measured at fair value Derivative liability – conversion feature Derivative liability - warrants Warrants fair value Total GOING CONCERN CONVERTIBLE NOTES PAYABLE Schedule of financial liabilities measured at fair value Issuances to debt discount Issuances to interest expense Change in fair value of derivative liabilities Change in fair value of warrant liabilities Schedule of fair value of conversion features and warrant liabilities Dividend yield Dividend rate Expected volatility Volatility rate Risk free interest rate Contractual terms (in years) EX-101.PRE 11 brsf-20200331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2020	May 18, 2020
Document Information Line Items
Entity Registrant Name	BRAIN SCIENTIFIC INC.
Document Type	10-Q/A
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		19,383,794
Amendment Flag	true
Amendment Description	As disclosed in Item 4.02 of Brain Scientific Inc.’s (the Company) current report on Form 8-K filed with the U.S Securities and Exchange Commission (“SEC”) on August 18, 2020, on August 12, 2020 the Company, under the authority of its board of directors, following discussion with Sadler, Gibb & Associates, LLC, the Company’s independent registered public accounting firm, concluded that the Company’s previously filed financial statements for the three months ended March 31, 2020, can no longer be relied upon.The Company is filing this Amendment No. 1 (“Form 10-Q/A”) to the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, which was filed with the SEC on May 19, 2020 (the “Original Filing”), to reflect restatements of the Consolidated Balance Sheet at March 31, 2020, the Consolidated Statement of Operations, Consolidated Statement of Changes in Shareholders’ Equity (Deficit), and Consolidated Statement of Cash Flows for the three months ended March 31, 2020, and the related notes thereto.The following sections in the Original Filing are amended and restated in this Form 10-Q/A, solely as a result of, and to reflect, the restatement:Part I - Item 1 - Financial StatementsPart I - Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of OperationsIn addition, pursuant to the rules of the SEC, Part II, Item 6 of the Original Filing has been amended to include the currently-dated certifications from our principal executive officer and principal financial officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. The certifications of the principal executive officer and principal financial officer are included in this Form 10-Q/A as Exhibits 31.1, 31.2, 32.1 and 32.2.For the convenience of the reader, this Form 10-Q/A sets forth the information in the Original Filing in its entirety, as such information is modified and superseded where necessary to reflect the restatement. This Form 10-Q/A should be read in conjunction with our filings with the SEC subsequent to the date of the Original Filing, in each case as those filings may have been, or with respect to the Original Filing will be, superseded or amended.Except as described above, no other changes have been made to the Original Filing. This Form 10-Q/A speaks as of the date of the Original Filing and does not reflect events that may have occurred after the date of the Original Filing, or modify or update any disclosures that may have been affected by subsequent events.
Entity Central Index Key	0001662382
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	true
Entity File Number	333-209325
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	Yes

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash	$ 27,947	$ 261,436
Accounts receivable	6,706	5,555
Inventory	371
Prepaid expenses and other current assets	10,329	21,637
Prepaid expenses and other current assets - related party	700	700
TOTAL CURRENT ASSETS	46,053	289,328
Property and equipment, net	1,333	1,674
TOTAL ASSETS	47,386	291,002
CURRENT LIABILITIES:
Accounts payable and accrued expenses	495,091	298,578
Accounts payable and accrued expenses - related party	8,737	9,263
Notes payable	70,000	50,000
Convertible notes payable, net	406,482	499,232
Derivative liabilities	571,843
Finance lease - short term	4,595	6,377
Loans payable - related party	322,967	323,084
TOTAL CURRENT LIABILITIES:	1,879,715	1,186,534
TOTAL LIABILITIES	1,879,715	1,186,534
Commitments and contingencies
STOCKHOLDERS’ DEFICIT
Preferred stock, $0.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively
Common stock, $0.001 par value; 200,000,000 shares authorized, 19,383,794 and 19,380,460 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	19,384	19,381
Additional paid in capital	2,772,711	2,756,798
Accumulated deficit	(4,623,737)	(3,672,077)
Accumulated other comprehensive income	(687)	366
TOTAL STOCKHOLDERS’ DEFICIT	(1,832,329)	(895,532)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 47,386	$ 291,002

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	19,383,794	19,380,460
Common stock, shares outstanding	19,383,794	19,380,460

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
REVENUE	$ 133,845	$ 2,250
COST OF GOODS SOLD	104,982
GROSS PROFIT	28,863	2,250
SELLING, GENERAL AND ADMINISTRATIVE
Research and development	96,390	22,290
Professional fees	123,608	111,073
Sales and marketing expenses	40,584	47,792
Occupancy expenses	11,638	22,060
General and administrative expenses	208,635	201,241
TOTAL SELLING, GENERAL AND ADMINISTRATIVE	480,855	404,456
LOSS FROM OPERATIONS	(451,992)	(402,206)
OTHER INCOME (EXPENSE):
Interest expense	(453,616)	(8,053)
Other income	1,290
Change in fair market value of derivative liabilities	(47,219)
Foreign currency transaction loss	(123)
TOTAL OTHER EXPENSE	(499,668)	(8,053)
LOSS BEFORE INCOME TAXES	(951,660)	(410,259)
PROVISION FOR INCOME TAXES
NET LOSS	(951,660)	(410,259)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustment	(1,053)
TOTAL COMPREHENSIVE LOSS	$ (952,713)	$ (410,259)
NET LOSS PER COMMON SHARE
Basic and diluted (in Dollars per share)	$ (0.05)	$ (0.02)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic and diluted (in Shares)	19,380,460	19,205,624

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders’ Deficit - USD ($)	Common stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Balance at Dec. 31, 2018	$ 19,206	$ 2,595,034	$ (2,668,212)		$ (53,972)
Balance (in Shares) at Dec. 31, 2018	19,205,624
Balance at Mar. 31, 2019	$ 19,219	2,599,916	(3,078,471)		(459,336)
Balance (in Shares) at Mar. 31, 2019	19,218,958
Fair value of stock options vested		4,334			4,334
Issuance of common stock for services	$ 13	548			561
Issuance of common stock for services (in Shares)	13,334
Net loss			(410,259)		(410,259)
Balance at Dec. 31, 2019	$ 19,381	2,756,798	(3,672,077)	366	(895,532)
Balance (in Shares) at Dec. 31, 2019	19,380,460
Balance at Mar. 31, 2020	$ 19,384	2,772,711	(4,623,737)	(687)	(1,832,329)
Balance (in Shares) at Mar. 31, 2020	19,383,794
Fair value of stock options vested		5,914			5,914
Issuance of common stock for services	$ 3	9,999			10,002
Issuance of common stock for services (in Shares)	3,334
Foreign currency translation adjustment				$ (1,053)	(1,053)
Net loss			$ (951,660)		$ (951,660)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (951,660)	$ (410,259)
Change in net loss to net cash used in operating activities:
Depreciation and amortization expense	341	299
Amortization of debt discount and non-cash interest expense	431,874	3,117
Change in fair value of derivative liabilities	47,219
Fair value of stock options vested	5,914	4,334
Common stock issued for services	10,002	561
Changes in operating assets and liabilities:
Accounts receivable	(1,151)
Inventory	(371)
Other liabilities	(1,782)	(1,411)
Prepaid expenses and other current assets	11,308	(5,707)
Accounts payable and accrued expenses	196,513	17,163
Accounts payable - related party	(526)	(31,900)
NET CASH USED IN OPERATING ACTIVITIES	(252,319)	(423,803)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1,005)
NET CASH USED IN INVESTING ACTIVITIES		(1,005)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable		230,000
Proceeds from note payable	20,000
Proceeds from related party loans		75,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	20,000	305,000
Effect of exchange rate changes on cash	(1,170)
NET CHANGE IN CASH	(233,489)	(119,808)
CASH AT BEGINNING OF THE PERIOD	261,436	163,563
CASH AT END OF THE PERIOD	27,947	43,755
Supplemental Disclosure of Cash Flow Information
Cash paid for interest
Cash paid for taxes
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Financing fees payable to a related party related to the issuance of convertible debentures		18,400
Debt discount and derivative liability associated with convertible notes payable	$ 176,274

XML 18 R7.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND NATURE OF OPERATIONS

NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS

Reverse Merger and Corporate Restructure

Assignment and Assumption Agreement

Name Change and Increase in Authorized Shares

Unaudited Interim Financial Information

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with GAAP.

Principles of Consolidation

The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810").

Use of Estimates

Cash and Cash Equivalents

Inventory

Property, Equipment and Depreciation

Convertible Notes Payable

Derivative Instruments

Revenue Recognition

Research and Development Costs

Sales and Marketing

Stock-based Compensation

Basic and Diluted Net Loss Per Common Share

Fair Value of Financial Instruments

Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows:

●

Level 1 - Quoted prices in active markets for identical assets or liabilities.

●

Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of March 31, 2020.

Liabilities	Amounts at Fair Value		Level 1		Level 2		Level 3
Derivative liability – conversion feature	$	308,641	$	-	$	-	$	308,641
Derivative liability - warrants		263,202		-		-		263,202
Total	$	571,843	$	-	$	-	$	571,843

Income Taxes

Recent Issued Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Going Concern

3 Months Ended

Mar. 31, 2020

Going Concern [Abstract]

GOING CONCERN

NOTE 3 – GOING CONCERN

XML 21 R10.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

CONVERTIBLE NOTES PAYABLE

NOTE 4 – CONVERTIBLE NOTES PAYABLE

December 31, 2019 Securities Purchase Agreement

Derivative Accounting for the Convertible Notes Payable

Derivative Liabilities

	Amount
Balance on December 31, 2019	$	-
Issuances to debt discount		176,274
Issuances to interest expense		348,350
Change in fair value of derivative liabilities		39,916
Change in fair value of warrant liabilities		7,303
Balance on March 31, 2020	$	571,843

The fair value of the derivative conversion features and warrant liabilities as of March 31, 2020 were calculated using a Monte-Carlo option model valued with the following assumptions:

	March 31, 2020
Dividend yield		0	%
Expected volatility		108% - 130.3	%
Risk free interest rate		0.21% - 0.51	%
Contractual terms (in years)		0.08 – 4.50
Conversion/Exercise price	$	0.80 - $1.25

XML 22 R11.htm IDEA: XBRL DOCUMENT

Promissory Notes

3 Months Ended

Mar. 31, 2020

Promissory Notes [Abstract]

PROMISSORY NOTES

NOTE 5 – PROMISSORY NOTES

October 23, 2019 Note

On October 23, 2019, an investor of the Company subscribed for a promissory note (the “October Note”) and loaned to the Company $50,000.

February 21, 2020 Note

XML 23 R12.htm IDEA: XBRL DOCUMENT

Other Liabilities

3 Months Ended

Mar. 31, 2020

Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]

OTHER LIABILITIES

NOTE 6 – OTHER LIABILITIES

Future minimum commitments related to the EEG liability consisted of the following at March 31, 2020:

Years ended December 31,	Amount (USD)
Remainder 2020		4,595
Total	$	4,595

XML 24 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2020

RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

During the three months ended March 31, 2020 and 2019, the Company had expenses related to research and development costs of $10,200 and $0, respectively, to an entity controlled by Mr. Sakharov.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

3 Months Ended

Mar. 31, 2020

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' DEFICIT

NOTE 8 – STOCKHOLDERS’ DEFICIT

Preferred Stock

Common Stock

Shares Issued for Services

Warrants

The following table summarized the warrant activity for the three months ended March 31, 2020:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Warrants	Shares		Price		Term		Value
Balance Outstanding, December 31, 2019		502,250	$	0.57		3.98	$	-
Granted		-		-		-		-
Forfeited		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Balance Outstanding, March 31, 2020		502,250	$	0.57		3.73	$	-

Exercisable, March 31, 2020		502,250	$	0.57		3.73	$	-

Options

The following table summarized the option activity for the three months ended March 31, 2020:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Options	Shares		Price		Term		Value
Balance Outstanding, December 31, 2019		1,000,000	$	0.75		9.05	$	-
Granted		800,000		0.75		10		-
Forfeited		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Balance Outstanding, March 31, 2020		1,800,000	$	0.75		9.26	$	-

Exercisable, March 31, 2020		818,750	$	0.75		8.92	$	-

XML 26 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 9 – COMMITMENTS AND CONTINGENCIES

Operating Leases

●

The option to not reassess prior conclusions related to the identification, classification and accounting for initial direct costs for leases that commenced prior to January 1, 2019.

●

Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less.

●

The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment.

●

Beginning June 1, 2019, the Company entered into a 10-month lease agreement ending March 31, 2020 with a third party in Russia. The Company is paying rent at a rate of 12,000 Rubles ($152) per month.

Total rent expense for the three months ended March 31, 2020 and 2019 was $11,638 and $22,060 respectively.

Equity Incentive Plan

XML 27 R16.htm IDEA: XBRL DOCUMENT

Restatement

3 Months Ended

Mar. 31, 2020

RESTATEMENT

NOTE 10 - RESTATEMENT

The following table sets forth the effects of the adjustments on affected items within the Company’s previously reported Condensed Consolidated Balance Sheet at March 31, 2020:

	March 31, 2020
	As Reported			Adjustment			As Restated
Convertible notes payable, net	$	565,781		$	(159,299	)	$	406,482
Derivative liabilities	$	-		$	571,843		$	571,843
Current liabilities	$	1,467,171		$	412,544		$	1,879,715
Total liabilities	$	1,467,171		$	412,544		$	1,879,715
Accumulated deficit	$	(4,211,193	)	$	(412,544	)	$	(4,623,737	)
Total stockholders’ deficit	$	1,419,785		$	(412,544	)	$	(1,832,329	)

	March 31, 2020
	As Reported			Adjustment			As Restated
Interest expense	$	(88,291	)	$	(365,325	)	$	(453,616	)
Change in fair market value of derivative liabilities	$	-		$	(47,219	)	$	(47,219	)
Net Loss	$	(539,116	)	$	(412,544	)	$	(951,660	)
Total comprehensive loss	$	(540,169	)	$	(412,544	)	$	(952,713	)
Net loss per common share, basic and diluted	$	(0.03	)	$	(0.02	)	$	(0.05	)

XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2020

SUBSEQUENT EVENTS

NOTE 11 – SUBSEQUENT EVENTS

In accordance with ASC 855 “Subsequent Events,” Company management reviewed all material events through the date this report was issued, and the following subsequent events took place.

The Effects of COVID-19

Convertible Grid Notes

XML 29 R18.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810").

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Inventory

Inventory

Property, Equipment and Depreciation

Property, Equipment and Depreciation

Convertible Notes Payable

Convertible Notes Payable

Derivative Instruments

Derivative Instruments

Revenue Recognition

Revenue Recognition

Research and Development Costs

Research and Development Costs

Sales and Marketing

Sales and Marketing

Stock-based Compensation

Stock-based Compensation

Basic and Diluted Net Loss Per Common Share

Basic and Diluted Net Loss Per Common Share

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair value is determined for assets and liabilities using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows:

●

Level 1 - Quoted prices in active markets for identical assets or liabilities.

●

Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the consolidated balance sheet as of March 31, 2020.

Liabilities	Amounts at Fair Value		Level 1		Level 2		Level 3
Derivative liability – conversion feature	$	308,641	$	-	$	-	$	308,641
Derivative liability - warrants		263,202		-		-		263,202
Total	$	571,843	$	-	$	-	$	571,843

Income Taxes

Income Taxes

Recent Issued Accounting Pronouncements

Recent Issued Accounting Pronouncements

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Schedule of financial liabilities measured at fair value

Liabilities	Amounts at Fair Value		Level 1		Level 2		Level 3
Derivative liability – conversion feature	$	308,641	$	-	$	-	$	308,641
Derivative liability - warrants		263,202		-		-		263,202
Total	$	571,843	$	-	$	-	$	571,843

XML 31 R20.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Tables)

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Schedule of financial liabilities measured at fair value

	Amount
Balance on December 31, 2019	$	-
Issuances to debt discount		176,274
Issuances to interest expense		348,350
Change in fair value of derivative liabilities		39,916
Change in fair value of warrant liabilities		7,303
Balance on March 31, 2020	$	571,843

Schedule of fair value of conversion features and warrant liabilities

	March 31, 2020
Dividend yield		0	%
Expected volatility		108% - 130.3	%
Risk free interest rate		0.21% - 0.51	%
Contractual terms (in years)		0.08 – 4.50
Conversion/Exercise price	$	0.80 - $1.25

XML 32 R21.htm IDEA: XBRL DOCUMENT

Other Liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]

Schedule of future minimum commitments

Years ended December 31,	Amount (USD)
Remainder 2020		4,595
Total	$	4,595

XML 33 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Tables)

3 Months Ended

Mar. 31, 2020

Stockholders' Equity Note [Abstract]

Schedule of warrant activity

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Warrants	Shares		Price		Term		Value
Balance Outstanding, December 31, 2019		502,250	$	0.57		3.98	$	-
Granted		-		-		-		-
Forfeited		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Balance Outstanding, March 31, 2020		502,250	$	0.57		3.73	$	-

Exercisable, March 31, 2020		502,250	$	0.57		3.73	$	-

Schedule of option activity

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Options	Shares		Price		Term		Value
Balance Outstanding, December 31, 2019		1,000,000	$	0.75		9.05	$	-
Granted		800,000		0.75		10		-
Forfeited		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Balance Outstanding, March 31, 2020		1,800,000	$	0.75		9.26	$	-

Exercisable, March 31, 2020		818,750	$	0.75		8.92	$	-

XML 34 R23.htm IDEA: XBRL DOCUMENT

Restatement (Tables)

3 Months Ended

Mar. 31, 2020

Restatementof Previously Issued Condensed Consolidated Interim Financial Statements [Abstract]

Schedule of previously reported condensed consolidated balance sheet

	March 31, 2020
	As Reported			Adjustment			As Restated
Convertible notes payable, net	$	565,781		$	(159,299	)	$	406,482
Derivative liabilities	$	-		$	571,843		$	571,843
Current liabilities	$	1,467,171		$	412,544		$	1,879,715
Total liabilities	$	1,467,171		$	412,544		$	1,879,715
Accumulated deficit	$	(4,211,193	)	$	(412,544	)	$	(4,623,737	)
Total stockholders’ deficit	$	1,419,785		$	(412,544	)	$	(1,832,329	)

Schedule of previously condensed consolidated statement of operations and comprehensive loss

	March 31, 2020
	As Reported			Adjustment			As Restated
Interest expense	$	(88,291	)	$	(365,325	)	$	(453,616	)
Change in fair market value of derivative liabilities	$	-		$	(47,219	)	$	(47,219	)
Net Loss	$	(539,116	)	$	(412,544	)	$	(951,660	)
Total comprehensive loss	$	(540,169	)	$	(412,544	)	$	(952,713	)
Net loss per common share, basic and diluted	$	(0.03	)	$	(0.02	)	$	(0.05	)

XML 35 R24.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations (Details) - USD ($)	Sep. 21, 2018	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Sep. 18, 2018
Organization and Nature of Operations (Textual)
Stock repurchase program, number of shares authorized to be repurchased	6,495,000
Cancellation of common stock, shares (in Dollars)				$ 6,375,000
Stock repurchase program, remaining number of shares authorized to be repurchased				120,000
Business acquisition, equity interest issued or issuable, number of shares	13,421,752
Common stock, shares authorized		200,000,000	200,000,000
Preferred stock, shares authorized		10,000,000	10,000,000		10,000,000
Minimum [Member]
Organization and Nature of Operations (Textual)
Common stock, shares authorized					50,000,000
Maximum [Member]
Organization and Nature of Operations (Textual)
Common stock, shares authorized					200,000,000
Memory MD [Member]
Organization and Nature of Operations (Textual)
Equity method investment, ownership percentage	100.00%
Memory MD [Member] \| Principal and Accrued Interest of Promissory Note Issued by Memory MD [Member] \| Automatic Conversion At Closing [Member]
Organization and Nature of Operations (Textual)
Debt conversion, converted instrument, shares issued	4,083,252
Debt conversion, original debt, amount (in Dollars)	$ 1,507,000
Memory MD [Member] \| Principal and Accrued Interest of Promissory Note Issued by Memory MD [Member] \| Automatic Conversion Immediately Subsequent To Closing [Member]
Organization and Nature of Operations (Textual)
Debt conversion, converted instrument, shares issued	1,604,378
Debt conversion, original debt, amount (in Dollars)	$ 640,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 22, 2017	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Summary of Significant Accounting Policies (Textual)
Basis of Accounting, Policy [Policy Text Block]		*Basis of Presentation* The accompanying consolidated financial statements have been prepared in accordance with GAAP.
Cash, FDIC Insured amount		$ 250,000
Cash uninsured amount		0		$ 11,436
Inventory		371		$ 0
Depreciation expense		341	$ 299
Research and development expense		96,390	22,290
Advertising and marketing costs		$ 40,584	$ 47,792
Anti-dilutive securities excluded from computation (in Shares)		2,302,250
Tax benefit, percentage		50.00%
Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Corporate income tax rate	34.00%
Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Corporate income tax rate	21.00%
Memory MD [Member]
Summary of Significant Accounting Policies (Textual)
Owned subsidiary, percentage		100.00%

XML 37 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value	3 Months Ended
	Mar. 31, 2020 USD ($)
Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value [Line Items]
Derivative liability – conversion feature	$ 308,641
Derivative liability - warrants	263,202
Total	571,843
Fair Value, Inputs, Level 1 [Member]
Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value [Line Items]
Derivative liability – conversion feature
Derivative liability - warrants
Total
Fair Value, Inputs, Level 2 [Member]
Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value [Line Items]
Derivative liability – conversion feature
Derivative liability - warrants
Total
Fair Value, Inputs, Level 3 [Member]
Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value [Line Items]
Derivative liability – conversion feature	308,641
Derivative liability - warrants	263,202
Total	$ 571,843

XML 38 R27.htm IDEA: XBRL DOCUMENT

Going Concern (Details) - USD ($)	3 Months Ended
Going Concern (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Going Concern (Textual)
Revenues	$ 133,845	$ 2,250
Net loss	(951,660)	(410,259)
Net cash used in operation activity	(252,319)	(423,803)
Working capital deficit	1,833,662
Stockholders' deficit	(1,832,329)	$ (459,336)	$ (895,532)	$ (53,972)
Accumulated deficit	$ (4,623,737)		$ (3,672,077)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

+ References + Details

XML 39 R28.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details) - USD ($)			1 Months Ended			3 Months Ended		12 Months Ended
Convertible Notes Payable (Details) - USD ($)	Jul. 23, 2019	Feb. 02, 2019	Mar. 18, 2020	Jan. 31, 2019	Jan. 18, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Convertible Notes Payable (Textual)
Proceeds from convertible debt						$ 20,000
Warrants fair value						263,202
Interest Expense, Debt, Excluding Amortization						$ 83,523
Debt Instrument, Redemption, Period One [Member]
Convertible Notes Payable (Textual)
Convertible notes payable, description						The unpaid outstanding principal amount and accrued and unpaid interest under the Note shall be convertible into shares of the Company’s common stock at any time at the option of the Investor. The conversion price shall be equal to 80% multiplied by the price per share paid by the investors in the next capital raising transaction consummated by the Company in the amount of $1,000,000 or more (the “Qualified Financing”), subject to adjustments as provided in the Note. In the event the Investor elects to convert the Note prior to a Qualified Financing, the conversion price shall be the effective exercise price per share from time to time pursuant to the Warrant. At any time prior to the Maturity Date, upon 10 business days’ notice to the Investor, the Company shall have the right to pre-pay the entire remaining principal amount of the Note subject to the pre-payment terms contained in the Note. The note is valued at face value and not considered a derivative since the Qualified Financing is at the control of the Company. The Company recorded $9,429 of accrued interest and has a total outstanding principal balance of $275,000 as of March 31, 2020.
Convertible Notes Payable [Member] \| Debt Instrument, Redemption, Period One [Member]
Convertible Notes Payable (Textual)
Maximum amount of private offering.				$ 500,000
Proceeds from convertible debt	$ 150,000	$ 130,000			$ 100,000
Convertible notes payable, description				The notes bear interest at a fixed rate of 10% per annum, computed based on a 360-day year and mature on the earlier of one year from the date of issuance or the consummation of an equity or equity-linked round of financing of the Company in excess of $1,000,000 (“Qualified Financing”) or other event pursuant to which conversion shares are to be issued pursuant to the terms of the note.
Principle amount						$ 380,000
Convertible Notes Payable [Member] \| Securities Purchase Agreement [Member]
Convertible Notes Payable (Textual)
Principle amount									$ 275,000
Warrant purchase shares (in Shares)									100,000
Purchase price received									$ 250,000
Original issue discount								$ 25,000
Interest charge in percentage								8.00%
Beneficial ownership percentage									4.99%
Outstanding balance percentage									130.00%
Conversion price redefined									65.00%
Warrant exercise price per share (in Dollars per share)									$ 1.25
Debt discounts			$ 176,274
Convertible Notes Payable [Member] \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]
Convertible Notes Payable (Textual)
Beneficial ownership percentage of warrant									9.99%
Warrants fair value									$ 130,768
Debt discounts									$ 155,768

XML 40 R29.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details) - Schedule of change in fair value including net transfers	3 Months Ended
	Mar. 31, 2020 USD ($)
Schedule of change in fair value including net transfers [Abstract]
Balance on December 31, 2019
Issuances to debt discount	176,274
Issuances to interest expense	348,350
Change in fair value of derivative liabilities	39,916
Change in fair value of warrant liabilities	7,303
Balance on March 31, 2020	$ 571,843

XML 41 R30.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details) - Schedule of fair value of conversion features and warrant liabilities	3 Months Ended
	Mar. 31, 2020 $ / shares
Convertible Notes Payable (Details) - Schedule of fair value of conversion features and warrant liabilities [Line Items]
Dividend yield	0.00%
Minimum [Member]
Convertible Notes Payable (Details) - Schedule of fair value of conversion features and warrant liabilities [Line Items]
Expected volatility	108.00%
Risk free interest rate	0.21%
Contractual terms (in years)	29 days
Conversion/Exercise price (in Dollars per share)	$ 0.80
Maximum [Member]
Convertible Notes Payable (Details) - Schedule of fair value of conversion features and warrant liabilities [Line Items]
Expected volatility	130.30%
Risk free interest rate	0.51%
Contractual terms (in years)	4 years 6 months
Conversion/Exercise price (in Dollars per share)	$ 1.25

XML 42 R31.htm IDEA: XBRL DOCUMENT

Promissory Notes (Details) - USD ($)	3 Months Ended
Promissory Notes (Details) - USD ($)	Mar. 31, 2020	Feb. 21, 2020	Oct. 23, 2019
Promissory Notes (Details) [Line Items]
Loaned amount			$ 50,000
Description of non-convertible promissory note	The October Note bears interest at a fixed rate of 14% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date.
Accrued interest	$ 1,359
Outstanding principal balance	$ 50,000
February 21, 2020 Note [Member]
Promissory Notes (Details) [Line Items]
Loaned amount		$ 20,000
Description of non-convertible promissory note	The February Note bears interest at a fixed rate of 12% per annum, computed based on a 360-day year of twelve 30-day months, which interest will be payable quarterly until the maturity date.
Accrued interest	$ 260
Outstanding principal balance	$ 20,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Other Liabilities (Details)	1 Months Ended	12 Months Ended
Other Liabilities (Details)	Jul. 31, 2017 USD ($)	Dec. 31, 2016	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Other Liabilities (Textual)
Number of machines		2
Gain (Loss) on Sale of Assets and Asset Impairment Charges	$ 19,107
Other liabilities			$ 4,595	$ 6,377

XML 44 R33.htm IDEA: XBRL DOCUMENT

Other Liabilities (Details) - Schedule of future minimum commitments	Mar. 31, 2020 USD ($)
Schedule of future minimum commitments [Abstract]
Remainder 2020	$ 4,595
Total	$ 4,595

XML 45 R34.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	3 Months Ended
Related Party Transactions (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Mr. Sakharov shareholder and executive managerr [Member]
Related Party Transactions (Details) [Line Items]
Expenses related to research and development cost	$ 10,200	$ 0
Medical devices for resale and distribution	101,613	0
Affiliate of Boris Goldstein [Member]
Related Party Transactions (Details) [Line Items]
Loan amount			$ 50,000
Due to related parties	50,000		50,000
Affiliate of Nickolay Kukekov [Member]
Related Party Transactions (Details) [Line Items]
Loan amount			217,000
Due to related parties	217,000		217,000
Chief Executive Officer [Member]
Related Party Transactions (Details) [Line Items]
Loan amount			5,530	$ 50,000
Due to related parties	55,530		$ 55,530
Chairman [Member] \| Shared Office Space [Member]
Related Party Transactions (Details) [Line Items]
Related party transaction, rent payments	$ 0	$ 4,900

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details) - USD ($)			1 Months Ended		3 Months Ended		12 Months Ended
Stockholders' Deficit (Details) - USD ($)	Jan. 14, 2019	Aug. 08, 2018	Jan. 30, 2020	Aug. 28, 2018	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Sep. 18, 2018
Stockholders' Deficit (Textual)
Preferred stock, authorized (in Shares)					10,000,000		10,000,000	10,000,000
Preferred stock, par value (in Dollars per share)					$ 0.001		$ 0.001
Common stock, authorized (in Shares)					200,000,000		200,000,000
Common stock, par value (in Dollars per share)					$ 0.001		$ 0.001
Deemed shares (in Shares)					19,383,794
Value of share issued for services				$ 5,001	$ 10,002	$ 561
Aggregate fair value of options			$ 51,757
Dividend rate					0.00%
Option [Member]
Stockholders' Deficit (Textual)
Option, exercise price (in Dollars per share)					$ 0.75
Remaining stock options will be amortized					$ 52,523
Advisor [Member] \| Four Month Agreement [Member]
Stockholders' Deficit (Textual)
Value of common stock issued				$ 6,667	$ 3.00
Number of share issued for services (in Shares)				1,667
Share price (in Dollars per share)				$ 3
Advisor [Member] \| Issue Price One [Member] \| One Year Agreement [Member]
Stockholders' Deficit (Textual)
Value of common stock issued		$ 5,000
Number of common stock issued (in Shares)		6,667
Number of share issued for services (in Shares)		1,667
Share price (in Dollars per share)					$ 3.00
Value of share issued for services		$ 5,001
Board of Directors Chairman [Member] \| Option [Member]
Stockholders' Deficit (Textual)
Share price (in Dollars per share)	$ 0.042
Number of shares purchase for issuance of options (in Shares)	800,000
Description of options vesting period	The options have an exercise price of $0.75 per share which will vest over a 24-month period as follows: 25% (or 200,000 and 50,000, respectively) shall vest six months after the grant date with the remaining options will vest on a monthly basis at a rate of 1/24th per month.
Option, exercise price (in Dollars per share)	$ 0.75
Vesting period	24 months
Expiration date	Jan. 14, 2029
Aggregate fair value of options	$ 17,111
Expected life (years)	10 years
Volatility rate	77.00%
Risk free interest rate	2.71%
Dividend rate	0.00%
Exercise price (in Dollars per share)	$ 0.75
Stock option expense					$ 1,595		$ 10,432
Mr. Vadim Sakharov [Member]
Stockholders' Deficit (Textual)
Number of common stock issued (in Shares)	200,000
Boris Goldstein [Member] \| Option [Member] \| Employment Agreement [Member]
Stockholders' Deficit (Textual)
Share price (in Dollars per share)			$ 0.12
Number of shares purchase for issuance of options (in Shares)			800,000
Option, exercise price (in Dollars per share)			$ 0.75
Expiration date			Jan. 30, 2030
Volatility rate			76.00%
Risk free interest rate			1.57%
Exercise price (in Dollars per share)			$ 0.75
Stock option expense					$ 4,319
Jesse W. Crowne [Member] \| Option [Member] \| Employment Agreement [Member]
Stockholders' Deficit (Textual)
Expected life (years)			10 years

XML 47 R36.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details) - Schedule of warrant activity - Warrant [Member]	3 Months Ended
	Mar. 31, 2020 USD ($) $ / shares shares
Class of Warrant or Right [Line Items]
Warrant outstanding at beginning \| shares	502,250
Warrant outstanding at beginning \| $ / shares	$ 0.57
Warrant outstanding at beginning	3 years 357 days
Warrant outstanding at beginning \| $
Granted \| $
Forfeited \| shares
Forfeited \| $ / shares
Forfeited \| $
Exercised \| shares
Exercised \| $ / shares
Exercised \| $
Expired \| shares
Expired \| $ / shares
Expired \| $
Warrant outstanding at ending \| shares	502,250
Warrant outstanding at ending \| $ / shares	$ 0.57
Warrant outstanding at ending	3 years 266 days
Warrant exercisable at ending \| shares	502,250
Warrant exercisable at ending \| $ / shares	$ 0.57
Warrant exercisable at ending	3 years 266 days

XML 48 R37.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details) - Schedule of option activity - Options [Member]	3 Months Ended
	Mar. 31, 2020 USD ($) $ / shares shares
Stockholders' Deficit (Details) - Schedule of option activity [Line Items]
Option outstanding at beginning (in Shares) \| shares	1,000,000
Option outstanding at beginning	$ 0.75
Option outstanding at beginning	9 years 18 days
Option outstanding at beginning (in Dollars) \| $
Granted (in Shares) \| shares	800,000
Granted	$ 0.75
Granted	10 years
Granted
Forfeited (in Shares) \| shares
Forfeited
Forfeited (in Dollars) \| $
Exercised (in Shares) \| shares
Exercised
Exercised (in Dollars) \| $
Expired (in Shares) \| shares
Expired
Expired (in Dollars) \| $
Option outstanding at ending (in Shares) \| shares	1,800,000
Option outstanding at ending	$ 0.75
Option outstanding at ending	9 years 94 days
Option exercisable at ending (in Shares) \| shares	818,750
Option exercisable at ending	$ 0.75
Option exercisable at ending	8 years 335 days

XML 49 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)							3 Months Ended
Commitments and Contingencies (Details)	Jan. 02, 2020 USD ($)	Jan. 02, 2020 RUB (₽)	Jun. 01, 2019 USD ($)	Jun. 01, 2019 RUB (₽)	Dec. 01, 2018 USD ($)	Sep. 21, 2018 shares	Mar. 31, 2020 USD ($) shares	Mar. 31, 2019 USD ($)
Commitments And Contingencies (Textual)
Monthly rental expense							$ 150
Short-term leases							3,200
Lessee, Operating Lease, Description					The lease was renewed on June 1, 2019 for an additional year ending May 31, 2020, for $3,171 per month.
Rent expense, monthly rent							$ 11,638	$ 22,060
2018 Equity Incentive Plan [Member]
Commitments And Contingencies (Textual)
Plan term						The 2018 Plan has a 10-year term, which terminates on the day prior to the 10th anniversary of its adoption by the Board.
Number of shares reserved for future issuance (in Shares) \| shares						3,500,000
Number options granted (in Shares) \| shares							1,800,000
Number of option outstanding (in Shares) \| shares							1,800,000
Twelve Month Year Agreement Member \| Third Party Member
Commitments And Contingencies (Textual)
Monthly rental expense	$ (227)	₽ 17,900	$ (152)
10-Month Year Agreement [Member] \| Third Party Member
Commitments And Contingencies (Textual)
Monthly rental expense \| ₽				₽ 12,000
Six Month Warehouse Rental Agreement [Member]
Commitments And Contingencies (Textual)
Monthly rental expense					$ 2,980

XML 50 R39.htm IDEA: XBRL DOCUMENT

Restatement (Details) - Schedule of previously reported condensed consolidated balance sheet	Mar. 31, 2020 USD ($)
As Reported [Member]
Restatement (Details) - Schedule of previously reported condensed consolidated balance sheet [Line Items]
Convertible notes payable, net	$ 565,781
Derivative liabilities
Current liabilities	1,467,171
Total liabilities	1,467,171
Accumulated deficit	(4,211,193)
Total stockholders’ deficit	1,419,785
Adjustment [Member]
Restatement (Details) - Schedule of previously reported condensed consolidated balance sheet [Line Items]
Convertible notes payable, net	(159,299)
Derivative liabilities	571,843
Current liabilities	412,544
Total liabilities	412,544
Accumulated deficit	(412,544)
Total stockholders’ deficit	(412,544)
As Restated [Member]
Restatement (Details) - Schedule of previously reported condensed consolidated balance sheet [Line Items]
Convertible notes payable, net	406,482
Derivative liabilities	571,843
Current liabilities	1,879,715
Total liabilities	1,879,715
Accumulated deficit	(4,623,737)
Total stockholders’ deficit	$ (1,832,329)

XML 51 R40.htm IDEA: XBRL DOCUMENT

Restatement (Details) - Schedule of previously condensed consolidated statement of operations and comprehensive loss	3 Months Ended
	Mar. 31, 2020 USD ($) $ / shares
As Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Interest expense	$ (88,291)
Change in fair market value of derivative liabilities
Net Loss	(539,116)
Total comprehensive loss	$ (540,169)
Net loss per common share, basic and diluted (in Dollars per share) \| $ / shares	$ (0.03)
Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Interest expense	$ (365,325)
Change in fair market value of derivative liabilities	(47,219)
Net Loss	(412,544)
Total comprehensive loss	$ (412,544)
Net loss per common share, basic and diluted (in Dollars per share) \| $ / shares	$ (0.02)
As Restated [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Interest expense	$ (453,616)
Change in fair market value of derivative liabilities	(47,219)
Net Loss	(951,660)
Total comprehensive loss	$ (952,713)
Net loss per common share, basic and diluted (in Dollars per share) \| $ / shares	$ (0.05)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 52 R41.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)	1 Months Ended	3 Months Ended
Subsequent Events (Details) - USD ($)	Apr. 21, 2020	Mar. 31, 2020	Apr. 22, 2020
Subsequent Event [Member] \| Convertible Grid Notes [Member]
Subsequent Events (Textual)
Debt instrument, face amount	$ 125,000
Convertible Grid Notes [Member]
Subsequent Events (Textual)
Interest rate			12.00%
Maturity Date Description		The unpaid outstanding principal amount and accrued and unpaid interest under the Grid Notes shall be convertible at any time prior to the Maturity Date at the election of the Grid Investors into such number of shares of the Company’s common stock obtained by dividing the amount so converted by $1.00 (the “Conversion Price”).
Convertible Grid Notes [Member] \| Subsequent Event [Member]
Subsequent Events (Textual)
Convertible promissory note, description	an existing stockholder of the Company, pursuant to which Caleca agreed to advance to the Company the aggregate principal amount of $125,000 (the “Caleca Aggregate Advance”). The Company also issued to Caleca a common stock purchase warrant (the “Caleca Warrant”), granting Caleca the right to purchase up to 750,000 shares of the Company’s common stock at a per share exercise price of $0.80 (subject to adjustment as set forth in the Caleca Warrant).
Number of common stock issued (in Shares)	750,000
Common stock exercise price (in Dollars per share)	$ 0.80
convertible promissory notes [Member]
Subsequent Events (Textual)
Cash advance			$ 25,000
Grid Investors [Member] \| Subsequent Event [Member]
Subsequent Events (Textual)
Cash advance			$ 50,000

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
&PO=V]R:W-H965TU !X;"]W;W)K M&UL4$L! A0#% @ ,&&PO=V]R:W-H965T&UL4$L! A0#% @ ,&&PO=V]R:W-H965T M&UL4$L! A0# M% @ ,&&PO=V]R:W-H965T&UL4$L! A0#% @ ,&CUX[4$ !]$0 &0 @(% \ >&PO M=V]R:W-H965T&UL4$L! A0#% @ ,&&PO=V]R:W-H965T7!E&UL4$L%!@ Q #$ 3@T #8- 0 $! end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 124 335 1 false 47 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://allsoftgels.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets Sheet http://allsoftgels.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://allsoftgels.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://allsoftgels.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders??? Deficit Sheet http://allsoftgels.com/role/ShareholdersEquityType2or3 Consolidated Statements of Stockholders??? Deficit Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://allsoftgels.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Organization and Nature of Operations Sheet http://allsoftgels.com/role/OrganizationandNatureofOperations Organization and Nature of Operations Notes 7 false false R8.htm 007 - Disclosure - Summary of Significant Accounting Policies Sheet http://allsoftgels.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Going Concern Sheet http://allsoftgels.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 009 - Disclosure - Convertible Notes Payable Notes http://allsoftgels.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 10 false false R11.htm 010 - Disclosure - Promissory Notes Notes http://allsoftgels.com/role/PromissoryNotes Promissory Notes Notes 11 false false R12.htm 011 - Disclosure - Other Liabilities Sheet http://allsoftgels.com/role/OtherLiabilities Other Liabilities Notes 12 false false R13.htm 012 - Disclosure - Related Party Transactions Sheet http://allsoftgels.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 013 - Disclosure - Stockholders' Deficit Sheet http://allsoftgels.com/role/StockholdersDeficit Stockholders' Deficit Notes 14 false false R15.htm 014 - Disclosure - Commitments and Contingencies Sheet http://allsoftgels.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 015 - Disclosure - Restatement Sheet http://allsoftgels.com/role/Restatement Restatement Notes 16 false false R17.htm 016 - Disclosure - Subsequent Events Sheet http://allsoftgels.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 017 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://allsoftgels.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://allsoftgels.com/role/SummaryofSignificantAccountingPolicies 18 false false R19.htm 018 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://allsoftgels.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://allsoftgels.com/role/SummaryofSignificantAccountingPolicies 19 false false R20.htm 019 - Disclosure - Convertible Notes Payable (Tables) Notes http://allsoftgels.com/role/ConvertibleNotesPayableTables Convertible Notes Payable (Tables) Tables http://allsoftgels.com/role/ConvertibleNotesPayable 20 false false R21.htm 020 - Disclosure - Other Liabilities (Tables) Sheet http://allsoftgels.com/role/OtherLiabilitiesTables Other Liabilities (Tables) Tables http://allsoftgels.com/role/OtherLiabilities 21 false false R22.htm 021 - Disclosure - Stockholders' Deficit (Tables) Sheet http://allsoftgels.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://allsoftgels.com/role/StockholdersDeficit 22 false false R23.htm 022 - Disclosure - Restatement (Tables) Sheet http://allsoftgels.com/role/RestatementTables Restatement (Tables) Tables http://allsoftgels.com/role/Restatement 23 false false R24.htm 023 - Disclosure - Organization and Nature of Operations (Details) Sheet http://allsoftgels.com/role/OrganizationandNatureofOperationsDetails Organization and Nature of Operations (Details) Details http://allsoftgels.com/role/OrganizationandNatureofOperations 24 false false R25.htm 024 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://allsoftgels.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://allsoftgels.com/role/SummaryofSignificantAccountingPoliciesTables 25 false false R26.htm 025 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value Sheet http://allsoftgels.com/role/ScheduleoffinancialliabilitiesmeasuredatfairvalueTable Summary of Significant Accounting Policies (Details) - Schedule of financial liabilities measured at fair value Details http://allsoftgels.com/role/SummaryofSignificantAccountingPoliciesTables 26 false false R27.htm 026 - Disclosure - Going Concern (Details) Sheet http://allsoftgels.com/role/GoingConcernDetails Going Concern (Details) Details http://allsoftgels.com/role/GoingConcern 27 false false R28.htm 027 - Disclosure - Convertible Notes Payable (Details) Notes http://allsoftgels.com/role/ConvertibleNotesPayableDetails Convertible Notes Payable (Details) Details http://allsoftgels.com/role/ConvertibleNotesPayableTables 28 false false R29.htm 028 - Disclosure - Convertible Notes Payable (Details) - Schedule of change in fair value including net transfers Notes http://allsoftgels.com/role/ScheduleofchangeinfairvalueincludingnettransfersTable Convertible Notes Payable (Details) - Schedule of change in fair value including net transfers Details http://allsoftgels.com/role/ConvertibleNotesPayableTables 29 false false R30.htm 029 - Disclosure - Convertible Notes Payable (Details) - Schedule of fair value of conversion features and warrant liabilities Notes http://allsoftgels.com/role/ScheduleoffairvalueofconversionfeaturesandwarrantliabilitiesTable Convertible Notes Payable (Details) - Schedule of fair value of conversion features and warrant liabilities Details http://allsoftgels.com/role/ConvertibleNotesPayableTables 30 false false R31.htm 030 - Disclosure - Promissory Notes (Details) Notes http://allsoftgels.com/role/PromissoryNotesDetails Promissory Notes (Details) Details http://allsoftgels.com/role/PromissoryNotes 31 false false R32.htm 031 - Disclosure - Other Liabilities (Details) Sheet http://allsoftgels.com/role/OtherLiabilitiesDetails Other Liabilities (Details) Details http://allsoftgels.com/role/OtherLiabilitiesTables 32 false false R33.htm 032 - Disclosure - Other Liabilities (Details) - Schedule of future minimum commitments Sheet http://allsoftgels.com/role/ScheduleoffutureminimumcommitmentsTable Other Liabilities (Details) - Schedule of future minimum commitments Details http://allsoftgels.com/role/OtherLiabilitiesTables 33 false false R34.htm 033 - Disclosure - Related Party Transactions (Details) Sheet http://allsoftgels.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://allsoftgels.com/role/RelatedPartyTransactions 34 false false R35.htm 034 - Disclosure - Stockholders' Deficit (Details) Sheet http://allsoftgels.com/role/StockholdersDeficitDetails Stockholders' Deficit (Details) Details http://allsoftgels.com/role/StockholdersDeficitTables 35 false false R36.htm 035 - Disclosure - Stockholders' Deficit (Details) - Schedule of warrant activity Sheet http://allsoftgels.com/role/ScheduleofwarrantactivityTable Stockholders' Deficit (Details) - Schedule of warrant activity Details http://allsoftgels.com/role/StockholdersDeficitTables 36 false false R37.htm 036 - Disclosure - Stockholders' Deficit (Details) - Schedule of option activity Sheet http://allsoftgels.com/role/ScheduleofoptionactivityTable Stockholders' Deficit (Details) - Schedule of option activity Details http://allsoftgels.com/role/StockholdersDeficitTables 37 false false R38.htm 037 - Disclosure - Commitments and Contingencies (Details) Sheet http://allsoftgels.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://allsoftgels.com/role/CommitmentsandContingencies 38 false false R39.htm 038 - Disclosure - Restatement (Details) - Schedule of previously reported condensed consolidated balance sheet Sheet http://allsoftgels.com/role/ScheduleofpreviouslyreportedcondensedconsolidatedbalancesheetTable Restatement (Details) - Schedule of previously reported condensed consolidated balance sheet Details http://allsoftgels.com/role/RestatementTables 39 false false R40.htm 039 - Disclosure - Restatement (Details) - Schedule of previously condensed consolidated statement of operations and comprehensive loss Sheet http://allsoftgels.com/role/ScheduleofpreviouslycondensedconsolidatedstatementofoperationsandcomprehensivelossTable Restatement (Details) - Schedule of previously condensed consolidated statement of operations and comprehensive loss Details http://allsoftgels.com/role/RestatementTables 40 false false R41.htm 040 - Disclosure - Subsequent Events (Details) Sheet http://allsoftgels.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://allsoftgels.com/role/SubsequentEvents 41 false false All Reports Book All Reports brsf-20200331.xml brsf-20200331.xsd brsf-20200331_cal.xml brsf-20200331_def.xml brsf-20200331_lab.xml brsf-20200331_pre.xml http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 58 0001213900-20-026881-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-026881-xbrl.zip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
IS%Z7S%^&;:RML@DP7H&TS\U?GP"F\59^\,!IR*,1(U;90K!K=$ ]$8*M- M6-D]U994AA M,S-6I85N>QXI9":L)/:XQ=O&Q5Z&/JI/7EA790. 5_9DUMLK0Y[*_!^/Q3 ^ M&Y_<#:F'H$YDG]"#A!&*)UM[@MW/R@3S VVV8![DKS9:NSK OC@@O$5K-K%E:M"&)1 M54V\3U[0&'Q5B;O$%,OX;@N+B*&NXJY:=WY34ZRZ"B/HQGX8+;CJ#)4-J5[+ ME,/F$F.(!TVR04CE4A?S7^SD1N*;J>!M[6;A.OPD=>Z3@D$YZ%XFR<%!*L MBL;#?WCQ3U,KBN\]\<]__#D+XI_&\.8KRZY/8^O2G8!V]U'<6I^"B>/7^(N: M=0'+'_]D39SPRO5?6?AHG5_^QQ7\/PPYP \?SRY/+-OZAS.9_O1?=["4YD_6 MV:=W1Q]/__?H\O3LHW7T\8WU\>CR\Z<3Z^RM=79^\HF^O\ 17@[46"^G>M3P MI?JX$9A_LA!'^X[G7L%7&,+KCN^3A;P.'=>W+H8NL%QW[ XM8!@'U@_QM3#6 M-/P)KT8=_S[Y:O33CS7>HULGLES@,B$F.'*)HY$(+1S!]9V)L(X\S[H(QK'U3G@10W8)OTE@<(@+ M,8UY#(*E8=- /NA;>R'HC M8"'8)DDM$N^AQT$X@?$!>6_%()PYX3W.W#ZP/D_A5VL/V.[4$_2HQ #!%%$@ M5$W#9;F1%8,.@8@#1!*F9N$-Z/W^E85[$M];C@^_L1,2OY5K"RW'BZ^#V=4U MO:60BS4S06PHY0E( _4$*!8XU](+9R$*LS?"YFC5R8@<&<+S[V!U& M-!0@G. :";PT!L(>7ON!%US=TWNX>M@.!.2CF(7!)?Q,KPV(QJV]20"<*<"P M4'AN-$,-#XY1),17_"H.<)0)QJG#8?E+6"XL]N3DG9R-(1@ZTRA-A #\M7!& M?P(%H+Y %($G\_<@_%K3GPZ>])!K;H4?7/R +7'"2,B==^IP%L(K$29_PV*3 M/X[5X4Z^(@5Y-D2>3$MS-2=[>IYV9O(%Q1)2%(_T29NUY_JP[PY0%B[?YX",(.M(/9%B&M8MR,.$H)%2CMZ^>V<=)4?>0B0>()7)$Y \3G-9>^9L MQHNIB9CVXJ3@I)2"P&N(A0SN:9E98*U;0>S+CV:3"3T8%.$( :]9TUF($1LQ MLU0 &$<$=$TT+\\.#SP3.'5@1-!RX*S)(1@$(>VC$?)/XZE2;C2D0%:")$(U MK9R+)3S?KM>_3TT-1U)-3//B6ZX,2\$'EX"#H: =UL,/Q!"E5>F[M]>!![(D MN/4!N&@VB-R1"_(BRT>H49KC6XZ.EK5:M7JO66NT&P:(R)98OB! #,X,90[) MF%D,IP<8)FXV'G&D/">FWX##1K@W, ;.<@6[=R5E\G=VK5WOUNKU.LH^8/E3 M%!P3Y-G6U)M%*'["&3$W-HH 'C-W/%AH@W"&,$$U@/8L7S4#-7B@#H3@8$H M=&-K/ OQ!KMX_7:M4V_5FMU>PGC6080[00G"DAWW0?PYP\,A27P>?CJM^ASL M[.70LQYR#JRWC!7X4]10+Y"D*4$$]0'%.3 MZ\*9.*,:GU24P ',,()3, 1! M1R@6=V(X0RT>Q@#]#EY!0>SQ<(HA&%K*D:FE(&[=&/D%XDB0=H8':(@GQ^.* M%5:GUNJW"3M\3"L?)GF4(FL*LE,O,?!Y^R.2R&K!\.OMM0L"O0/DP+-=.["H M@1"^ @?))P9M;2@UPKVFP=.3@1=AM$3'B@$H&H(#2E/ U#).;]=H9P2&:N,@K '8_L(+$/"2UF0-TX-@B MVP_D=YGC5+![S)OY6"7@HK(W0I$WFH<>G(/U?:WTPGN1.W$])V1F V3*A(,_ MCH$A&..ES 006R"EZ7##.["^JR 8W;H>+3=@QND#CJ^(MT*SZBJ1*9/"V4,1A@.1W@U(+A8LC&1=,X*&/''%7 M3HS KIBZ33K&0X& A;J&P=#.*'GHEB;DO<;CI.(4(,> M;9M94*JQH;=OF[5RQ,J,H9IH;F7R*-JC(AE=9-:P5>-; M%?#!ILOQ-6HELXG5:%GOWQ\;1@ ,Q()7/X)^%GH*^$=4:P]C*D3&/*:=X1HIFR]^JE8D-!0S@VH0E2 02,<&\):,-#30? MN&+9=Z?.*G) T-*9_=1>22O,#;O!@]>? H=2PGSLVXP]'(*0E? M%3M- 802:-^>?OQT9#E34/UOT/8>)RY..3H0\BUHH*PH@=;Y%27"_600>/*) MFCR%*$T%72RB2L_T;SI!]^P^SWH 0&E3*HTP5Y+ B!;E)$20T'I*0R<%I4W: M,VG0@(%&/?F3_&)*FL:RK!FGO"!C]"\T_+9=V: M,H'G!%BI.['>:JWCU$>?+Y'.UAT3TY-P3<:+ *-*)(HH_23ER![:6!@^/B(+ M,/#<$6U#H;O7% 2D:=?D7H>B0K@HU(UTYM*_BW)LPLE%0G9*<@J M/#,NW>H+$F].4OVD1M.Z%"R("_>1*A X6#LYEXUGE>\^G#D>\ \P3:,(&0RN MS['&CALJ94J;5B!4X+V!XY'E%%T+@5/JKFO2<(AJTA\=75MC+[B-M&.+=;3( M4-*LL^S+Y0\3PA +?A!K>%T/F0;ZWJ4C0>J!'.L5R%41OLN&;3@B M-!*K-^T?]N,@*5]QKUD/'8AH;/&[N,#//A$-8H.D092^/GIW='2>IMI$:P^D MVZ0 BL6'Z.1X 7VGS!_3VG,4EOZ8^<.TC%-'H/B42*M.[<=G;K8S\:=WHNPB&2_I5Q:0S\1F2C23CBI6&#H*-R:TH3R^?I-UX< MV@?FW7YE"')!!W@=?JQ]A_*R&^/S\.(#!S'K_QAA"84U(YI<-*11ETNX#,I6 M\^5(>2Z3R8_B8U9OY2/GR@N)6>3L>E31*F?C<^U?Q%MY!N_U?3G*J$!%J]YK M-MI&-MMRJ\]GU9MOGX7N%;IH\-LC,G#G1G%L,:XP#*-=[Z:B.!>N]? AZ:JY M#JY.$Z/S0KO#+X.')C:[4V\UN[UUB&V#U/;,, @DV&G5UZ) BG?Z)(#3@GH6 M8=[(5>A,4@VCHL0TO Q>B^3A11VLFJTTK\YM?J?53T=!KP6-D?EW;-Q)G(V- M C@\Q!HAE9VFC(VO,D])<9K< C\IG\AF\#YO"7SH,F'SFX$JR_A?2P>^X1!A M":P(7A[BLY#* F#H6&HB_G41C;5+CVQ!*;]6P^Z:DFTS(.8:+::IP/"L+%@+ M5VZR>YKG /HGLTD)ZT0Z3._CG*ESH<>K0]G-0NGNDVV)CRQD0Y/O/C\ MXGQTGYY<\,H?R\4Q MSR^#70O)0#HWK.6M],*DS*@R^RUEP"56HV&\&I%8&?L1SQ5D2P%=,HJ*/'292"ICDA2GXREJY-/2 M;J3D=O-H&KH88X3^\OX!11M'"6M/(R85[CWIHC,/L/!<#$:(L]ZJ+;P7 M^LSWY2?P($8$;M_-#](%,T3M&BVDSKT"']OG@XL#8I16*.BN+H*I?>=*J+NA MB?-56$*M786*R,M1Z=)T. 6-79WH>$;OZ$13OG&5241IWB'BEZ8WDVY42$V@ MJ]CB2U 9IC>2=U7XN6C!-1U@DH,*[X(BD0.;_;E#\B>.7%A^R'<_'%VAT75@&1J0@<4LGYA%8CSS8(UC6M!4UB=@ MR'1AA"SN9U'B@67V+'<_F":G[U;60-FV4X4Y; 0@?3"RV;;R>"G&3?<96+R3 MKCJNW:MK8+2>"] CGXM5[RJ^;7"U%S62;G78'>ES ABO "Z9P(.A;! ZX^O M^9(= [M4P!T,)!+L W&%BC$PVN+8_8:?*V8C^7KIZ\RY4U^;KQM06TF[I'P M%W%6">'.U F1D\%(\8S(O):-([.TO)DX(/&06S"$&",F;_K>BA'>90#>I@&8 MMM:I#_R'V.*Q<>_]P]LWI\<_PD:J'U%JQ0< @"IU(R4F,B\=4XXO6;,I[N!W MC;8,AT4.H9=@@)^.;<8;2;Q/0G8$2@%,B5=Q0&)!%!'? %D^O$[T"LXKDC<7 MD2B> HF&XS+FT$TYU7S'3WYGV[56LU-#[C<5,LR*[@@!!,0LT&QP(Y.2" 59 MM&T9!U(E]NZMK6,Y"6CR C620MV-KH$B,+11BE[0N4/F_AS3ZP6WL 4D13&X M.L1IOV).;J2DVJT KD6R$#8++Y0F=.5SD-A12U/+GDDNKH8]QE!@G/:[9M=F M&JJGR><)XQ=4#:":=9(2L&;IX:VCB_,2Q2!, EB1"#AR(8IK+$E&QI(.4@M$ M%LN)9.@MTB02@0Z/1+(/NZ?H(SG;2HT9)6K+31+&SBH;Q?A0Z;V1&Y-BA_?H M5)F/@^W1>1H+GV.>0XKN":_8J#0#DTE5PMZ/H'R5+%Z>$(X6DHL)D]]K!H\$ M^5L _%@D,OA>.&&4P9%4#2F@Z+MF2U)RH]_7L0$I^8VQ_Z/LX>%P8#XQCW@ MEM?*C/0+2E6V9*[RUAV%K-24J09F_@A=S5/T(T>$H6&!814W8&]3_K61\#(6 M=$4?8?28"(64Y&9FBI'0HB)5S#P6G49# 1(2# XOU9E9*N,#32;@YG<4T(7Y MF0R?C RA7T.@KIS)X%E9:@;$+^T-ZL])-_@ET,8"'''FF\*2,F8M\$1FSK#&>91%/@DF"W M7YL58S-KR(W,P"1*P2 )X$I=B/P *&!('=(A^6H!"5QH0$2&Q,104N5?N)?B M";2FT7X<[$O]23AP0%.A9N1^H-A1FH7(N0B,\IF29#05.>N7O2BM?,.90V:^ M*2A5C@M6,:&-8[$ET^P-!D"_<9,QBJ*#+3%QXVI:YU.>_(T0,6)P7PU(5=ID M,@>Y9J19YC-:'_"*RCIV0B^P M.$9*;AZLC!8E4WMMDDFV''6/*0/K+:KX[%%X*!FHX\ M6K"/P:UOA7!$1DR1ZA Y49"*Y80CZA4-2PTQN(0>-2&3"J'?2 MO6B]]ISAU_V+(4@<>"SQ=8T"P?:R\LNH! MUL%+)V EZ"2VA&%/2:.:\(A X M)$IBC$,'"N2 MG9,+P$<^-$.%"XR.N%BCR^\^)7HI%CB2+-R5J91 XVD7B&0#^J2@LH4F<\*F:\8('LZ;!6*6"I* #*@RN?H$ES5!*< M+$6BC!@QWL'L?MFX2>IGY$TBDI&YAT92,>'CBM,:0Q06L"AZOF!SX71(=CZ4 M&2,(+F_*UBEVG]CQ;WUBS&REI7_F6[\X/A7+*2S+X8P""L#>P_-R&4S=H=6I M=RRU-+J,.$Z(AS+78 [0#4(JRP+D?C5S6>O2-S]H'W/^*M,OTXVZ*$&^!QR1 M*JLSTPP\+[CE5(D]L,"GT2O#B?2#_:,%+!GS?NZU'8#@2%^X-93PP*.-S*.@ MV%#D.U6=& "*I)HCU2 U$KS9_-'08"7/-](WR;R"QUH_HF0(*+NI\!E<,>EX MQ5/G9T9^^$/[QP(TH;F)-YSS1HLL;)X3H?9S8)WAKZS> 0[)# ,V4M,#2D60 M#W'-",,G"RVDIBF436%Y<. XN0FU 0K2IZGEW930.)<",$EM]_&F#[-(0/IS MUI05S,G^*(Z-3Z?Y$XGJA$Q-H]NCX&FD1AK5&E%V>I$=M4EDHLK>A$7,Q@[5! I)0*7K-45\Q6[MZ8$K.YJ 5G)0 M9 8WX*%':758(:I&V\?E<;#0Q-9YISZ!2*3ELJ/V1G@!^P"/@VC;+7-UO^Q0 MPKNQCI&Q#O+:1E(6WZMH#.G__%3VEKQ-CG@2Y7#EL I?&-DMKK]_'AW^!TC_DN :_9@/DK^4[I2"YY]]FS2\DYZ/7GY$W'4Q?9041NKF T M&^(@YI,X09(:2C56N- #6A"(=..,:>FA8)=USX8@A(0LD4&6NRY=5M/$K!+R MRE:=9$;/4$D:AXXNV47N0YK(G3A7-"J^S78!I\"JM;&]JRNMS=DPWN6T8I8R M[S/6/>*C,@=0CF96P;[K=VK-OKS!:S1JC?[C7L$L?<8O')7P]8$\+X#RK3O8 M1R/RJ]%]B?86Q1S&&,D[87G@1YQ[GYSB1>]6IXHE;A^,^P=)%JUZK=UK,5FT MNK5NO['E9(&.[WUV?IC=![>.-DRF/Q$.1S5Q_J+6-H9FFT:^/NBU)?%P*>A/=A M&N86U3$>1FE*%FUWAZN1M*4;TT-+W MT_A#5S5IT>PN"F:AO+IA8\.0:VA4&3%=6$F-ZG:P7]:GA J"<3;X0]8R4/=7 MD4I^U5\H58 +2R$;0D\615^0&&0;4J<>FR#=!)BHPZY+15H4TA1.]-4NH:,F M[[\H$D[*PC]X/(U^'E@2EW8V#\2U<^,&X4,''2T*CQ^R_NAZ=.V-%V-P!X<*2M=/R_O-',G.:$Q=\^[U:,!B==D&&7>0N!>'(4GIW#QTV\3Y46RQF[!U:IOV!:K.8U:LPX:;KN> MAM!<[YZJK5J^XB=D3F]1*OVJI))93^597#^7N8A,E[V"]35U- MC@2 GM3VD^Y!G.O6J!8HW!M%0!&(\M0,,#ZV("6[$QV-&!YNWC!+/0>O8JE5 M9%)A1TE6VBP.T])Z1]U3MF@XI M,XN/W=W1]]&/"RD(W^EI+T!W*MC1)@# ^P$5H0%E+W+)/:^AD*4^JW!P; M860_I'(FI.K)''$?OL)SQ(-$JPFV9AQF!J7I"4(%;4?<3!-O[6'_]"+H]2+96OS]V)JYW_VK1^NG9"*Q*1E<.N$9[.&;P\$DM+1; NM X?QB8WZ./ MS+*M?>L_\)6*CHLX2(A$.;,/5AZTBE!RQA(]9JA5,D[ MJ7R\:K$PXY -?=.GXKI27D=8GPH;%T;!0QF3A)=2^EI/E5C'VRKW3XY>=&)2 MOTT@9WDD2%O#R?A4*31TQ&5@5=B34V@#TE6DJSA?LR;#)#.#&:HHQUT-27E/ M@!MJA!D@8ICQ!(>*%'[1EXE>!C/ +[&>#JQ_!;=8$#P7!9@&"'FG(HUBNQ:C M!G408D0AN#D.)Q%8D<J>2]LN[+,?RIZ6*KP6G65 TC5.=7>-E&T*32111)=L?(W-QZA6E!"B MLR>GG-M2@T6"V:C^9,\5AQ_2L!'?:=]1XE"*2/@ANJ2[!GZP3]YRW]%)#CK! MPHW%9'MR;8%-<+X&Q6Y2@SA"'Y/XGFUI453YC(0M^2BLLQU=Y0H5^^-Q= "/R@?&$5S?])5<:F$SY:X]Y*5F'N1>.^D MPPY6(X683\Y@M90!52-BD3F!>>E>>R!0*AF5'XQK/;.22#K=HHCDRC=_,SK@ M@!QT^QACXDPCT!;4IY32Q_I$%=POK1X.@C@.)N9K90H3J31\@X*O>:.?+ D] MC_&*;WXM^Z -4!*2#;4GV=N,0%H\B\2OGH8F6*2BII8!2(6M\.44C1)=/#.M M2;5#ZN:PS(*/Y"4$T&]R&!L[9>2U)E=2J6I@^2R:^=A3LO#[)3E4X1CS0/^N$AS]S!@A[E\R M2+/>JW5:"YA4)7"JGJ;GA1\#M U_VM].G#\]RG>(>;JSN@J_KN:RS0*S4(86 M9H7=)-O>$B-WA=8?71V8'VW4#3%.J#[)J M*A68NG3NMK02NJZ0H6YYN[;"]&715BHNWDC_5)DMLF@>OHS78UQKAJH(QJ$[ MF/%-%R;L41UR_DT%DG66QPGS!ZX9&JBC!-7#T/;QN MH$F9/?0& @[+=^6TL"Y*)"M&#&>J9B.4]84C[YWP'2Y>!>^%5.].Y[1A.V\L M4D(7\\Z=C%RAK9%Q!E3CTXQHQTIV2>EN3)1)$*E2>=78'/R/425X:1GJ$C<4 MLI NG#&JL.U4M"NI_J;6H^O3I3.!98Z3+,HE0X$XO@+P8:0#'!DULK#NR2U1 M<*J@W-ARN:!;$ H@_:_"N]_'B,1]JN.(,^Q1& N5P.>J<4;S\J*UW;KPNZR< M%0K'4Y!+^I5Y/ML3!"%CV6D]NA:.[$RRIP_YOETG1H#UMXGV9KX*OL*U4_5P MKK%]R;G:U.R$:R5P@2I$6^I1SMW"*@MC5VY@F)0B(A3#X\02!L(78S?6E6\* MZZX,J :!3*SC?KGQ;;"/U60X<@4KT5##@V022CTW Z$N:?0PBJD*#59Q#KP; M%:F0K/[V6LC@59%:5#DI<05(V B'$AMD!IRC8ZN,2"]<*(>D88CJ!+8WEGA% M("*!Q:DRX)EQ1"J ;J(*IPY,?GJ K-G8!$Y'P<@"2JDI/@; Y[#*J>SUNV?& M/7!86GA%Q5]Y2KES)-)**QAW.(C!G& M0 !5:[+0Y2ZS5*!62"LNH@*9\1D*3]Q0-.3<%1%G20HMZ9J[4EA,@?UYQ$[- M@A^IS4XO6)?&7*317LYF#WB3G?F9\LJM&@175Y45,XW9AM"YCP MQ)4;>;HN =:CP?14#XE*,?Q )<;A<3I6>7F_!(,(VZ.D.SA='O]RE&[\C$6T ME?3F2%0=3DBSW+B1++5'G6D,/"(XGG/+E($#&]&P7/BN)B4Z@#F3%;6&LIF# M,$>BORESK]GZ'A?4L+\GOLF:0=+VR!GCL4W1 H&!N,.R7448O:"*.4FW.^OU MS/.PP(?U,3BP;+N7QM#%T6O\DO>)T2,K67,V'4DHQY*=TM)UV0@6XOQX58MY M,%*9HPPZ-T[*8U($'J=28XQI+E*B$V4C MU?R!RXLZG(4,Y.]Q'6BLD(F(CU-E>Y56FU9Z:&,E+J0P4^4BLRR>&VL$/BMR MO(^6XHRJ1H-6B)XPF_>3P& %2S;J-"CB/ S\ 'G%=F;T%I01]6'<5$]X"_J8/P]NCB=9I5Z 03K52ALDU1A<'(%4;1YU11 MQ(@K[DAE ,T4+C+,RCE:+*PC?_:I.0)-<8O9^!B,. -%9Y3F]?H02=F73)M( MUI"V&AB81 *W+91M[U+9,_=82UI#0H*-PV.3\GMJV$KE][3DI2)0#%A0G[-7-H+:!4JS5C3*-&D#(# MM.$IS6?9!4@K7:[/O3X<-K;=2):$9G\ U=6OH;33V6:F)2M_9HB($)/"DK*( M(]>+!:H/LY!IHY*9-*D*)HPLI9%M))959! ^OC2&\P:XFB]T$TJQVTH32Z01 M:8+N1->0X#X?I,8&U TIF2&M4:KRJ;#U:K<3[1>-H#]G3AAS[9%4;+LZ1IG@ M]N3T(BJ2$RS+\(^X%-C"!I+%A]-H15VIGVZN33 %E)^-,Z_<\[_;U8972\]O MK(_MYMK8&OVY*VUKOK>UT6OSR4E@UT#7;*"[ZZ"[ZZ"[V0ZZ9E_Y\G-_R"QB M$$;C5V>XX N]WG,1HFZ+#@+=3GX*.DNVF7R_C%E\4?CZ0 +=[#+?>'%H'V!_ M^?D3'Z;XU^=(G(UU,]YGP+&^F?[!EK5K(;QK(9QA*^GC>&AE=4]L[WODC_ _ M1I/?YZ=W?'O]BG?MBG?MBFGL7;OB!>V*#26J"C<[S#% '/^4L4(K+J$Z1D*$W! V*$ZJDQSA\]Y /"IS[Z[&1 RLV?&+18!2TS>E)/# M7N,.9R:W;=C5Q0"8\^MNRL]/ZGP;/:I5<-,WT*8ZH;PRJLKZ6_1S6&AZY3,' MH!5,#4.N.MW\4U8OF\R<2C5D/O?0'^F/="/M)S]G\QU(WW+C[UW?[^?6]SLY M:57/4U["IN"><^C+SUZ&V[0,;F,.GN4V52=N&1/;?3UQCN\ =JM./'AZ-K-K MKQZI8[9KL/ZL&JR;ARQWD(KXBV[2^_P.W3?8QWW7Q7W7Q7W7Q7W7Q7W7Q7W7 MQ7W7Q7W7Q?V1N[B;VF.98GB8UB!E8W*CY?KS4R1W?>-W?>-W?>-W?>-W?>.K M]XU/1,5""9!U\:GVV4?^R.CU?L(&$;_[+(3&-]ZS7ETZ[-K66[NV]4_1MMYD M,0LY1D8M-;JQTWE\?DKIA>-)HO^@.LEO'5-9U/->%=GP50/NU/W?HK>K$^02 M]W;&S9VDR%:]UNZUF");W5JWWZA D0OH*WV?KC<0Z-=X4=+O)N[U6G580@+= M_ DW!5S5N[]6%W"Z&G#4K_LUJB;'1I?Y,S+NX?53'R/)89?P9C5Z-JK#A=&6 MWES7UIUO4VF0*8V1F<_XE^!P [4 #L%CPE%MH"-CL5/G7EH&*?>(CD0@PS-R MR6<3HFZJHZM3GE_IY\SX'67^'J7.&\VSTKT&7!:!@CP*VT3(-K# R M*P6]B6["!:/<*]#!J!L\#<+Y64JV\F& M3H3^ ",&'50KF%.Z QRCZ7LT&_PA\T75C3*G<4;&%TJ-K%F#69)F31& 39Q45 NA0[8VYLA]J4?]P>-I])M]VI.;F8&X M=F[<("R.G5^!;>6"&T^D*_!@^ MK.:QQO ,=5]");R,>WFZ74GY_LT%D#56L A6?&6R8.)L2VJL\'4^5MR3SC7D MLC#JOAJ-8N65]XQYW4 ?LI&DD2DE6C!%J/0E)7=5ZOR4TZP%U[K2C6+UU?AB MG;E1:];!4FO7TQ":Z]TC57KNB@L9Y0(FE_4<'<'\:OH+/?N)G!99X'$RX=DX M.WHV1)T):165^_3CVQ>'#4 +8,4P"C8!7EH!QB96U,/*J%+Q#)+\R[KF/9,X MG3+?MGD[N)3S68+TR1E' MZ65V,E:-<+4HA1/^8T1#6 MX9*%L45]%(UPE0-N>*9#.$9B3!79Y,VAO-3 N7A8U BTO- .-3 M/TYT5^'U"&8RFI$X4L7%D)61"+$JG'&)H@J5%BU,!J2815(X6H M*1_U].0RZ6DO4;*4)ZTMCB$S$G53Z;W2ZF !M ]?X3GB073'6 X#U7L6B=*T M7SB,6%5_2NTE=>')7%/;B'Q0LD+HJU*D;4NG\6JM!7:]QHMA7>B6>X[:U M;_T'OE*ARA$'4Y+FQ.Q#5K!6&EE)@_"R5?-'H\51:3WQ;2'F'2D_4U)N "F? M9?O%UV1(*]4?4R3/E)[(M3\K' #5L[Z8L]]$-&FW?,#'!\2H,/PC 84.%1=H;E>L'CW5S53O"[8[L[M@]X;)MP;#_[ M0?;@)B0>S::R]LD BT=0B";0.H7^$#'3(5%!]\EKAE(EK[+S5PAO6I'!YTM6,%AC'V%>?83;S+UM$ \NAS:?$_9ZIT**K?)I"S/!*D MK>%DW.D40C^BX"\='NH4&H"6+$@H45V3X>29P0Q5E.-3AZ2\)\ --<(,$#$= M8X)#10J_Z,9&IXX9"&T6>?]7< MPA+EHZ31 R#L5:10;M1A=K8.UJ4U GL-) M!%;D<5O0ZP0->\Q+!Z/0H]6G=D N*+%:(FU3PG:E"M"CU E%R2:H.VIMN_!U MC6[((=,0T#<))"T+,KM&=2$*X2911!?D'/W"QZA6E)^GBV],.=6P!HL$LU'] MR8Y"#M.F82,.A;F3->@-(N&'Z(+]&OC!/EV4^([..-/9;FXL)MM3JB53JA.^ M8/0QB>_9EB;W1C$[LIRR0@-QU5G@)36%<;A4RQ.+O33Y*7.%#)X6J=J!5^:W M.TJ4J_?IYC;6W@?E Z.LET_H]R2G/U6QW!+?7K(24TL?Z1!7<+ZT>&3OV:SW:IW6 B95"9RJI^EYX<< ;<.?%K1C?2J\D^VD^, MYQV:=VC>(MZ1^/2?P"0H;,*NOL0%@ @V]_H22[\NAYE=>_NUVMMO +O/#+U+ MLKDG1.P.KSN\/C([F',#G,3+5PYNSR1WGU(5O4OG[LECX%>H^TX% 'V+>T7 MI.L)J=ME+@.I>BSKN%UU24Y7G?L.R/?$UI-5MDJ*1W+AEVZKGF[#F<*,T5H3 MBS>K%M7.75F8ER4KT1LYXRJ#299.Q9?Q7HZ+@5$MV3AT![-8M=7D7CW\FXI> MCXO;!R6W^D8K(TQ]=2/*7R\+4N:;93@,!YQZ< M-"VLBY(7BQ'#Z>W9T&A]T\F;IQIUJZ;94:J!*-5TDJW69<@,;8T,<."^GD8H M/98:35K.8$)4@DA5 4"-S5D'&,["K:A5#3**E4C7&1I5V':JJICN.$U-P/?< MHO(!,I=-5DV4,4@(,>Q0_0VVBN*RG+'Y8MC9JU2I+&X;"\13DDGYE/M?V1%_(('I:3](, MEML7[NE#OF_7B1%@WQBB/6POS5%?N';5YEBV<=4=H:FV"U<01+2E'N40/AB[,:Z4%AAF:K!O>Q,KO(>'2N^#?:Q^!:'S&#A+FX& MK2>A>A5F!-;EM>HP2^^Y_DW@W:@0B63UM]="1LV*U*+*28E+],)&.)11(3,= M'1W49828X4(Y%@YC8R>PO;'$*P(1":P>F $OTX.=./I$E<\>F/ST %FSL0F< M!X,A#93+4WP,@,]AK6MB P""&7#!\7#A%94 YRGESLE-D^IYV3'P V#1Y-)4;G8/>).=^9 MGRRJT:!%=7E14SC=F%4-F/#$E1MYJA0&U<_"-&1JO*T8?J R\O X':N$P%^" M080M!--M7B^/?SE*=S#'GA5*>G,(K(YCI%ENW$C60J7NC08>$1S/N67*P(&- M,%RN3%K37]Q00W[>^*;\SM^$RT0&(@[K')8 MA-$+JO!EM'A_/?,\+!=C?0P.+-ONI3%TI]=A?#-4 TKP5MI8SLQHO#^H&9C%U]\GQ;A.)WL<(A\'6/&Y<\6S6P3.*/DSH.1 M*XS6%*E"RA'7JI,:,=KJW I!*+J4AN)GGQIRT12W6'H$0X%GH.V/T@J/EB12 M 4RF3=3+D#8;I+A$ M505@WB4[EK]]CQ0D-"VAT'IR]6PE4KV:O63*F=R M_^),Q<<]4JVY@F^JEL<34->I;_TR\T7B>X0%=6KE%&/M76@\2J+!9^<3CIL[ M<\D@GZ0VQC1JLRE;6'M?I ])MG#5EHZ#Z, N9]JRPID+ZL@DCJZK(.!+W0F00/KXTAO,&N)JO M>2:48K>5.9*H9&0.N1-=,(=[RY$M%U KVV2&M%FE2J[#UJO=3DQ ] 3\.7/" MF LMI3)+U#'*I)8DIQ=1D9Q@V2IHQ&4T4[D%1:9FHXQP^Z-8^_(OD716DZ>[;(==ML,NVV&7[?"\8_1WV0Z[;(==MD/ED(:M MB:!^UOC993OLLAVV!3&[;(==ML,V1"SOLAV>$9YW:-ZA>8MXQR[;81?>O/I9 MW&4[[*+R=WC]^["#2MD.JUZAR(B&01B-7^7?O#_6?I^WLGG]!OJ)@0D'%MS/ M+RM/JNZ+-@)EJU$&YA>-HU.J0DA^0EL%E-Q%KWS7^^>+.)R)%R]U1YW-P-1< M"J;&H\#46@JF9C[P9L6M+NQ0<33"FWJ\4CP;_Z;:J6R %D'S@V\+LH:*)LS' MTU82\@V(]!3.&?@;7XZBLW$9W8$$ M 0&2 +9PJNR=^5JPM=IIX%;B?)N!I%,!DD7\;C.0="M 4DQEJVRFYM/O FKS MB='I_C-(-OQX=GEB-=.W0^_.3C^^LX[//AZ??/I(6MP6A EB, W&!%(X#04W M%V5.4' ,T1$UIM<1UMQ0&J.PT>-*^1T4\_[NZ.A8_[M^VZYU.AQG1"D6(N;ZV;.(\65$].'S MC7:CUK3[V(EWY#+Q>_>UPA*E>;!N@_ K1]<-G:D;4SOYL3MTXYI%O=4P[P?T M!C/F4#TANRX.9Y,9YYNH[Q$H4-MAO9U.H\:? <1&7W;GK74:S5JWV4WWY[5. M8^H%9W0(2D(B*&D' M3RI7/\7J$V4))B-K;SXAQ;?"N]$TH"E)A=XO055/?G@+S^LHH)@VF5W"=$K1 MI M-%+9TTG'+.I- 0J@M!?:!S=*\K_B^Z?%_L5LB)DHXYFG,D7R7"U-KYB8:_1\ MGX;!5>A,N+&C2IG#TT_XBW&-*DH5'AV[')MG,! ,1AZ)*?(PE-H8'JRV[X9B M5HT0RV" X^&G/6&_YH9>O"D"KNEUHH8**KX,O6PC#'MZ$:H4X1\ MA=8AJ&>;@IN70:LJIE%IZQ5J-:;:\QMS^&-F[V\DCUY9G[:!KP-;E[,7#EZ@ M+@[B-UQ=&_#Q7'2O5EKW JWKUY-/EZ>OWY]8^/N%=7[T^Q'\M25J&,;3.Z 8 MA?<%J9J8P8BI_"-BXW!,QH)*HNM,LN_:]7JM7J];TUF(4HN250NZ[-'QQJ#Z M?"\#?(,)&QLJ8V*@@L?NJ7CMMV(0TE< APSBYL3)&1QHT H*0)B M_,RJ60+U/\#G-!PDM[^S>7&HBS1YF3@I O&=W98_I941BEFGL0>H*>ID6\S? M *9W!Q"%4M3;]>^IA:OC^[-)S6CHJSI&.E:S4]\?@6 BK9.2SMDK))L!4_$" M&5TO==2T?JJTBD2C"'6%>BQEK^6GKS@,/,"?]CW7_XK0XGT6-1K7'#NC/5O< M"5+<#8741&W"#*(KE23QGQG0("72O%5CE:3KD PI("DCRDVV 48YQ.G12=Z, M^1YIW2*W!PB,DU2C5Z1DJNB]5F156]G*3-'4Y9S!72$QP4FAV,GY#"T M<8A@4]%;/!H,DGZH88.^CNTI@X4KL&2"=WX5^L7V@E546,/^90B_9@04\?)5/MH2[= R=2^H%(J-RR+9=Z'_IY([A6;I2C_N2NJ? S[ MAIKDJ'9'-PK*'D\T]0H.C^HZ-(BU!B&7PEN'N3-\?'DEFK$0$&$PF@TU'&;; M[J2;JK340CQ8>YJ735"9P@(=E*IG'S3;!(G/?J2R-Q"/Q*I0B371'= K!'0+>ULOEX+U63ZKMFMM5LVGCC)L5@Q40H8><60 M0\08+U-R"%6W'M1BFCVI\BW5L^>15'9B.J0EY5*8M?30]8<,W2W%YCXH@?X& M'DYU]"R1-XID,!,_F,"&, V2N8N(#[D4D#5V;H)0:=9,C8EFK4C>< '@E(6: M6BT1DG#F@%Z<61R@8!Q2DBG:S!/VHQI.)1H] \=>&N2G;[BE$_9S/2#IU1&2 M-3&65R3*0!L79M1QIL .0#'$K41WUOD,*!48!6[]$>IQY!+%]:;Z];E/;GF: M)6"**P51YE!RDD&1*ERH7B41J%$!)L+J4_1:?.T"/T?-ZSZ?_WTJ:3,M_1SK MV!!^'X-8U\ CE3!TK[#"E*DMZ3I6WS6Z;;9_LE/A,*EI9,=Y%3&.T$[5NJ3Y M:?Z]E%S)32SO4%-S,R=UK@!]5ZC2ZXE9]&;EF&;[J MWH>.%V!Y-52W$=)SM267]*X0VZ&%?4S8[Z# 6JI G6DE+*8^BD0# M*)WFXI*[:"9:!5.F!D;KA+WZ]QF[A(V3#8*+G#6S.^TL*[ M(9)/AFJ:2-?;A1)@N3\)#O(E$FCD=!BK0?U;"[OE]I) MY:K XA>D_LI^E4-EYT@O#UZZ&?H[MC;6F4F #EG1KF>D'QD#6U;25J)4[Q MW %*T8DZ3%R'SV@?3384%=8E,U'62N2);Y);XTAYK#1!)QH3(#<2,?JV05#F MR,R RX0(Z0,]CB8/,DW!X-:'MZ[=J>6Y$S=6]0\1A-9!O_^]UN=G),C13Y'U M(;!@,(G$=":PBG'ETHV=O!W6K@4-R1_9#6#V!)V2LX;/&F'*W%O@%2/"T#P"/P^UOC%M].N(^W.T:^1G8?:$9YT MV?OS>7P"-HPFHP 4A1(5]].REN9T(IVDR-E)-YB"8TU M=:^N[O]T3$HH.#!D M>PH<+K(EJWJG/+PNWJ)J?=(P.I"SG=Q)=PT\/@$(GKPF5IY%*1 MFIEVSB"O3.CKV<$>"'L(V6@6 M*M+22&'#BEJ7#'5@? MW>'7P ,EZ=^SK^)K<%,CAR,[4#-:A;)[#<.\9NT)++:-B@-HBQ%'I%E7,P>5 M02$KVV( X+U9L9J(YLF/GU196>OQL\HO&0,'C;:5<57GS($3]=XYOI>Q!*I; M 1*:FJF((6^G>]P;H>J967LFZ)7TFX7:37[E!D!Y]<92U0674G%0.LY7:S0& MI*P%K15OZ@.I7JACGWATK+V<@L*>MWMU)-0:Y.V3!DL>?[Z=,HXDEX'CP (N M49=&ACH"&*1)A201" -]$M&R.X+Z/H-0T,Z64LS@]?Y=5,L' MHGCM@))LFI@N>PAEZ7B056&L7M#22%U#[&'@H>0YRL93ITA?G&S%30!%?;!K MJL2C:D2;:0M.&6=T0Y/RUMGM-B$^/53&XBN%&+9";L M1Z&HWR2^VXS?( :0^#5U75'X&=N6].QVSA NN&0U \CXNCET24_2\15*<(T= MNCFN:1M0UOY7/5U, ;G0;RI=08N,Z%0P%#(Z\\H8X'C(N1<98R#2T%P**(Y/ M!0>YR'G5K3R557XSTV8T8C"YX:P.P!"C,R@D3=)&<1 _-\SX2ZHAK)*1K&3^ M)6/BA'_CA@$'1 .T% N1JHJKU/_2=LY"6LS2048$KPZ"Z7U>*ME7BB42:L5 M-VLO%;U@./&,B/4#O/K2JI8YPW\;3L M]%B>YGF'12C$XS5<-C(BXMB= ;M%35TJ10HQ-;J9AT7*)3&JJ,_":1 I/571 M >%MQ$<(E/G9&+5!NAM-J#W92N[ A0N+TD8O^8+A] '.8%8Y'GL,I!,'GO"Y M%+3RDT3"?"WA>04N(.VM&SJLT\X%5=_(Z%X;,FW NU'P;=F_CIN%T+9P"\E('P@MND\8ECT0U=J /NZ$C(-C?L;U7,T$Q3 MP7PYNND;"XY2@>U^B7Z+62SKE1L93^:Q-/M:&48,17"'N*\AL[,]D,6NZJ!H MM.Z!\QL,(A'>R'9[F,QJ_2"+H/ZXE.+YJG1'GD%U[4W7UYZO)/_M*CUS9O-* M);36*:J[W+YNK(K6W,U_K2X>"P),<@A:I8K3RD5O5J\5M$[AFLT7TI3IK=Z=?Z=N?!-F<[ M#M-"Y:-L3U5XZ;P-_1O7)N[6FO75^@UL;?GJ4HI)5?LS-*&T);$<,BJ5O-S5 M$%RIAN 3F=9I_I%Q1AI.+O0I*S^7X3-,-Z$OZA1\RS42]'T@V\4.W_'M\QV? M#$ZBJSX5_JBC,HI+C>>T-'AB&SAS4*LQ^\7F M;.8D#N:S9[9NTTZJ7*(,6:5C9^)Z]Z\6;00]&[E_"=ZW O=70IT&S2 N-#=, M7%ZI1)KET+:RPI=7*O[K^/CDY.W;Y0RR[B*#[.%0_8;2@X%%W+O"&\U!Y$*3 M;0U94S3&3#\U3>$L@<#\/LR #,2[I'MG(=;\(EJAGD38-]WK%!5 MND?+\M3US*M'(TJ[WOO>VL?8R8-F.7UFU_6T)/B(;/>)"/.3&WVUQES11OI9 M,()WGO!Z! *]O79!LT/]"@#V@]O0F3X5*SUHV$BV]8.V78VK/C.RW6KJ/)87 MJ)2[1P$V/[@^ATC^^,0D^D346.^EBX:U#MISI/TVZYE/1U+2('UYD@I 7@^+ MC\F>4470[F,50?GQ"TZ9-&/_)$:"O0SG%)ITY@NN./W%B**D $H9/UE< MC[J._Y.U$(NA/4Q50CP/ PQEBQ!(<_2Y:^IGUF3W'G)-MES3(I#77UB;2SXV MWHH!+TQ]>IAU-:NN2]'@6FNS>=/JO\P\N;BF_/@PJVM77IT^7B7COQ'1,'2G M*DO^$0_7H4J2?O"JBQ05^N05%[>GVN+B4HN2R2VFF50/FHV3-8^0*PT_U?UEEC,W>BWH@AG:BYL'])$EE5\1Q=.Z>X/4>W MO=3J3/9WC+&3NGG'6?@)]9,S(XY2+Y"I*[O&EJPG_ K._WX-B^P%L&;%EP7 MLRFL'(>G^L4B#,5(S4RY>]NQ?QGVOA#JU"D\DR5],'!#O%$9-?/6U3;W#$[< M ZQ&$F,A;*:4.I5"X)BJ"YWB(<=;!>?*V!E@7R*[A$Z.?3S 8AHO#M'HDVLI M!W4=L=ONKLL(6;!6J2:T%<6$GKZ2T/86$=J* D*%&?&/6CUH2PH'/77-H"/Q5ID0IAGR"-3'NSU0>=541\BC2O44BI-7O)]*],O@%7>#4 M[GZBHG\XBGS\W(GB-S-ASU_R RIK("OM@Z:AQ"R&M;"31"+P#. NKP%16'(G M0<[9^ )%"ZE#EW"*K[ T]Y-O-VD,G7;:%;;&D@XK*.O*DTKO)6WXY*^1G5(% MSY'('EF/)])HM!?H$N6D?$>OM85% I.CGY]/DGD/1[55G^,$4$#JOQZ(XYP M(NYH=9DH#[^Y\?4YEDNY#,J>+F,6?6062ZPQ;?&LW"ARZ[#!7KUNI[=$WTD3 M$V;5@;.Q9D?'011'1_Y(62//#RGM=@HI5=>9%R<;P9#T7TNC!?W7RG[9K%EI M=SN-;FNE99MKUE*7$QJ0/Y_3"5)V*#73%[37;#:.?9=6I2PZTD>7Y0>8R MGOF?5.;B:\Q:_&RD*%*[S4]84'L(;]' J_5FVOJ.Q2P89)>/N,M'+-_3 M73[B@O#773[B+A^Q<*MW^8B[?,3-[LXN'W'.GN[R$7?YB+M\Q&>9CUC@--F@ M 9GW)23EB(QIYAG1S;3#\85U%[WR7>^?+^)P)EZ\3%UQ:QW@,E"QA8LNN:O: MZ,JM,&^>PV)0,O;$J !90%TA3PTF:G243C$O$]]O<]GXZ4WHS)\?9"6ZN*F MXKP9QVW!:]*#MV%8N\"B]', MP[L!=-M3:\%SOET\ ND\HAN#,TZH_97*;,*GHR3)]A)/\E/Z?1XT"W>7A[O+ MP]WEX2YR5:RA8^WR[BX/=Y>'NPV$N7A;B]U[O)P=WFXNSS< M71[NW#Q<(WEDHQZ#O$-"#XJAP\*/^/TD9NGU??&\2>Q6,I?2")6M\\F)YP?M M5O+]<-J&F4_ST##GW:$/,N6O6F]>B*A.*::^?'!]3%TNB=.L]QX8;^E%/ Y] M+8,XNQQQG/.=1UR38Y^;CX^YAT,=ZL1O0256GN<'H3@.>*TW[ ?"7-$B#K<* M:2M0FT1:^ZF1-E@\WV 9\KX$W=9>D:8.SQO]-QE\/ A\V4N"1\-$54(Y/&_] MWOGP6*AX2-9MI -42F'H9.Y?Y@HZU,H>C%T;D&\=DII9))6QF5S6QB,@259: M4?W'*&I\M9.Y&G[#KHEAH\ M].H(4P%I;U]Q:U77-V[=SH9Q@(&OC28'OE(R8]ZN<9]\I6>^E8456[GJ/&"5 M#JD[;D:S :8<#L2(6WB9C? H3S.7T*O&)Q2DJG9@JJ07.'[2'%/-\EV;LH2? MOA6R"3P59(D**[+LZ9(LK>5*LB!Z;X5W(ZPF?\L-D50K6#W7KW8Z6*S+&?6KC7;F\J99?K(IW8A#.J\3A,TMK+LLF'XY%I+!A,<@_6\\L,(% 9_270)XW M6GO;T0"*N,E8*B#-,@4?6CTDT@:MR0R(7#"105)&P:]S1>XJ*'WU"$V#P.9,D+96*Q,W%]UJV%0% M$PSOS,$I+J553O+KTGLG7T%+N02*(3LLDXC;( \?YAQL[!ATNAFO2Z7-[]27 M.AS6VL=C-3 KGQH3G6=8T])834&YX"WW]W32_IZSRW^=?++>GQZ]/GU_>GFZ M-0Z?4Q]='YUT$:RD%[Q.[;HGKN;ZJF$XED#0/9PBQV,MXS:P3K"R6!B@WCV] M=KS@*G0P),74JT].WJ7=(1-G>(TUNU!S<^.DF)EC7<'!=6";==4N5I9$F*XF M9^TE95:',\DSK&],S5/*4IJ63RA20TOONS7'P#=O(J2*(F4 M*+NW9F=DB>P&T :0*,!GPQ845B-C&$%T]L183"9WFM]56MTE2> =.@X/WFG M=P, B F%;R$%[VWJ?4Z_ ^]Z8>G9B%I8(<[SF,][PJ?L7L_!TFC&,\.^Z[RS M5EB<-:X08NH:O"D(Y!%6/.$\]E$XLG8\*2DS FNXBCE?^^ MI;;[;9KH?4=M=H&J /V,%WZS7O9K;7\)J-;O X_P4[%!4Q3+RY#S")@Q01"J MI>81+TPR[1.(O,A1X*_0DUV:26ZHKHE&/*AK*\7]N M+SXL1[J"6AI[N(2\ (MD?8M>_4YJ>JN Q#TCNM1V@7_,!DOZ M8)?&%%L7AJP_FZ7XYF&3%O#4XI5M=4,\-6T'3-+UICV/K<2]7XNMTO:3 MAI\T_*3A)PT_:?A)PZ]&AE]FLUZX&Y\MW;EYY$>D=HHL0R_2&U@(U@-FPWVG M5(MF(PB68E(1>//7 FYX0(R7&HZ#B_4(N2^*KG?3T?6;R]\'=Y<7RO?!S=U? MRMW-X-OMX/SNZOI;7<+L%X%+[4.FHM78O,F#$=H>3R7#MF)4]#]LS6#Q%):O M[JGRAS$V'Y1;XR>8[=3_PW9.\)HI9=]DLA=/E4$Z6MY6 MVTU*[D@.I8BAHI%FHEV=\@2_)_(B,WD]XT(T[*>CXLTX=VA!2!R&"W-(,*K_ MOLV!IL V_ZQRF:E/>#O!3?X4[Z7S8U!!D412(,\*)%QB;$-Z3HUQ6")@ &&>B4/VK0T5E_&3 M*D32 &'!.F=T=O/9<4U/^14,#L]GIITB;/IH"OQK<+2-J)719\=PQTF)@Y'O M[UUV3VD[/-$I2O-4\?@E7PR/DG+HS0MBC@P4%P&11T4B( "I#_=?V_#6S.=8 M1(HSR=GDAF%R,G6C,C!UVV*&QX#2HH0\/[LTHO.N-(^N7$Q,.( 9,EV?'HR? M+'%Z*)8$%0>7+9ZUB&=]=/=B+/2O0C4<,#L.6(K#B:N BVO:ACB73*XDZK@O MHB7E4OF/%EUD*,]K ^ '@-=9L"/SR;VLK)>0*3YTK?4?G;EB2%I2\FBF4+R M8 1[7K*_F:.?CF6\*/\3_&0_<8LUXNTSO<6NEF)=ZY(D+93B4(@1D@H$.9R? MEE/\42=1+F0RA/^:VXJ+.V$O:FH4 MSUX*E%JV$5%Q*-O-8D"F8 S8G9-8"9-YY\*H7@9E]J[A.E"FP5PX?SF ;D/. M]0"EDY,%/"WJEGKB9QR(VZ#8J26V0*EYRU)TFHNOP;JAH-[&(@K#1[A^Y?*9 MCZP&0X19;"7@D,K&JYHFK;D>14036.SM:%(R/;97#>T,+P_"?7W,>^B5JKLV M$[=.1B]L!&+%*J$4,FZC#6ZH": P+Y=!NK@W[I_$SH$7=I,BK^MZ#_[K@;FNV#> M8G">E8I8U9OG.CBE*BWP^;S+OP-0R?#X7&V%@ZF,D*G6=WMW??X_OUW_?G%Y M7J_.JN)A']K>_B?G?9!+@#O%8JN5;'2[AWF5B1$?A3QZ6L=JT1 M-307W=[YK45$U(/1>"PH0I'W>1=!M_=8GTC#2!%O);,H8F\[R1'X+-29>\B8 M#>ZV%UY0]:=@6B;@P [CB:[80\NP00BF#$"8&Y!@@IFH=*:J6.:#Z=.:P1\8 M&J#NLIBG[XS(!HIN/3SL-W2R-?_AF2 HOT-D/KT1GX?6>C1N=>1A\0U6SH5<6RF/.)M$@P8,0,8E7>RA_?X(4?BW2FSQF%W=>I; M#P\]4E/W?$;/GLIH?;79:ZK=?BODTN3=9P>OK+ 'C O'WQXX,]YR-*^X3".) M 0K:$NO(FM>V,@CNX5NEM^SX(3I_ -XYH4AT]OP!3TL?30_019119066CVOL M">Q5O#X$H/" *-6=29VP1B,#5YO..'W%/GI/E$C &4$@#]UG>!^&B+2#^_H M?P]<;"OCAX'HZ T"Q7B@$>>/$>@( '4EOC;,)%%6>Y(;H&T)L* M2Z$X=-1.IZLL$&.Z!!K?WQQB&Z(,FN*F$O;_HZFTY'@3<5 24I03(PK^1/YAL"(!EC.HQR?"I@4 M39>03_?#I,HN6N#.$[=OKN _VBII@_D/ KSE6;3K)4>7E#>?D'EZ MDHW+A7KENJR-5A5+LT&;@59CM53[BZ]^2VTSB:RU2_*8SN))OC;'" N3U MP[M2M!/-Q.J'>=7,?@6XF[9GCFJL3-;!3\0KUKF/G(JVO(4+V/S@83FZ)5Z] MKHZ0>Z;C]Z@]W$&3<<]4Q,8I!T_$/=.06HGLC(@;WFXOJ9R""-*V]55]R,/J MGHD*G.K\#9+E5"NA=$*IA1&*E3UH-W2@YXIB$57 53F=5M0#*$:>QFF[6T?: MU(B#FJ?]7AU)E-WU]\- "=A*_G12)=$3>GO7K:!_I8JV\['C@EOJHGDVX[8E M*[N"_AO-O;[ 2Q0EBCM'<8\5LI;7-7;<"3/75!Y2?4@4)8IU5Q\E&!9AS%IJ MAU?*5Q+%UX!BO8R+E5&^R^>9Z:Y*=2DE_)^3F;BDZN4N*FMNSA<+0HS; [U] M3%:269)9DOEUDWF#?+4M3-#$)D/BX?7W$6VK]2](U=E8\=P M/Y[A)D.4X 7O+60C\97X;AGRV-EIZPJ+5$1*\0YEY9;H@>[@T@R59J@T0Z49 M6CLS-+=5('X\B$(WU]1;OI;5#*YMY=^&'1CNBZ*UDB7%J=@DEI.(RDWB6E#- M^$=1Y@!+6E",!YYR.(I48T-4YIXKS-UKQ"T&]'0=L6QI#1@FTVV!E[0_RK9" M294UI]H;(214- Q[4H@#4F6&V>I4(*-QVFTG"F0\34VP!9Y,RU(>L54)((AE M0/36"55I$&5,L,@(K_O@?>3J46__0SEVW @7A#"O<$'G"<0A+R#.\J?$ M9>(OPIU>3I.,)F!T](-3I!E#[_.'XR6=&*8;EQTY>J]U54W3J @]F'6C@/<& M"+RPD DIFI/;T=2QJ-2)2=W''YPQLV*T$[VW@;T>.&0?E6/S _4MH7(JECEA M( E4Z!_8_MB$'Q\=F$XTK<>:=-WN/^@7^ GXZ*[MXK?_,M>!-^$GSHI)MFFT=-Y3YOB1X,GEK%, DEVJQPJ@Z!< \. M&+Q8(X08#)'%Q4140P[#UO.)3@):0VTU=2(H]I9W,X5AEC?$.1HD1Z*^[8L& M6EF29._%C4)6Q+X\;,,NAWBAUIQIG"@ M2$JEE,K=L^>V>,N"2!4MN2R() LB58&X+(A4/\RK9G99$"EU7E.< =;QD>6 M0Y+ED*K=2F4Y)%D.299#R@RQNV(V6M@XJ2!R;["B#1[FU)$Z->*B_FFCEB2J M!P,E8*OLDRR.M-_D_UX1+5IV9OA>,%VM#LM/@-\+HMI;6,W77LX@?D_62EK7 MD) H2A0/0GV48&?(6DFOG*\DBJ\!Q7H9%[)64LW+GI1":4EF269)YK=#9EDK MZ6#O]VIJH3BTL'MX#VMIW9EO21IAAZR&=H[[>L'1.;#XN&W6"_IB^,JD\ /7";* M'7AJIJ(-+R:A\$HM^!.OOA"7Y_!A;"P+@84\GLT'PV?6B_*^K:MMO9E39L&T M?4>, X\^,-OGU3X8K\GD*2/XE^GY^$-4?4*4V" PL!8!+\E!HS#WT1PQ+YK) MQ;($+AN?$N,-/&D=X@= M+@A]-VK\^.(Z#]J_#1MWZCNGJ<'>C1_?*6,V EI:WK_>77W[\NY,ZS=[S6Z_ M]<]?YN8X(SG[9P0Y+L^5YP5L?$%5*;X3[2C-&%B&?DG %7CC#% ]C4,U".[U MAM:['^H)$HC_[:9N([^/07,]S!ODB$X509&3(P?'7-I7BR8M6J?3Z:Y$- /UF5)H.?E;_'N0X=M0"O:. MLU868Y:(9G+*I=*9:Y,!,L0L6T$K$4" MMN42-?-EJ5RV:B_:6C> >5X%E,E6&^B'SB*6*E/.Y_B$+)]SYP$+:)&M-G!= MP[XGHGU^F3..!D^&*]CPNRC@AA/0UZMDIIM8/:U_YV@M\?$'U9&[GD15Y,ZG MANF"$2R6DW#D=T(72$^OT6C,J?,242NF(->T57H+Z?'5I3*;897-!4CK6:0+ MVB*E\ #]ZP]>5.T&72ZONM4^VUE9T3U7%%U1:)##+"H*EL#L\VMXIN1::YL, M+NYP)X[4PW)%HD!*F RZQD[5IYVJ'+T!^A_YI00RKH=IB21.KA^7=:U"(?RN MM[Z6S'0"Z!))0KF ]/ %"DYUU,!ZO"<-[41KE4"3--0Y&GJX>M#A K9$4K/Q MEF]_,+^#=76)T !&%?E&TA91MZ-RO75>*9)^!EK^6%J%>\5XXMQ:LIBN6" MC7A/%EJ3\&_I"Z)TU:JM5V*;KD0N/Z#! ?MN&?:E**V]Q%KH-S+LW]0NV*@4 M:Z'1:NH9!W<.M!Q66!\%;6%D:5L4VOUV(0SV&)GIZUGL&^+C#ZJX'Q7<7X3S MC\N'F>5P,%;$.7<0J:FM_]IO\J.,2JB[/W^VM2OX\PX8+Z,@URV#*K".W M=T^NWUI$NFQ46>NVL\9Q-8[97CRS_MS10<1"_V:>Q_X\=YVGZ+QM+0;:H9]6 M)S=M1YL&5VN=W;MM-?+;=D1J[L=I),5\>56#3;#6U?G'WA)*\HAKIB:>]/TW+^LP&43K=,N2Z"Y%;Y8JT];;> M%+EF1<#(6':C*1L'%KN>T"NI-+IOCL_^-'#Y?>_:Y4=)419=T>RX,TK/K'U# MH3???*'FX,WEU]:ID+UL*22;E[Q9!MT.\4/MV5+X+H642BF5NV?/;?&6+84J M6G+94DBV%*H"<=E2J'Z85\WLLJ70IS \L28%-N^%L^\6)+*ID&PJ5.UF*IL* MR:9"LJE09HC=M8-I-W2@9TU;"NV_'TSCM-VM(VUJQ$'-TWZOCB3*[OK[8: $ M;"5_DFV$]EL33Q:%ERB^413K5=H_?D_V#7KEC"=1? THRKY!DJ\DBA+%0S N M9-^@FK< *872DLR2S)+,;X?,LF_0P=:Y+G1@4:-2UX=5Z'KU>4>-2'NX3-P\ M[38/B,R'Q<.R9U MSD6X7G7$_&\>#P1MUA5(JPGNG"$E=W$0 NJ?(&.!14;H[%J M]K/5L*;*1$0_1HAKQL; MG1R;.&HB49>.48M_H6]@W>J=3AGVCK^)XSP^Q3\19*F*L]8!8 MK=/BUY95<\W%JV1N*P_$E1JJX,(W]\][S6QYS]CQRRVVEZS;-L"N1. 0WB%- M(@_PM=5=>^,%:FH.7FJ*NA7[D&779(&G-\N@VR%^J'6M"H>CI51*J=P]>VZ+ MMRR[5M&2R[)KLNQ:%8C+LFOUP[QJ9I=EUSZ)",6:!#C88F&RZ)HLNE;M5BJ+ MKLFB:[+H6F:(W97,TM1&HX'_+XC<&ZR;A:V"ZDB=&G%1_[112Q+5@X$2L%7V M299@V^\5HUX1+5KV_9.]8+I:'99_S68OB&IO835?>]&4^#U9D6U=0T*B*%$\ M"/51@ITA*[*])PLI3 %N4P5D7_:D7<0V7D_JG>.2 R'Q8/RZILM0@];S*$K-HE\7V#^,JJ M; >W@_>TGMJ55=FD&7K(9FCOM*\?$)D/BX?K695MP\OYV=O^N<,,L([ /7M@ MMO_Y)7[DN_&"7PV>#'W8,=;8R:]EL#G]=&#Y;HF?*8;\J-8](/@P QA"Q4C7/TDIR6PM/#O0[5@V+ M"_F5RVV;5.#<#I',4N$;5YX7L/%% )#<<[#X-IT&W+2"'4M6&C MDE77''YWCF]8:]0+KHW"HLPE>N<0%58.]/OFM-(4UOKU2+<4D?WZ]6OYJ-RO M+]ON7N+7EV)OK>_09>L[KNN/]EL7)=F*&\!>-D\E#B,JXZF>UNNV2V2I.9A+ M]] 3,QQ\I*@@+N5'BA9/7(T/U_NKV6R7&"K: /YY(L+4#Z9/V^[ 'N/S\!JS M1R;S+DQO9#D>. 91('BM*JVS5,2[:!753\J#X=Z;]D<%'VVLN-N/\PSQP[?K MNTNEKXA N=[0FI^4\^NO7Z_NOEY^N[M5!M\NX.]O=U???KW\=GYU>4O1\F$4 M1Y]%H[F_A!]WA8")'ZYG#(T:^U[YG<&"\[(LYM[AN[*5+VSH!H;[@F42.JKB M3YGR97#[63')DU$&M_]1OCFGP%;X^TE#5P4&RO&=,S-'2J^E?U"5IZDYFBHN M^SL D\93+.9Y#/[K._#=R+FWS?\RY<'Q?/B%7G9LG,ETE:%(DO2FC/F>8L _ M_+#EQ)F6#^ MU!F'RV',9I:)JP"CS%SGT?10L2C.) V$X=/?,2QCPV=$<2<()XN 06QB+K, @+G'$PLY0&"B"3SKPL$D@1.@$,X3_XT*Y*J>\='%Y3%2;3N=T%$H'\9U9L4P0,8W> MFCUOFI:1/X3%D9W#_F1B/)C6R\=5^-.S'B@ 3JXYX/3V:,+!PR?CH\_BEY]R MU6XU,"-W.[1!(^_9C@^LB!K*\X"M35 [L(6.K( +6HI+F6*.@=/-":PNOJ\J M(RS1'OU-$I#@]0D,!KL\JB=E#.H$Y'X$"M2C'X06]:<&?OL JF $\W (8+:, M,CE=1-W<_*3XD+FF@B/%YN#$YG;JN/Z)#T:JV*^S2OV%*W^2@U#Q)XP(+FBA M(3%O'_#](S0"<(=(2 G9#H9"L\/>I^E@B=C^%#9"E^8H)!Y2-*1H[&A'\1B9 M6"P4%>!LV[%/^%]H@#DVF4S(XB-87' &%30Y9V01BI?(:H:=A=T[+LJ#%Z!! M""^YY$S"3ZZJ/#*P$RW&I>?)<7_&X\@]0PK&_@4#...G<<]0;>=[#>3AD(4% MVP8^9OJ>T/LJF$]@BI&3>&Q^2!EK^-W3%)PE\ O146$B% \2Q9Y-[NZ,1'2% M>W;,>Y>)8?<:S4FB-#40PD< "O7_F,1# 'X$G ]0 M^XFG35P*;F_A)B%6(V(ZW(S@.Y*VA+>"<[!G$',;^9F$*18:LKJ\@ 34]7"O ML<<.?A@!V,X#?*<8#%8JA811C8K>)ZSP@Q5WGV40NAX?>:^T&4N9]4]4;C3 @92&-8CQS]"2N MG9>QP#,2,'8 O4BNV#/YL!3C4H[(W":F(.([%JE;#.]PT]L4,B?6E>#BJYU8 M+2Y=W-)(3X8C"1&-5%B""8GY4 -$"B'6!OL5M\\,'L4X?-K?UAMJ2K9 %-=.8KHJ+7UVM QCE];+VGJB? T64Y(PDA1G2HQ M\2/VXPO0RU\ 0?V.('ZL\G!X4#[Q.J"Z?*^K_5XC02"B=*AKGPS4#Z"@<1NQ M4ZLO;!S%B&/RI$*CQ7U)2 G-U%2UKE:7I: <(LX_J(UML7L@0?TI$"B,1)!] M8>,.EF%75)=$!Z31>TU3.\T>?0F2JS8Z#;2?9CQL;[WL%]?HK.L2?$@0JRL; M*YSC)O+=,NR:''@-:%^Y93.?\[B>Q^09BT Y&CIXL O M!T\=:XQ6#>W9C^(8 \=6<@FB',?3C#Y%SQ*MHA_&GSYP48E^X\;!E,[)0/61 M,."N'I[YX&?83/WHC TVT)%/1 MOCM\H=<_(S%.E?]$%L=1!%Q:53S Q/>8HDE1!?_EA(ZZT2L39##PN#OEI_&9 MX"M@:]\UZ32(B,OIS&U%^D(,%@YQ)$R2:(%4, IGEO/"R*\:/X+]Y@H/"YT# M\#DP=Y0;:'0V!L8G//((MIP7$DH@PE?@D7$?BY]ZJ3R<2*=6(H\!3\'0$B1G M8@AT9WPM6'3"Y@/;AF8-$>94&8!J"]L\X4_!#"=OJFU>"R5\.I7HZ]&PSG M4H6:&0AT\>G'W1.S'AD-^!=HG$&XN?/LEQ]W:$U]1V-J/J,(R=7M-U81;/-% MJPSL$S".BR[S^K1N": #&\7YS@D__;AC]L:$UALK"+T%E=L+ =Z.RF ZET/E M/* [!+3>_^8\HO(!J/G]M=Z/6_.9AOL3-.=O8+GF J>#U5J$<4-5]3N%4*)D M'Y+*"^:-7',F0@DIZ+J+H'MW=A?%$2NUCF,MNP+T=(IZ^C$/B2)(\HWYI6A8 M#0S=&+BE\\VMPL;0M1+0(8L+Z+1^EBUT,+TWA6[CC$K,\?.N)_0YRTD]#GD7 M+%O.2;HF/O[@UF=D?.+VB]^'B8MIZW)+PQ)]ZZ(69 DYIDF*G,TE/HJ[[^?& MS 21Y?=P;H2)],5QOU#P]BHVDI8G'O?M"T3-KUGBF4=Q$BVE>!Z<*3$6?R'4.UL"%:+_PR M&QC<8]1E^"$Z5+G",)#Y\"4\6KF-3E8.)9M8:R@GRLWE[=W@[A*3B/>:,?PI M]Q"'5*\E_+=[)SQ>% =50KFN/.J*(DZ>^1S&FWBLB4R)9B,T$.)$,CQ2>32L MP CC[:3%XY0=DRP96R3L4$@5)R!_[CAQ^@+/T7>M#P0$8&$^BF3:UTLG M,WPP"N]K[5.P8&R#L[?BN"80D7)UQVA?4GPE&? EMQW\[HGYS*>&S8I.Y^A, M)C'WDQ-8_!#19O#DD,6I1>-3Y=I6!L$]+ L&>05E8@_6"'QPN3":(SSS^=!0 M.@B2B )0K&$.: 2/QKSDZ MC)D8IJL\TIW%\!R%O\ $E:+1S.C$E$MYFJ$B-L)A'&[GA.X_G8NQ*;R%4%BX M@<1N?>O#J3*@906LLG'H*9FT-/8X/7N<19$"P^3J)I^_$18>0A*CA0G82C(] M.S?NFA=SW?\9;IS[S--GZ)0-X!=BQH^Z/1Y<"0_.HY1P,L\,>@0)!T3B1XUB MG7,C2;-(Y0/M9C 1O!FI?26I]Y6PJ/$MYNMC8(L3CV )*?@QM]]9M?G8HIK3 M"$AGS#SV40D_I7*">+I)D57;(%6[ND;I&_8K7=RN5%N4955JO])MJ@ONNG'I M02S;3KK,#KP8K!NA#7:V=A61=.^M>P>1?I:DW)H_%>&O[(XM-RWB6FXSY$YK M:0]0V*<)#MQ.P;IEE+_ Z[S:; 7?%6_+NO^>K.U.6^WVM((([;II[?[I+]KS>AD\'TJBR_Z)TFITU%9O1474P&)FZ_S&&Y$<=N MO"*;%TXMNY[X+E%K=S6UUVKN%L%7@6&\N^ZY-UQF/PUL8"!>'7[:E/G>H8<-8T5>MO;$7,NR0UL?^.MQ2MM1#;L4S! MLG7TIMIM=LO";D>=&O-VHV2V=O(<9 /1V<,>I8%NZY6OV^J$Y:N6)-B>FKK: MU%>$9S:5I+W>Z%WG\'+G)Y>WR:/LZ_@HFVZAGJ?.LG_'L^S"!\95EYJJ\&CS ME9V/R6/-@UPV>:QYL&=Q\EA3'FM6?*Q)J:9 F? &[7+JK'%4M_]#J>,>4*M? MQDEF60=U-3G!;';:8"*O\'+>V GF<:O=5#O:BM[B&Q%ELP.8;;WQ,+PHD7W]"KK;'X M'+>;?55;I=\.-.KSFB-:_;:F=CHK'.&-1&@/P>'Y2PUKD'ZWXM)JJ%IG5SI9 MBDMYXJ*K7:VT\Z_:'DKBED.7@F94%Y#7*L$KBBH5P!OQ4G"F%>1YO#61L<9I MXQ4>5 )6*Q(A#Q2KC8_%-CA3$64A*KDZFRZ($G5X3\SEI5NXKW77MO:G$J\O MPBT/)@YRV>3!Q,%&T^7!A#R8D/>MY'TK>=]J/T21]ZUJ$=Y^Q6<2\K[5IAC* M^U;;I^'*JR*O0,#J=U5DV_U)WK>20O3FA4C>MXI]$WG?ZB /">5]JUJL@[QO M=?"2M+/[5F%+AM6G==E2SHE (M;.]+[S,&+H#RTK<*_IF3+#YX;K8B'1\"1A M\(!U5K\8IOL')E;-RZ]VW.^UN3TM6J5X&V5EY:#0S:,3Q^T5- _IZO[\' M0%M90+TP.)X+:*O1:?7TXG FP8QC3;_']OQNF.+9^VB;UK_>^6[ WOUR%DIM M":"MN=#MKM9K-6/Z+9OXK"P8UUSC+6#<^<*FFRR P;^5Z('1!Z\VT&\YGK# M3@0;T0J(MH%GS;75P+ET':?7+JNXYX[KLM['&#CN>_8ZH8W&(FIL6&[B_JGX+VR3"Z9@'>0 MRR83\ XV:TPFX,D$/%D98.$8LC+ 9G21E0'RXO>R,H"L#+"O4UA9&6#=>YJU MRF60E0'DV6M5N,G* 'O)^9&5 0X3-UD90%8&V/L=>ED98,/LGS(.$=+'3&%\ MXY*'-Y:?C[07]F;?[K2IU]/[B5/E#$Q; -Q9"/"*PZ9FI]W4VU6 U%T,THHT MGW83_.\5(%%Z&'=MKVPD_U?R:VD1KB>Y62,[6_)%"3^EP[SQJI^TNN"-B22[ M]2 ZJPB7C=EE>UQ"1H.M],J&+911R?*]*(@3\,ZT)/.G8)H[8UT#XBUX)7,< M/0?2AA!MON+@"H$G5!"B5#5Z_A@\?SVY,Y[WM<:M!G@4R3S&A1#.)5MNB$MY MJ[\4V%)@W88O=##Y-X US%4!8^(6;>?/:#F#A7'![>84O/ ,V=?>;AA&![S0 M/HZQ6@%LAF7*06TS_A&PZVO 7C[HF[&3 +V](>BWP=!C?P= EI:)H2WRII?E)N__/Y]O)__W/Y[4ZY_ /^?4N&^C RX/,:=>P" MZBM;,48CQQT;]HA18Q-E<'NN]-KM!/RC3_$RX*; ET*-'QA_"ANAP.2V<<\[ MFF#=,?8$_&58%GR/!<8,2V'T,C8P<8)[WGX%*Y#!!],3[5*4)\-33"I6II+; M[:=:N'@I8,+Q'.>G,K.,$3O=*T%Q'I/B@KXTR4\^L_KBY.M#[YE[^8 M>U]X!.]/Q[7&RF_,L K]U[PS;_2_UGE.,_?[O^@%)L@8".E2-< . 2QS8> M33< A )_Z#+CIV(HL.IC]F".L$\.R%]@N"]*L\&3C4Z56Q/Y"E^/7C%MY7QJ MV@9^N& CTA@*WKU28R)-@0'8,PV-37<\LM=,X+"1#RNM7 :N,V.J\C0%AX;8 M"RCL!*[BQ!UT0(698W@&1GIB\(3AT1/L868Y+PRIY@6SF66"OB,>&P&%8%]S MO5/ESZEI<:#'IN<&,R*)R8$8\?QJZX7.]ZDI$ TA,=A9,<%[%5\$\""%T!' M(1 N)=8%0 D74SK]%\6@2!:?(N 0*Z+U$&Y@J!X)*&_*+)";$],^(=[&#D68 MH>%%8A%8OHFRI0CJP"CWSB-S;11!$#<3=+M)]CH@]IOS!.+BJER@PEI_X:L4 MX JA&1FV[?B(&"R:!PL_1)0]/MF82&'X7&CAN[H('7[ *>;C*,#+#D?M(U"> MN99IL\39;J)JTJ^N.5;H'@SAA,-%TKI_N;VVE<',-2U%%PE]:K(/E=":():P M/G-(?8<]$AYP0$(1/^48WTRJ^7/#8B.#?DPJ]P_(XG=3 -U3_GVJB*>.Y]], MO82J&X3$! 10:<>)KDK<9TN K2JSP/4"PR;I?IJ:HVDXBW'O,BYCQOB1-BGX MF,28VG7=PU/W* 5 &N#I&3"U0:8ARL-[L+S51J.Q$-^C0?3^@$^20N14N4O, M!U:-$Y(90 G!C$+&B">B,P(=!CLJ&*R(UJ*I_^2_9PB'%+K'[Y%RXDD<@&*( M.<?C##/[OM!B'(+3.T M!Z2#3??_&->^<7,T5*H>\T4GM; E6@JS#Z>98.N^!&> Z^84DA[4;$1%HQSSW!;X"96@DSX. U4E'F4ZP0Y15K,??N/)76UA1DN$3:0A!B M767!7\O1%2L0$F_,HX&LKQR)G[.+'6D>/NT.% ]8\7.J9VV]DR*26 K",T13 M2>@XLL@0"F0[T"G+66B= B6&&NS9,==''L2&C)U5Q6@TIS #U@6OS8(S))#==P-WU?#!0O6FD2)!?A&;( MIZV@1*Q756JE:=@)A9,:,:.::&W>"VZ?D\\O!-%BC9!!"IB>/.*?V&AT;*)1 MBJDF][/Q)K!3NCR41 ZK$J.W7%K]+D1DX'WC4#'.B!?<&]LPP:9\=&A;' MES3"Q'P&Z?# 'P'I1%$A],!]>V2H+3!+73G6]']\(-T!G!\\I#4$?PGV#71: MX$-*'Y$*0F<25IU"&-S"48XNV,0 /XJD%@F8+)^,N78;KAB]Y M,CD!0X@K37P<_YN5N:28/9G ZZ#_0D2R)I@V+TY?#3]P\>X=KHV1\454X!Z+ M>2!%CF-3J@;9:;1D,/VZ.U%!=;%_F1(RXP2^YP-C("?-,0%U#8:-QB4?T!Z' M+T7R1ZYO!C6ACH8L)*69W1MGF!\0$BA:'%P9A6( L$]:/)M 2?AV&:[AJX-< M"%([Y+;CNHOE#/F56&3,L?EH$A7(:N3X Y_'[$"PP(/OM=-]!#H[VAS M9-3VP)_'5@U#3602L0> !0$HLC*X&#QHLF1UYF"\3@SYF6O*M#^P9#V-P >V MHUPJZR4D2V(5E*,*UB$'X%")9.G-]9ARE <+241=)JYC&@3O2P<-!L\"@>U M"&XJH%,P6 Q&+]">GN.<^@0KYH-JP_ ;BW5C0L.F>'/_LIV@ 1YK &U%.!*- M.A'@/J([!K11J=RM4G%_"^Q1X&*<'!XR?1&VS(@>[HR1]2F"CND-2'!BSJ[" M/0QDJ!7,Z]AJ04LDD96TZ'0GE1P1:Z78!G0!.\5=!&@ MT\E3 ^FPU@.=1S\E7*(,)K*Z^?7EWUD6T&IDJ"BLA3C?0OE3P-+P:[/1W9\BS$=_E@YC2CN U"I%?REIT3 ^L%4+\8[2(J;U<5A*< ME)US(U"T#"A(IFBW6H.]!1?,P[18$,, M@7KQ.L^MJ*8ODL%E\,QEJ:5?#4U3M$P7;X5ZAZY%^\W_ U!+ P04 " P9S!1/GOE3H,2 @S M$0 &)R'-D[5U[<]NX$?__/@7JSK2YN3IZQ7'L)NG( MSSBQ+->6X_-U.C<0"4F(*5('D+*43U\ )"6^ ))Z./"5,S@IZ'P"V:@,8>^^^P7C^LOP.G)SW0K#?K?I>? MWL_H(35&: P!LM 8V>X9&_8$#:!GN1]V_O"@A0<8F3N \6730]L;?]B)H)GU MB?7:(<.:Z9*:.Y^@&FN!"#;"#I2XN_QWNN@V@+0ONBP>U3B@W7ICM]78 2XD M0^1>P3&B$VB@13=H6=09N$-D"99%GWJ+]_ 'LK#]F V-MZOQQWU(4=A\EFK_ MU!*M&P<'!S7Q-&S:)W10&(9'9>R&3V+S=A'!G-(L#!JA1^[5S M>2OTNFC+")KNHGU4.GLU_V&T*5;($MO4A;:!=CZ"GP#@4PC:MN-"E\UY/@]_ MXG-1_#R98'O@? Q^8C]RN1Z&NKA! R D?<@9_+!#\7AB<0V)WT8$,;%SX>^& M0O[=@OW7#&/8!!*#.!92J[$V(.31T+FSQ('$&+6_+M""%F_MCTN?Z=_"YMM!P[ M''TI^8_,\[!H=DC %T#9%3DK0B'7#4P0N'L8C\$8?_OKNV9C_Y^ Y?C8P&YE MGOGF>0SIZ,QRGJ1VN6B0-?MC2MM;Q2(Y><#IYYE>I3FFN2X90AM_%V,R!W8% M78\@9[!T:S$UYK?.Y#&FU+=,D2>8&I9#66?VCRA1X41]LG'OFNTZ*QT*W^F- MQY#,G<$M'MJ8.2IHNVW#<#S;Q?;PFMF)P7+JN!\MUB5?F_M);0:4A2-=T@9+ MXB"D7JE4KM)SATF*.3D#$3NFN-B#O(SF75(YHC<(NE,B M>@WGL,^7N_%XEMDFWV .DCJ)D *"%@B(9=I'I2&FH6OBC#&E#ID+@<4TDWR6 MEV0TZDF%+"GX^JBR=GGVP%:NY!+#/K:PFXPQJ8?*#+W12.4%O#^($*@"AEP3 M-\CBN? U)&Q)Q#=$H)%.WZ2-U+6-1C.IFH 0$)1 E%1E+/(T+;*N#-:3\9PL MXWF.8EJI["M"X^^*56NEDS#6C\?8%6M'MO)@H9AGJ,A.YCF:6_**_JR/,7MJ-+;I6-J)87O8I^L-CS)Y.^9Q-+"03 M#]4J2"W^E_V!3Z *\G)-I%?H1W/QUSRF$T4SM792B_F,5?L_^-$+GQIX%?Y8 M5;;7K<[T^(IOE1I-T#$G44A5 HJ7:< K?XA*QZ5+!AE*5;?,T6+QVH%2:97* M,I:N&;J2-,G)]YJI@D)J(5N9U$JKI2P?*6V55_=IINH-F6LGM:HJ3<43\PP- MI9_FV4]&M6%!HE+'^CMZ)\B%V"JYL1=VRC6K5$FBT/8>>!4,('&)E6J+IY)9 M^BW7,U?)J9)&F72RTG0!31LC9'H6,T$&&]H&9JV6^<,802YW$[H#B,D46IZ? M0,95OAH)=0K:3-505M$\[Q:@X_T6^$ $( @1 N@"CA$(D%7&5&C/.,L'9#W/ MT7:J7!/;0%::]?S/?>?KWG__ M\ZLQ\68/]MZ!^7U_.GR8VW;4VM_:GRO6Y_=FGN+/G_? M;SW.&L:E6__M[*QY^Z4VG1T=/]2GYBUYN'IW?-XZ,:_>GM5^:7;NIKAY\*4^ M=QN#[]9>9_\ ]N]/#J[JAM/<:S6'QVAX4+L;SH>]"WBZ9S<=\LM#QQ@][,/' M_B_.X.W=X[7[*WHZ:/3'7QO__D9_^][Y].WTY,VL^_"]VWUW /?N&GWRT"%6 M_8LU:/6MGG=YL'?Y^;+S[C?[W)IYC2=X[GWN7D[V3.]SO5G#$]?H>KU_OW'= MD]F[T:?N/II]G9_LMT^;WZ['5[?F;P?#?=R[>?HRVCN#GSZ]O;FDSI?Z?\'Q M[4WXDNSJ$SM9/LVL.TC:Y,;!5OYQH6JE63*.>=R'CQGXL3] MNFBE"GT*%28CD1@7! .#R,C54J3< ;$LJ\QKJ]Q%;J4J@/+38O]' 6@-"TWO M<626^.3-U/I*%_.R-T(J595PID$2S.?YE+^EIO"AF4WSTOE6NA"GUEK"@89) M>CAJ%2*+:-69B V2 DK-:ID3#M-GHTIIU!\Q1Z&5/M6'/K,K<[G-]I*@S&+9#Q/L>-1:T[0Q"$LS3#"ET2-R#NB??^U>\K?NE>9[[U,Q4C>@+_DR= MRM719L?(*_>D"GPE)YED;BUIB" 3N^X@AA1PJ%78*7R..GN?/KM-;CWD3:K8 MESI97=5#BFCIQ#$\/MO;MGG*@K([O[#YW7("@Z\J98L<(ZT+-04$HG\R8L"G M!B+D_@\2@/>UV-5G_$?_I]@E:>)G]BL>\T ([-2%=XI[UX!_9=^E8PARBB[\ M7[MAOUW^TVZCN=MJO)Y1,[Q'JB0*SK1_D54Y%&&_55"H+]&3X! 8HCV'$$Y$ MQQJR7+J@M;NDM0!43B[IRP^+B";9BPOF@ NF\79M'-&[ LMA<>PK!9Q\0-D7 M"Q:<*F$'/O9><2'D7"E9:'ZPKI&YL2"4,3D*28 BX_70F=8H-G*Q4%DG_H=J M=@97=@H,'W;")*@[. N/'T4*SYW@\%';/8.8?.5;GNT^=0E;7>\ _Q(\<>_C M(?N-+=PN6(;$O=H.@$&K#SLN\?CU=:(5RYJP8_9$/],C03"QL67QS"YL2UG$ M9A' XT_/B>--PD$P(Q])$U:'+A=']'"0/IQFHJI% X),J;-F?!3OV+.^X]TN!D2FDHUC6X"+NB^-B M2FRMZ\.Y#)B*F8BTQ/Y8Q]\>BU2;].&O!-8B3CQ0?SNH?NK(IPQB,8UV17E7 M9_XD".7:B]0GG,'UHA!Q0:F'S,5=;_$K'5T&?KP(>\N;W_01R%:XBJ3]L@FR M'.HFJ!9F#A:]XE0?H6V&C5)2RB2[$'TW\NY+FU?](X4N?JVGWJ+;$&^*3"N: MI70@>41N$)Q/&'-31IN1BMX+%)72V+&1"\D\2TX#:-$<0?G/@I(W>X#Z_"*5 M5<57DA%9NI5N/6^SZ,W,F4G^'KLCR?EN)O\[IBMBS=G$"2+$5L5EL*7!.O+: M+*.*&7:"^BXO:/+72%CG568SR&$O&_HW#HAK^O M*)--K.V6V&3VE4B'=6-&"D^JFDVF";I)8SN\%5GW1T;V=\UT$TT1I"I&R[S' MN>I+A,^STE([<\@ X910*/\R$M7!K)8 2_-V.F/!!5-T M3;"QC+8TE&J*=;Z29QR)KT+IP'IA_.5<;8'I))D5?PI324ZH\O-)6UM9 MRT MK:18?V&V$I?,1FU%,BO^%+:2G%!EYM,$$YTMQ8_VFF6=1S4#2=F,%\S2A/EO-1EA02 MXHS9:H8@5O8M6Q9$43:V4AMHO7AK:2DWZZ0W,N2\4:Y/66]5%C8J%8W*<.N MEV\TLOQY^)>^I[#FZ"\M<]T.OWG3>PU+B^32+RJL M_PB^BYSV2L6+U:^PT"=/V I_SR5-C?*+K7&F6O 6_?B#=K.N''"%CRQ*2*.9 M4AZR? G'YXOEO\#/WZX;LX I$EWA'S=Q1&/]16P.1,4K8F4.MVDWPU= OZG3 MHQK-]15Q2R=\]\E&)K\?!9N8T66)J\&OS1@FJS7\UV?.6N30%'K-^+*#=C-9 MBK'0RPOZS4DE.E6TO7?((^\*)]B%UN)#T+H>!\F&JZR?*X\J:3;PG>(AM:(D7D#9XO'Y++C<;KO)L?7 V M_9AEP_S$LDX9C0*;K"9XA&P19Z#%TR%"1WBR[+78J?GQK!7$6>+^$5V#I JF MW-=D]](H)N8!E$W02P>R-'UC'G-+?B2&4NH<(V&C.[AB">W2R\;%HT'D*XY5 M'@N695T>0%C\@%9PF<06-;ENZ%.AEMN?Y.LJVGD7)4YEY3*[HT8>)A>A7'M7 MWKB/2'?0@<:(-4\P@UE8'2+RS :8PJ2ZW4?Y$1'M)F$AO+* D--9HPE9&*EB ME22A$;P928/'/><&402),1)W6_"KK">3T1^Y>9M4/V0\[,Q^ H77=P=D&P'QQUN&>#'O$J M"DNEOVM]>J80?-FTY-"Z@^4)D-Z)PZDE;H8QQ8_/.Q=ER*1'DW,_2:.=+RD* M6;Y+G4M (^=2!JPJ6'18SQ&_"M%VH:7_=1F9<)5GTYC-NHB,+Q&D6E\3F$2J MW&7/_(:'=A:IQ*G,8+([:F1^N0@+[8_$2TK:[@')82I]:7" )O;&APYOPLF@ M*50&Z:AM3C4OX451%LY0VC/\_.;$?(:)Q_P^6/_0KBI1$0!E[+3-;QX54;"# M>-U(@TPK!4EJ(TQ7F!F51LBC>*0B'PRPQ2\,[=I('^AI4%+\-#@":^J#/@E) M/F4\U^$?;C*6=[^UW6/+H?SP@3;LY(.4N]J,SA=CMO#DRK7FR[#;NY8)G41MK5A-1-6P1-;YP2;8B]4&VX4X*2&>#J>6([_1L>0(*15 M!))C4ZGH] ]/?&F.'R[ 4W3-DI)FO?%.'ZZ4^.0.Y_?HZ_U+F#!D>]PP=:,,A(OKDU641J[:W MR%?(5DXA/8U8S,(E/R)CHP<$B7X>60),H9'%81FFT+9AL-',\#PB_UY*M'#B MWTY_--?.]M;GH<0!1(VXSL(EOT.!&2L1)VRN/6*,($7Z3=]\C-(-53P3F<@] MOSA;)"*+GK$Q_^]K_Y*Q+,_P%02P,$% @ M,&+%_UZJU7X[:.B_/+A/\6B<@U-2 "#FC*8*W4\GO15I-P18%(=D['R7S;^ MGU)41HQ-SDJEY^?GMRI_AZJ(0(HMHD(J'BC%(B_0*[).H"CP3+FSH-*'$Z5R MS/^=E^-Y_/K+?KM1JM9+]U\6K% 6]R(NME+ZU;_KJ"(Y!$9F4 5,5 M !2=4?OA#58!LYG<:)<2^H;XK>B]5A2/BI5J\:CR=D:U@L.;HGP@V( ]J"NV MY6=L/H'G!8K&$T,89#\;$:B?%P:$ZD7!8/G(*>)7\>0'^5'')L4&T@3WE\ 0 M5>F/(&0%111]WVLM*@$,@V*=#:%AJU<2?R^%?KPDQ\06]\HQ[#/^\QB:::Q< M+<$Q-'M+ZX".F@9^3F'BXJ/W5!51@J)9AMXD;;JZO(G#&H*E!S:N*@$CIJ #NSVZ7ZN)*@N08-1 M[XE-?K%<<9OIK\$ KQZ7V%+A&1>F[2!7?UMH"@Q!]P6K T+FO+/^ @P+RJA! M/.#2JP)+DE\0?Q4!43T3^8\^O=>[0?>-$K7&8[NT(N(-U_N\3O!X@XX,)Z8/ M$PT2/@P6E&>(AB,F?G2:8G+74E5L<8P>5"''X\WB%C*9GA:%YW.\O10HFBY7 ME^J*+JF$:9E37B8F\VN"*94AQ0K"JZ%[R?PJ'R[71ZM0S+>LD1,,!$!["V4U!]% MX.W)X!S4\%XJFSB;9LIP(-2/@\G*$IW$W7 M%XEW(-U<-&=A,X,TZC21*58_;R"@"ZRY1'4B\0Y$G6C.7'7>9Z'.B[SGR3X3CG@ M]!E6GT;8X(52,<]DPR9 YA*8JR5NBX'+>@0E7SQ_" M1/"5X>9+EY,.N9MJMEG2]L:"8/*-\^/)$$A/Z&I.VH:!3;GLKV'DVH'&;P!^ M7D)G5BE7,30-"4N!T05(:YEU,$$,&%(6*T*@<@\IXDD1RE38/"J-'#W( #*A M=@6(R;LZ>J&JUMBRXY<&U)&*I 2 ,5 /H9N*0U[H=DO*)4 /P%X*$?EM!(Z@ M2?F4SDD?NL&4WD+6T>_ 3-(*8"(3#F+83\QKR&1LRP">AQR["3(W8N:L6EQ. M0F8 4:'_854JZ*V0.$ADLY56TMD^2LYQ6\U83-<"[+R.+L&ZG,%FN?B4;;0' MI]"TY,R9%F7G'I8$Z. ?[3P2,IY8US'E_>HUQIK=,""9(A72/O=Z.5%Y*%JN M\?D&]J-(6N\1BELEV4Q$!CT/:-S4$2ENOPZ2.BKJ00HYTR)_LL%]U,!V!H!; MKIPF&P68;^0:*IZ_*4X)(Y4A8MP]'V7XHHJL(7/U*%^F)GA^/T>&,#AD0]@H'V7XH0 M@K+=.'9.B!DB<4<3!T0H(_:6J$0]-D$*9>RC9G]^;7\Y_NO/;^K$FCV8QS7M MY60Z?)B;]PWK^?J$U$X^5Q_O[^;4.)FJ+V7C$RNQ/OST5-OW4U2M?2[/645_,8[;)S4P^-JH MW9957#T^J@[K<%@KW0_GP[L6N#HVJYB\>6BKHX<3\#1X@_7W]T]=]@T^URJ# M\9?*'X_T^TO[]\>KQKM9Y^&ETSFM@>/[RH \M(E1_FSH1P/CSKJI'=]\NFF? M?C>OC9E5>0;7UJ?.S>18LSZ5JR4T86K'NOOC'6.-V>GH]\X)G'V9-TXNKJJ/ MW?%M7P,7]Y]AZ^7%(-WJZ$U[_GA]TF;67TJ]W_/.Z.VW2V_TMO!\W*UBM]=5 M"ZG1VQ+,GL0]ZQ7WR;$<94=NZ.QQ)0(<+WP*D"X_P,1^4R1VCN%@6YX3< J3 MED3G%I^KPVP4:BU[SB,ERQB_B0DOPW0VWM6Y?=H:J,+T:X!,X<674.?O2%J2 M3@*?^R)+(L42$9OM!*)E,D@@E3F-7H7(>X$VD31K_*Q/%8K)6Y1]*KH^ N80 MMLPF0,29DMA;L1T],'W/KTS(0>N$1>Y_GY:*J/5Y1'&KA".%M(U,3!";>^[#XT)_* MUT\N^5Q;TB9B&-2AB!M 4K93QH"4"9EI*%%P.8\U,9CP]7I^ 3-L'F&I+.&S M"MZ*[=]>=+*X@RKUW%;@8>QE?!U4BU)+'&+NZ';J,N^K MOP+"PTY&>63J92UV2-T :"RG^24R(/4[[V7# MX0]\Y$S$=,C1\FP47KDEQW_.?3Y(2M)UF5=7S%J&>Y,KJ-X]JCMKJ\N _ZYHUT>EMUQ0SNCXQ3J<>Y-GPST4 M'WCAZFXDC67)OTOK>.1[3E#9T@GLO(;UR=25V1U,BND9L[^:EX+UT'HZ>_C!G/G>QKPA?JW MA0@,O>%51@T3H.^GCT=X@N_T40*6UU?#BZFG%"%6.Q>?Y>6_0>A;W">/50@U M+Y'"ZRO$>J<4AXV VT\/C=!ZY7Q<.(_97[:]P%KNU&4+YL/:RZ IA5A^ K.\ M)7?%)9QM:K$=+.T"H0V(>[IXF*Z%K=&9[8VZW,Z5[[;I\8&*(-7=T+G=;@[Q]*Q_!5C;E8T?Q MH0/"3P+CA8@;\FM_$KBI?\VTMW1,ZNC+9G;,X*\(D]'7)<+/.6TN=R]))E;X M4?:=Y=+%_9+$M-[KI2:ZIW ,D%C>Z>A- M1+D:#Q"0'=0KB36Y;W*&R!Z4M)J&[,@;W8+:S8?%-]F*#NH?4$L#!!0 ( M #!G,%&T7H_7-#L *6Q P 5 8G)S9BTR,#(P,#,S,5]D968N>&UL[7WK M<]RXL>_W\U?H^'RYMU**_(CC]=;N/35Z.4HLC2+)ZVQ.G=JB.!@-UAQR%B3' M&O_U%^!CA@\ !$ T,915E_?GE MBP,4^M$,AP\_O_AT>SBY/;FX>/'?_^_@X#]^^L_#PX,/*$3$2]#LX'YS'!XLDF3UX]'1UZ]?_^S3WXE]3% $A'; <\H0@-N"/!W7/QR!'^.R,/1ZYOW]_E/WK]E=CS/M%.NRKHW]=?KSU%VCI'>(P3KS09P1B_&.<_?!CY'M) M)LE.O@Z$O\'^=EC^VB'[T>&KUX=O7OWY,9YM6:2_,TNV9*H#O#W*__$%D]?! MP4\D"M -FA]D4_PQV:S0SR]BO%P%C//L9PN"YC^_N"?Q_)")^N6;G-9_L9_\ M1GX[B<(X"O",@73L!6S.MPN$DA<';.A/-Q=;-KP@B*-Y\H""#.8C]N]'PL^/ M$/?DN#D:T 0NZ/I;HMN$_GE)R1DPW1PA9]0.I[<+ M*H1%%,RHS3C[(\7)YHX.\CHB;Q09E0R0\6E=GB=>O#@/HJ\&@MQ^2CFSPM>4 M/'@A_I89"2^<77E)2E TGZZ84:4_4U71[G&.;"W_VW2Y],@FFM_BAQ#/J>J' MR<3WHS1,Z"9Q347E8Z3*M^)@UIC_$-%A*:(^(J$BB[5/;*X<.B;=:!-\'Z"K M*$'QM;?Q[MG7JFK)_=J:J*Y)M,1Q')%--KXB6\VOK"T4:F;)1^S=XP GZOK5 M^LR>2;E! 3,)= ^@%HLY/)ZOLV*%GUO<16Z3R/]2F-931%<75MT]>%]:W=Z6 M2YRPO2BFUHJJ,EOMU,]4!U8V@LU%>H-BS8VW^H4];;M-[V/T1TH'/5NS22O; MU\9G]CAJF^GC3?:GC2)OD@%LRDUE@[ECIM/NGE4,:=KV!$MSMK?694;/=?.TH#ZEG-,/4T?4QYV0"V1 M%U/'D_K*DN6JI"M5L<)L[YI8#?^'1#06'6UHX](.4W8.$*$FR"PX* MO=GL=,:VY[?OA%N2I9QD]H!=]LQ1=F9@N^E7CU >DJ"Q /5!-*1C:P55.$D9 MS24.\3)=^CO7P7!>TM% M+$0%?,1U^R$;,0W=Q#[PHY6V2FT%ZN\,4 $NR)H MC:,T#C8$K2)"/7*JJC,4QMD?M@?_^_S:)V;7/F8S,B9DT1?B,,-E8KN!,"#* M&P2Z8-G=+4$+^OMXC8(H-EP_=JG;W-TZKU%.4>)AY8M#Y>&L+4(EUU1O$GIC MVII)]=9%CU_>E_!>N!Z/'8/8$F+C,D:/1\''5I=;P\_77%V"KZUY3*(K&CTV MNT:Q:-_;9Q+-I2X>P.95O/#F1G<1=0YDTV5HW*3H&E'^U_UU]33R4R:#23@[ MHQ)(-AWG-]A=%YJ1#5-:[1WQ5/@6/F>5;)'O%?)NQ/\-+MJ%'X>$,S;TT M2%X<%&2J;&_'P&%R1#\Y*G[GJ/UY83N!>8V6'@Z-6T0TI5O[=&NM(+BD:TB/-_;!EB.JI_3@R);61TJ[ MQA5Z3!#UAV&7 M1&(9182Z #^_>$E_-U/^'WUZWD*SGU\D)-V=2 VA.$D)"YN 1Z1):*M @^/" MU\$V BW1 '!XACH;L_^PT(NUE[ G)))U"_LU@X""E7DY@DJ@ MHU7$%&78B:#10LK/W_$-\A&ES(Z1*"EX!EE/,GH[IV"O\9++K(#IE7BAF>!T M$3)OGQZA/Y HCB&0:5!PN/XZ0DP *\-Q+PC-#+:-4Y 1-0LVUTZ E$Q6!3Y_D>'3WY<# M]^'V8I-1]M]4MA-CJ\;>1)+-=>#E%S;4]5@QC_\* 9DS";U] *6A@74#)I.5 M@FO=8V' K0CG%JE[&8#MZ97;?HIG];HZCQR'/%,JTW:ZNYO> *A+5L6T]<1V M@!L""35WZTM7O04 FMPB]#J&%L^7E&?Z$SKDK,T,Y*E4A;S;K:I;MWDG526Q M=F-K!]G<^7<+;P.TE>(V&L9-2>F.RB7+!==]DF("5.\GH(_+B+=4- M(%A2>F,"2RZX JRW=L&J+N-*6!5C./#B&,\QF@%BIT-^3%!JB;5 ]J]VD1W& M4NZS?;1PX%/P$7MB PS*^(_>2HZ@H2>XC7:GEV$)]X*)UX !7$V(8!>OE8/'D-N?"ME1FDTE>:KD&_0$2@'+ M]YBQZK*,)Q8-6V9@0]Y$ZG$P"N!TI=I]$#7;7F)$Y\=*A9PB5K'R[O$&VLC81EQ>F&OXB1SH*2/3"81?:!(I$A8Q#_\\$ MBJJ NG/*#.&XBL*H3G" $UR.SJ,4$$Q9#GJ28)IV]WRJI: M+[C7$!)(7'\6N)GS!&+,*L.[V_V-Y%^3C-U+NZPX_4G63NHB//\\(@@_A'GNIE]M#?&!3IIM><=H3G\'*(1< MA[S;G6[?H*($]L]<)C :(AEQ*)U<: M/& :KM3,#"NSPB!/ZRIDQ[+-*HFP1!"BW!R' ;&[1NUQ]K<@L]^3V>]I;H!+ MEJ\CDOU#DA!\GR99-^LH3PL".X8.-@&W2;BJ"ZUUUAT.8)@T&\G-NEA4)3KBTZ\-:(Z]&/LL;@,':0(3!MY% MTF$-D X]E0'5$AQ0E,MG:IX7E,!D38]*#^@J9=.9SEL!S04?ISAF=%-ZEJ+* M!]I>S1)G8W'/; %1KFO+!91D[%6X&V"]&W+BT%[;76.J2B-#1FK1PM[V\/R6]. 6I%9(U2>>M MC$J]MDA=#FU=C<*$JME9D/W6SR]B]+#,CWTV8[-++G*59(YN%&8E!!\QK#)Q M"4)AQ6T7+,6NIIU@O,_+>I-N=U49!>9"D-M9 MR@:FHRN_[" <'G*"SFN5*D#3(3*@ZG_-PH-P" DHC6+9B*0$4K=/H7H@X#I2 M)NZZ!JW*DE*7)%BVP7=:A5'U3"2LU6?=+1BD'(2@!L1^@R L\B![X3#S"LK7 ML/@N$NQW&3?W'J7&5BM=JE[QJG;V2$]T.$;3>:8UTU46 /C2]AG MJ&#$C$I>2^8T)51KKQ'!45Z_*?_Q>43* @-@)E>9@?THD=5MC-4EVIE,9!'5 M:N4@-["*.-B#"G8FH H%"M/IZ@Y17XUX9)-O\KSHB6:\! BX1GSL_PYN)EZ% M)";3^@(X@0HHK(P^ I-:E85*S+>#NEDG7KPX#Z*O+TSQKI09*\<"?3^7TNN3 M-HD2-AZ%;(VI-(\WGV)656R;NSGQ$[S.BXQ#YE'J<[$?ZT""?B.R5EO*(#>4 MWU7HL[EN=T=%V[XXKIQ!;I ?A3X.4(WR7;0'ZQ2$3X?7U'8T! 8]F,)PIVA% MD(_+\^MDR0)SOV5_A5 8&3F7'B;D@JMW0Y:(&ZHX8Y4*RXB]3U@0$NM4?TW0 M$J=+$-/02=3M9C 4X@K"!RND1:="6%FA4Y3_]R)42!ZWEH6F1-JAL1]* Y11 M@.E_5<0;UZ\JP6[]VY2^![,N$C+4M2^[LF+]DHIK9KJ3?/8(\>@T*]=84W(2 M>!@F.%*/ :=GL\&6N1XF,)UPV[9F.XOBZ0*XD+@Z+2BLN0SDR/*$"G+P;Y-FU0E"^L%@?EJ5H-LT.*L0 MUN0(%5W!89I%W&PY']SI%I-W7H7 *KH2,0-%<;1YH.>YE8=9I^*L-599SRC, MHZXF<8S 2L:8R*!\T^XV1Q$E'#0Q),]XRK M*$'QM;=A^P=E[E-(^0DV=-*EHUC7#D$5-[L4':>B&Z@!A-BA&IR)/8F"GQN4 MQ65>>V2X/4'.PO@4PEC8,%$>ZJ<+MR^G^Q'18?W!%"Q'0,!"7CW,]EJ"5212(/Z'MZD**R) M6GR0AJA5WLB E[?;9?T4S#97J KNN45V =9>DZ+;E@X0ZZ\E4Z"K377FW6Z53\$5X@I5H2F.4=6. M^1SYE-^S1S]KEW!#9S -&5?4QV;_87[VV@N@\DZTZ(_" /. UI,R6$-F2JA! M[(;ZW 3[1;9#UFJN^H/*;^;94>W[-#](9UDKK=W,\ME":,O ,QB5NSTTNIU) M4J8JVEX2$[KV"&'7\UG*)91F=1,>T^:B*,K.Y"O#W*=TMY%.(_( M,H]SADR#4B3M<#?1Q5)9F@JM*OKU7V,I[W0OA'F5JI-P:WWU])?7A6TK*IA" M>)76)HP2T#MAC<1X$6F("N:X6W)U%84^_>/N1C.<\ MGSJN.[]%)LK0%!I897]D]'1>S(+@>'E4TV#"51#-:Q0\M= M**U-D.V*7S5M:J!R E/RX(5%HI<7SJZ\A$HAFN^ZE+TP;,%:&7=7LB#/'[RF MO@?;)//DL@(/+]@:4] W+3N,&8?99/*=5N4+<1G9IN(V<-:J-M3N)SGR5'WB M&:J6?+I<>F03S6_Q0XCGV&?1 7F(%ROI0T7ALSLYXWJ3C8% $^?%U$SS_&0R MN:/"/J;??P'Q1]0H.T[W[82WYH4H"G.?.BU\B%B8)-VE$0E?Z'NOV=Y<'8.O M_@(_A_NAH7]6'4N@N IJU=^RM;P8U!M*RF MZ%N#RP?>>'K&4_BQ@ULA%RS2IDG5Z>6]&.5OO7+D'O MUUJKI/I4V])F:\ZL001_/,A%U4FS1[L+_L@#K2 =\FX]'E78ZUTR-(2[5_Y0 MM0_!*1W8QXGI>FFW-&![,VQ!5"G%GAT3:@.7!C4K^+--7@&]8M'EP76A?17T M6P64M(2L4GYCL /RIW=! T-Y/^*>N:A#RENM2,!@#YOW M,?HC9>U$UUE:P+-Q>S9NKEIC-W01]EPC)+;'9DE!4IW693C;TGZ_/MYD?]J8 M6YFQQTK4 F=R80"?+R3TQA07(1<<3.S[)]9-[RQ.\-)+8#).&Q1[/(,AMBX)-7>WQ[K@B 6F MT#33]&6:&MX4L38-#[EL!@"KF^B8?'0%$7;G@9MA%R,ZJT66U+-&0909W*(8 M7;\IM/I2W MGJ=:=!'Z5(&H&6>^4 RW#DW8& NX1B(NC^-V.X2<>22D7+,J+AE7 RS1+I)C M0;%3="5BTGM;;<3./4RR BR7R&//Z[MCR #8J1,?"XH:XBSQM'V54E28&.0J M14!K-&<\L;1*=*QWQ[M"7RL\DBBD?_3S%^#!UITV#V,Z8N@+N,1:=LVR;XG$ MV3.L<<3XV-_(;OT%FJ4!8CUK.=U*)\G6#F=R@GTF-N5E+'N:N;#W+$5?D"O: M;RF--V5T"UL%S,)MF4W#&^2GA% 5H2<+''\*H_L8D:R[X$6X2I.R5VG>+7P8 M+]$FGPY=%/5,51B$H*JZ[NQ$*S9^\M4CLRSP/C^6QFQ6>660.$[S)*]X2%-M MA<.Q)#S;!F:OPA.;^7\[:VZHQL_YJUNBE8!\^,790?$)9JU*Q+M?J0V4_!VUI5+HFSD."4W^&$!';-JS(S;BM+:*7GF0@=K#Z@VDLQC$%0;, ]?%Z9L6]C/5E%JY(,"&&C_*BM=E18DKHV@AFI MC./$80$'>IOZI"1*E3SH'G;VC)"(>E&$H*+R 2LSB2.2-Y&8S'Y/XV2 _/<^ M_#Q=+;$#UW[9XG(NT7Q>"B'8G0J6Q=6,E\P]3-;;&U'=J\5\?2D] YRBQ,-! MK,W71WX&GLC<#<2+:6DQ6/XXF7].Y#1P?J ++=SM+D,@VCN'L=>M^_%F^\>_ M84186-WF(PNJFSQBD$PB1','N M]GA47P^+WNNGBM[K!GJ=/5.LH/=F6/3>/%7TWC30D_5[-NJ'U.K DX?QL"WC M'&5]093.9DH#.:K&[^J4I29O-J"+DDO051EQ!\@K(M"] MG/LENFXU[BIBPO:"R9+-&B9PKHNHVT@>I;7 SWX52G'/0B]WJIOW;\;A5DEQ MV=LY1$G"2A+/J?TI[TW-7WCF)QFAB["R:16$KE!R5Q+2>L@R'MS02'+C;8=9 M(3BO->/$)O:$4+Y2,%*ZP]%6//9N0FTRBN^B:A-!);T2?>O&+%D#02X7JVY% MDU39^KA(3=9%H?GYB%="IV14_'9M*%K\"I('E(!1'LS=8ZHUI-0%9[G8CXAZ MX8=8P(PSDHO3,#A>/(FI%/)Q\XY=NF'4,]L>_>;YT8\5C/^:3R9H!%B;M:,2 M)."TCS?:3.F]9P_!AY$3 <>8^B,V- ]P1IK_A#V@TNVL C2._?F@=8I>G?M MXM&7JWXU@6H\ /40JM(SK)%8';RLJ@I5Z4E45ZB7=)[+=&E75^N#.CD,"%9A M*=;&M&W'%F0DO$< R=8&W4O)UJ>M JJ9S5A%G^AVSG/=[PY3#\;8>MJT'G':JR^]]U\W^LL MO3M$EJ_ ]!:&6W?7]2XU%@AYJ%+QEC<*1'PH8Z^ MF^>0E EKF1_3_49]#K,\ONU+TWDV=G$%4.UU:A:"TCF\"OR0*)I>W"S%_$3JK#+RL/H( 6 ]]@:@"L]Z#H3Z]E((%T MKWJ$[^Q?L45XUE#ID0UJ<&FO?$+PR8Z2W%8EA:WU#N +"Z3Z"I<63'ZJ$!HG[Z5VT5%+-#5; M.\7*ADMPJQ-PFSPA-115&!I2@>D'R[6MTS2)$WK^QN'#8-Y"E:;+G$-+_D-- MA&!YHES2M9N+75Y.65D0Y-+5C!&W"]$2TMWBMMJ"-K]@XS'R&;'_1[/)&A'O M >4'O:R!5IB=VU,OX%RZBX(J>U%P5X!1'50;@K3ZW")F*)X\/!#T0+?QBEFY MH,Q@NOW[VX%XFX(IW>*-B"J2,-ZJULQU8Y]V0)$RA3&;3[5!=G9"7C)5Z9AK>1E;6*=/ *:*-*QWP#6V !8AZJ3PI$UI&UU)N]OAC*D%?+6H MC'Z5ZLG4;I](!6T *VV' M.Z0)[8FN!HWQ+T\=@:KTPAWV@O4U^ 7KZY&[0>J"+-&57-E8P39.2DM2&!CU MZ@/*HXT:,X& 2GPD%SJ6\6GH3FT_L(N=*J5Q[Z@&DBU!%]_S#&YSWX#;W#?C M7K\:@BSAE=SNN(CTC+*X_%:@IWY\>[LW9"LQH4ZK)6EYP'N/\!%UYY2P076@K"YP#58B2AJ=S%H94T9H0-4,\="&9A0F'! M5,EI**T3;;)>SV@7&+QM+0L7>MLFXK1Q,Z EKBFX$/D\-@U^7V2 M)H?A9-P;]9"0=:<1&1I-)@K6CQ/-3E/"FGQG?&0LQY5W3E$:H,5G9#TNGLY% MM@$"2HE-;C;1DLOQ;J%Z,RCT\*?_/#P\^)_/E[^\_=__^9>_2A]_#=^^GWU[ MMW[X=1-^.DV_?GA'WK_[Q^O?/]UMXN#=VO_V,OA[_?FR^,K_V/R M\M_GYZ]O_W&T?CP^^?7E>G9+?KWZX>3#F]/9U5_/C_[T^O+3&K]^_X^7F^35 M_%OP]O+=>^_^\^G[JY=^]/KMF]/E#_\./P2/Z:NOWH?T[]./J[>S].\O M7Q_A5>)/T[M__B5)3A]_6/QM^@X]_K(Y?3_W[]?+J=N;-OGSP7__[[.VW M2?SNW>^;S_^\/#Z[_=^#D]N;P\,GLX '7C+VD]]L.?NMB=Q%B1?L_ZV"$M]/ M9\,9!&6ES#U'6KK")/MFK^\5>&P^WRM(053()W3E%+6X':%;I#>'YYL%4_ A MTB[[KC?SA'<8RJ/?C2%144CA'/P!5#_>2BWKTP5?3TCYAD94+?W4UJF?B)R;&6[9W[9XGUYQ.*-MAEC#Q(.F$/^RZ>@&+8TGY$ MR9M,8_0;O%,=*!6Z,TEI\"H3*X+6.$KC8$/0*B)T-GY$QPKC[ ]Q%."91W]X M[P5>Z*-X@5"RZSFF[S/?H+CLSM("T8"5%M)2QQB,N&D%&,L,J9>Y "$,E:O MKX !K4G;0P$,2(,V6HM)4IV&8MT,^E5E3Z)_:^Y'O&'![KC4:F5 KBBF$5Q) M6FWCU:"@7/Q"%RVGU2HD"LF1LD:1"3TCS*6C5!^BA[2=%'0P$;AB!S2C/DX> M(1OJ*=T4"W&RC-(PV;:E/L4QH\.:N8+5:=!EP<7EO=06U!HUZ:P!-I?33\!4ZGE 6SL]T=,"<3%ZS,=(38_&AOA=B:77.$W)-1RF5OM 5B2' ;<[Q=2"9!V6OYQ" $CZ.I!R!%L M2O40C""[8;,(T>S,(^R.,Y[X?KI, \9H<2L+@:0"552=GD!>--I7OQ.3RY*N2J^_PH8 [X:W$V&,,*H*[O)#^SI)^N6!W$VM$IQ%7 M7@_,VML3$I&3B.Y.?D:#E21R66DQ: [IKNF5-A'RW11Z#Z MIW4";CN!6E]S#>EUEUHV>RBM7-#DY"C=Z?S.>X1Y)163<]DHPSIX4KEV7M(; MW8P5E\.4Y3(,'_MT'J$_)@Q?B;]E% MK!?.KCQ6R"N:3[>7L\75]@LCYUYU=,'-JV"OUA_5*'%3E8QZ/+7>B$,W"S0& M:^M-:$K,46/ XS2F,XCCB?]'BN-&GH.^^;9Q$[QWM4T<.Z>GC%B M.HS&TX]!N%R+RO@-)4]TMB]%^+1@FZ(*:;EM;"K65#$H W0H%1&$,7Q2;)Q: MO'[P6&_YF=T_LQLPJZ_9VP&!SK7 EJLA%*LANMNQE9_HU$5>?7)S]CS=5*:: M0('>T1KC6WR*;HC5U1.T@E#!N@$S6Y2G*S FCS>?0OQ'BDY1[!.\@CP[JA%V MG$AKQ3U2$*]"_\#^X,([3%Q:[ATF9?T6(Z?G0]G$"LZ%$J+EW(6R"AC(R9&9 MYTLJG&6ZM+O5UP=U\GHN<&+*7:DQ;=L78AD)[Q% LK5!]U*R]6G#A-*D">4O MP?YNJ4R2$SHP#A]T@FNZAW&0D:*Z[^U";Q2D 1(5UJ9[L5RB&?82%&QNT_L8 M4:,7)G>1%6B4QG8:J=,',37)@:PF.GA$-I>G&O T/G&X2I2?'+;";T[7KB>4 MD;@F./3QR@LFX6SB^W2<61ET-9U?4_YQ'%,>6%IUWAOE>&, 0G\JSE>+[")T M"Y@%:4(]>.5I7ISNC?O0>0*$5UXHX29WL] M5AN(&/1I96>JB$(3 M+[7:!U(G4I.#,0.N*VR5.&,+J$$?L"A%["? MYD'X P#-(^HPFQ8 7ZY88<(CL_S<&[1*B;_P6(':Z(%XR[RH\G2>:Q7US!81 MP=_0["XZ1KM?AFL,9\S0F-=X3RA4"B,81*RS-.\@R&8QG9]$RV449HSF_"CY M9%UCC!$T->$ UBQH*+5YMSMS5D@)56/.78XWYVD!^ ;#GB^SD ^3D M>:\#D)\CZ)XCZ$890?<<\P/AYGDQCJ?SQB:ZR?__CI[NCNGW7T \/37*#I^. M^Y^U=:7?A&::3$87WB"I+"+]V=S-HZ0I$(AB0[A$G7KPX M/[TXN0A9Z<.B*"+(A3R7D*-77'MK2" _A0P>TZJ@\>)3B(= JTG&54\!NV"U MA*<0 F%67''-"K^3S14"0:@VOK,7+7O8U.75&0-A%H:V(LC'V4,-!"2U\9\ M)'5YJ31@,&B@$B,ZL06K&898+X05NZL'+$@J)SA^$]Q\:]Q2P IA!D897+,YZR\9%G?\\Y[O/$2=!*Q M:::4CUVL!(2.:%!_ CNTCJS+4[SEJQH^"S?(CT(?![GS4-9=/@L]/T&SXG>& M@U^)FR=QI=,'C5)!.AI9#!1V]"&B4Z>:[",25H*+M&^:...T)"B];)(.8!HA MSQE4/2!(^#'4UL8/^E&1[/9>2SSAW@$\9N<.>MI,81IM;L=V:%%4L6G+ Z2L MT'=1\MY(\/QR]G;O>"D-=O-U3:(UGK&DWD\QRP(LG -ZOF [!EC?60WJSCPR M ]24)6K]*CCC^'-$OC">O15.6,X?I]FL8/?@?^GH(EYK#Q',&:1OP/?8XE5W M%4C:M-J]N'UNL]Q[>U=NE2Q)'!O.^2]RU3'+4HH2%%][&^8L]DHRD(^I=R90 M'>Q_5(=E2(#UEBV@R),(+\,((?A^WWA 6Q# MRXA,YQ-"V*4A9#\$/J$Q6C>!R.R&T6T?@W9D6#^OJRCT=C^YHW^*O;S9%UR; M8%T6X([Y2K90JM&U=S9=T4)EK&DR F,ZC5!V:E6A@%:SMB9 G^/0"WWL!?#M M9T2DG&>5&AI=H>B@NB=G>C%'A&G,+2)K>HH.'Z9S#A\Q4\28_T]POJA5_J"N M!Y4,=L>JJ&V]5D$!\WEML@EC[6UKC].-P)$" 7KE B,)Y^/)"3I,8>HXW=0D^<=(*LTT">?*QDW@6?.HN' M,'VF$8D R NZ)I&/T"QF(<]5/B%6EY"6JS=@ XRZY:9P6+;WGKGMX=3O.7,W MS(B@4)8,3/A0@S)K#$%M\2K@9F^H =(:PU%(D24PVB+I3A0U\CX#+Z;[W.?, M&4JFY 8_+))IFL2)%\ZH#07Q*+MHCFGC41EO$ M&?L@FU$W48=A9#TP5!"F4IB29C&*HG-"5@+Y%,>^L@GD?SDRPR>8?G>JJ+:@ MRU+4)PN/L P4S;(?DL]')G*9(+K3.DW,U"\>P8RUDO)9F.!D,U!_)77BX\'1 M0+ J=9W[/!N&#S?(1_0$1MDIZ%Y[<7*:(I &.PI41^20Z\A2(972O%'2[OZB M,HL["ES,0JUW^C2=9_'7V;9X1TWXPQ"W2OHLC=,1Z0V$8C*EG>/"V2-E!A<>)K]X08HFL]_3HM/B5D= =F,IP3%NQ'()EM!)6Y<9!=LM(\KPMZ)X MQM8=.(GB[-VJ/""!@*A,VUU]FQZ(JDNV!%?2 \T0W:V;GE?18?M\7CB%96U6 M^(- 5YGV*-%5EVR)KK1'V8#99O7.Q[56-D;/@+S16J+K> ^4CZ%Y5RD94SV= M3/8]V'TQ/XM,4<259TG)U/MGC3TGC>E%^"IHHI5DL>=TL>=TL>=TL6'2Q7@+ M6R.^D?^ENV UA:A2V8QMVZ:,UL?("_DUGP5"K7W@[$E7=[.N3]-Z(Z*,1B7" M8CJ_BD)_Y_;6V562L_IHCIXW="'0$ ]4=LTI6D4Q3CYB[QX'66#PQ/?ID+/R MF %SU]U%U.%=F :(&D)4"2_2?U#?15VP,!H?K[S@V M8XW.U9W7)]Z.Q8U(A M*!2='_($/$T6B%349'<$UL>>/Y3>^;=S$#/_1#"L^AE8.@"@;> ?@U5%O5-) MZ?PME$_1AZ1L0G[I^0O6BD@)AM9'CO95;0#:L[7NWY2V_P/EG-44G(:W7L B MZ2=QC+)[UNP/%\N5ATGVN)G%H(#!LT1C! MLA/+1\'S&6X#OD%9,;8\<7U,%=XUGJ!38;^_('=UZ:0D=%RQZ4 M CE!=/ELD6+)D!G/C,D%7MU%>72B\HVV&5@=9 >X/!6T"Y;JK!"P+BEV0@F, MH[T&Q"9(.FM3# &F:NMSLR*V7.,!]>XG(P=VAP)C1I4D.#!L<(^"& M#BL IOY&:!TPF&?";LBI<121Z\!\2>?^B!^@9YP5F<4$8J MCQ%Y0;=K$E$KDVQL.IR&U)V&49AXHZ92[KZWL(;WE;=$)7&M\(M^0 O(NG-6 M^RV(3L!%8H8XF&@R8<^A-4';F4/K!'#[M2P9$Y\]@A91&JM7NU&"LSFLB[? M'K:KA*@E';N.4+8Y7));[\O"(]$ZZ_F8=^F8A+.S1^1GC2,OO9#.@!"-(!W= M,5W H^6V;^_9M*5E_@.*T$IXR,3#DQPT)::H%J7 M8'5P/G-;DT]O"?!F;=_K.UE@--^NJBFEZ2.N"3+7=1D)!PK?XV*V5'^IT"#\ MM>/(([/I_!03Y-/?B$\6[!W3"^T"U4'%U>;>$ZPNV<$4#J_G*Y][/F ;;B$M M5TF&)L]KW8*#NE \3=%=5&$9H_@D)00!@26FYNCUOA=:$ME9;9TIX[1(<(N+ M?V8,Q8C.?L%R&-$:!=$J+QH0-Y-$]1ZLM>@X"XNT_;:M)UV0\%4!9S=9#9!- M5H*T#ZZU<=RE>MH&KBX>N\7R\D,:FF&?U05;4_\G/H\(U0PO0'GF<$+P?:I< M2U)Q*(?A:,;HJ$JILQA>,?.! J"JO42+EI3]8I_$ [9D)Z^\KC".H9T1#ZT> M[-0UQJ!Q3AHRWU5^[Q+"O42"&PLM_Z! M9!:JJ V0*CFU_DZT26F/,-&F/,[K^^RZ;K!;",2EEN*IOWT_MUS7-/52=7YN MN?[<VX;=&"%$:;ANA7Y!&3OKJ"3UVB MT[>5KD@:(*(_CU)R&87)PD3XPH\=QJ7VE;Y8(%;]Q(S6V7(51/GB-)"^^&LG M,0FV ) (Q6XX:QXU.UOC.-()HJ]_X2;"H&>8(V_FUM^*GF-0QQ*#6F10_.+1 M"99I%%I9);POAP].M+$H!%*P720S[W$2$1Q_H,?D.$&8NRQ$;5]X'SJQ^39$ MSA>#Y9-_1NGO*([1YQ,2?=7*"^%\-EZKSY-!9ZB?MJ2S3I1Y7R4M4?.^<^A+ MJK^V[AI#\F8.=&-]38H.JQF'V8$OGJ3)@BZH;[O0/;L]U*44W<7":@:NJ4H0 MK+ACG?"U1Z;DEN6?SK*&2=>(9+S 0RBD[#!RU@J68I$J[.4FB)Y$RV44#K82 M9>2?"MG1&5$E6:K6R]9M X"6=,%G2J/D8-0^&,LZ MX4Q5)?C?^#(]\V%FIREAE<\1P5$.YA7ZFOT+3%B@$N&Q(*8IS@)-23LUBUCF M*N0"S";E\?D8JB(M 'UG.T1%1C[_^7E$;A')4H<&1[;-@:,,50AT.>(M4/[! M:N!(1BT[0(+@MQM]='Y&53*%Z-];/YC)++;+%29@8'P@ZLFW/(#;>990?C\7 M/9_GIN Z)?Z"_1-E-?LQV$JUR>/X5,4Z2J4VV0WU,^8S^[]?4)S099#WG-\K M1>*P]_WH$ ^;4GWL5*CHS6(>F!-7VE1]1HQ3-)NL$?$>T-DC(CZ.@;V) 5@? MX4%A*%!+G;160,/JRLDW]U=[I7L\_D9V3K$*3:E!EBI]]&;R['&%2?;+IUZS M?Z=CU6FP]IUH31.04F$DEX_&"G/?S=^]P&0RO6:-,7/%/O1 M[G0@L)5Z)KD6'5C3MMQ-Z$EUF?//REWYK,X5(LO]TK5N;L?IS@,A5ZJ;^-)V MT&U0QO$O$8OW"7"RN=FW+5*#;5?5)H?>/W60+)50?*<\N#_/8_\&QU_."4)E M&^I1J"&7Z=&]*,+#6.J@['+=N0:6"^B4A4&B<#8*#>0R_5UK(!_&,D1K\!1_ M/=;W]7:MF]MQ.GY R)7:9OE58)<[R1(MBZJX8"^&;4JCLRL"@97PV K8+*JS MLCG@\*%"-?Z,@^"8E0\G23ML4U@B6&&@<5P4:0BFQ*3KUGF@VK,L A$G6<:A M%U(+$;(+3A3ZN];B+TQ2HKJ';*U&DH. MRK1T:Y!8Q%!] V74FM56#.3LH$9*?RG#54$IBWE E9FJC0_F6H)9%[Z88*& MJR6X5U4 >9K'$SELT^@AZN[M6\4\/Q<9V]W%Y YM8(V40.QD7E5HS]2G&PN0I\:!KQ&S#2_ M?OGJ!YUR3](1'%9)$->14YDYR-EN@4F.L(9\6Q\-?VNG995W9XW6;*U7K\_I M?$7!&F6UT4RK]74,X>Y9HN,V8"?K#AD 21Z%_<0N^=[9,X&RR&63!RB$=8L? M,WJLR?O?HI1; UC4RXO_Z=Z+6#1E@'I[&9U@PWH->@'W44Q498SWH3N#T><6 MFB\#&+_C=A&1)$%D^1%YL6*1A.8WXY1R:^9@+2@^LII::$I/AQ[C+Z-WBF*? MX.SY#,(G[R+IZ,71$"]E0=KN%EL2KI.,V.9D?Z"\F<9FI\H%$\7[E:TO8=)A6Y,J0 MR$#K+,_C.(_[*@7K8V&=R7%ZF@!@=58#.ABT'7MZ'Z,_4N:"K9F0=G%P^D=( M_E M^G?(E<[?1N=U$U-XBNZ3BS"F MHV3K!N@1F$/%?:-,!7VLVB&>I& >#NN48.-3A+3<#FS\I/6<)$#KZRT>,)STH3UQ,$\KGZ\#,J==G#S&X\#U*:XU( M@NG"_T#P["I*D$Y@B.1S=U%F*I:CDCDG%L! '@-@=U\N(7?(=/JS$B]!'Q0' MBB>_BK"F=/KKW-]1O*8\XSB.R$9WM7<.XB(@3%OXW:*PWQ"7H7Q!R<:LZ:6& MQ'G?.8R(5I8Q=[Z6&U0U5U(=3&&<4O=.)A[(5;T#W=MS-:F )4W5U>3<\UF) MA30$"3@2TG)6A4T#K&Z!=:Z9YP8Z[N'3[)XCC?(SJXQ1Q*%(2C=)2F%P/Q[# M\NF8OD)K-GUA>_%B,ENW@Z=$\JW\_FAVC^H<51JR6=@DJI7Z\CY[= VQS"KO M 21*38.ZNWI3O7<2N52[H]%L('OI)=0F)AM68QLX>%R-\(CQ%,I2H2_;@#$Z MIY&?/W6&L[.L9_=%.(_(,@M%T@S4F2'\6SE<9926S'9J%)<0QO6=_.&1_J&A.Y_#ZJT P)"=RQQ:WVYB>0>)Y5!%A6BR7Q=!1/(R;7!]O MT .F:\K+S[ 64.$.Z\+0Z*+#EX?"R=!T2; [/XO+(!O.@:]JN@KRZ5O/V&(D M3E)"V.D1Q[X7L*32LW#&[S2B+6WAT,.[M+J"%TO%;@/NW6)J=?VNQ-1:,S52 M(ON/BHJD[*95,:H3RMXLNV$)/!M0U,=S\O2@*_B&"#I/=\8BEKKZYI)V[<@; MRYOGKLM.7H:V![$'S^""^NN/_T ;>^:F,:Z;"SI#*].4B>)AR43\^69S@U:L MHC"K-4P/;#;.*-+A1V%XY *RVG%Z1^X: M-O7P\\MO>\XG?]QQ6""!3+J[/_>Y==CYNN?T)S:O2)HCC\+R",72W36Y)P1% MZS<0$*ICC\$1DDBFN_VP\89\N_2"X#B-*5>\I&;##: ^ZE@V@(8L5!KLF@G] M;(G( ]W:A>:&_WY8\^@BL@J7"ZF]4:+H %"@+;$-0&'<4>P!.& MY7:O%8@?L]J&F1QR0V=/^=M#C\7\\*2BT@G5W/,751OHX?;O:@.,1NFKDNAN M!6J^U5Z$?D3HL2[C*7ML/F$A3&1S$LWL/;'(J8S!$5*2EE*[3%.<$L1BXO$: MT<.(5YS(+0+$'7Y$NX1(0 KM(\5/[#\=,4JL?2_[M?\/4$L#!!0 ( #!G M,%$[ZY1\\X4 -W@!@ 5 8G)S9BTR,#(P,#,S,5]L86(N>&UL[+U[<^.X ME3?\__,I\&3?VIJI=4_;W9N=3)+-4[(M]RBQ):^L[LYD*I6B1-R\$Y/P('YX8__K^770B>89(&'-Y.'J]GL-__O3P#\GS_^WS=OP <8P<3+H \>C^ JWNT? MU@%8)5Z4;N)D![[*=E^#-V";9?O?OWW[Y,#?@]4!@@>X!Q>_1?_W^_/SWY__#DRO5^#=^;MSVN7__#$,HI\> MO10"1'>4_O=OF)E>'I/PFSAY>OON_/S]VZ+A;VC+W[_@7]3:?WE/6E]\]]UW M;\E?RZ9IP&N(AKUX^]>[VX?U%NZ\-T&49EZTQA.DP>]3\LO;>.UEA)-*NH"P M!?[7FZ+9&_RK-Q?OWKR_^.8E]7]#^0; 'Y,XA$NX 83RWV?'/?SOWZ3!;A]B M@LCOM@G<\ D)D^0M[O\V@D^8]7B2[_ D%_^%)_FW_--U;"%]W$:8.A/'M,L\=89EU>$DHV7/A)R\N'>XN_[+0RSM/C-&_R;-^<7.>C_ MK=6\B%GYFC#1M545FU K3E&1&?/A'^%C2#86U!GOJ3!Z\_'A-W\JNX)X \K. MH.@-?BSZ__V/E(0_5;+"_YPD=8%YR;H@$OVH6%C>XNTZ1OO7/GM36^,FB7=F MHLYB ]:\-4;A)$UAEEX=D@1-,P3UL-9L^_)X!@PLTB,7%(D.PSK=_ MZIOAC-[:@N'G'([G?P9AU%T^?]?) #?XG6=UQF;NEWQWQOH\& 0OC- M7=CZ!R;ZLE98+(+O:OQ,/3\Y*%I>G^+U3]LX]!$;IS\?@NPXS&6I,8N+PZU) MAO0C>U@MKO[R_>+V>KI\^/=_^]V[BV__ *ZG-[.KV:H$B)-KD$AD]4L/=ZV] M'W![F 2QCZY82=:>];R/\=(+L2FK^@1?&8O/!]CD*).GD=^>Q1;8!UDKQ;>[P9@_#-,'F,3UK_G6K,8IGO[.'W] M/'_?C[(\B7P[Q[URSOZO62T4:RY)NMHVF,ROQZH8Z(I:H$N*^5+=@EI!;Q:M MXQTLK:]#6N-%4PV@9W?<5GYA;@XL-R\? [I>+&V8_<0(#CAA8T9\NQ?R46NRQ)S^( MGJ8O>QBEPQAVFI/8/X<:-,AOH-/;V]G\PQGX,)U/E]CHPA]FP2D-] A<> MCAH% @#/IRN 0>P2L%Q1U+;VQD+LN^8;-/#<%:@1"-'?G1H7V[-S""^%AAFW M00?//8%9>EMCZ2MAZD6'&S".7T_@%FDOP7.^4:+Q%QNT6PZQ5 MP80=-^WJED+3)1/W_I7+#.-:).F$IW.\>W00GO'<;8RZ6NB"('4%APRUWX>M MAZ2Z.&0X50CG5 T"O<8DS@).3BD1H"N/A0!?!1&@?;YVZR<6B:D&%N[B>CXP M]().>)1(PGJX?'Y5;.[A0* ?-3YXX@A?:B2A"03(G=C%RZ]4_AF>6I<>>GV)HR_I)94B^9\EIWM,EIT5 G< M"9!>7,>[6^5!*$V!SL#G@+'_'6G >,3[)'X.?.A?'C^FT)]%I;-FLLZ"Y\$B M\%O,;O^NJD^VCI?Q/#"-M M6&3[HMN./)'1;XVWCP/J"9!&$Q>6;N#1SD>WIY1-^9DK1()YJ+G?U2[#FWTT MNPR'.-U=9C;_-'UX%;N,1/X:*!6QR-QIQ)LE3R1WA%'>[*/!*([?8JEW"NK3QPCAPKU^Y2"Z,=_+) M>AT?<)SN_>@?0LA4-6.R^>Z0'G)(H#_);KP@(8CE(PR/17!S_CY'3@4U9!X^I"P)V^9C R\ &C0J>\;".0=D/&C!@>^!J!V=6.>#E ML?SQ^P FB 7;XRU\1IP50(LXQZ = %E'^!%/IA//HW"D=I. MVNQVVH(OK1U@Y OX$*.M^@HO(1'4$!5LFMR._5L:A!LB;WY1DBEN"O*V8]C M9$PO]R;A @W-9M?P,;L.TG48XTUM2!5,,)/5*#P^#0* X,:@:CV:*K!RD;'[ MA&2Y+>%R$9O.+"IWG]+>,X<9+4".;E:&ZE;+P2WH[YT(U%"UJ(D,NU$9 ME2HH!@41S$!6##N"&@F]@(&C;1GPU3B^XQHFZ%J;!<]PX&**_(D&L3DIS81< M6A1AH7$$KN$:[AYA MY?G(%WYQ??N2[.(15>?0,4+=A1B3(A0;*(422".ZS: MY?Q_=^[RXM^=]T;E&D\O9L46@7:-.,J?S+B!7H;..5S'Y[.7H/TB8XO[&-[] MS2>R=%GJC6 =FT!U/.%CJQP?;/()R 7K"YVB9C<8W:G5'4$\>T$WYK>UI:9) M]H\E/C,US0*H/7-PH7^='EKU 2UH5K4))3&K09H%:R\$N?$E+Q9UW"B)(Q 3,H.>>JEV)F$>I^(/490#X-R&)03@2JF5PCNU> U>H8=>9[=S?0 1^T M=T$4[ Z[JWBW"VC-#%/=3S6<$T>/@B@=+8X, 79T#)R]7 SBW,9E*%">*J;# MIPZ^&@+W:MS!MEQF"@<1>RK,3V@ES#$[]7=>TEV M)+8IG/<01X-&,2CGM&I,5U$C $O>#9!^@.THN"0ZP)*N<%EP:;'#U$M3&O%7 M\"6[1(U_>CCL]^'@987U)K;KP]$A2>32J;PYN#,@O4'5?01F"B.1U^QNVOSI MY@/*;1EY]+Z@GH=2QQ*-XL9X)J!&0ZF MY="+9!D\;;.!2W(HYW06M:T@3 "[O#V(JY8X&NL1/@51A/[A>N?2E7$MX%2' M%4X"M34(X_EN!$*"Y">G-;H&DHZ+X&P-LGAQV85L]HBB+7[].R5V"GX%G%^3 MC,RCM;FC3U]@L@Y2>)\$Z^J\2/._IA?6-G,E(0-H$UWV>!6]73?^L4!6%R!* M'&LQ;*!CW.2 T*'7_-3XWRG?(0JVFATQ.M3*SAV8]P=[/ ! ,*,G$#F KN,P M])*T^NW7KC/PG$O>I*HLN@(N%#EPIX^)"X1-<8'U?6@U%*RC!-,'"?B,WO\E@UN?>.Q SXQ4M\ M2@Y;W7%^P&&>0ZCM_1/I)H*V]W6( @XH\D4;K."JZJY>ZQ#X:Q0B[9WOKMXI M'F(QO.L$'T7T-C&J.K2O$CZG<4Z.4 MJS-?=O,9W=G?O$F]V(GU;H= M 7;2\XUH$Y4L8R)6<2!V;11%RK:;]WC:X^'DA9Z6/#-*.<$U_O)ZZO'F/H'/ M07Q(P^,L30]XBXU\_+(H_B&-P\#'P6[D\<)@5P;"E_78VX5<#S*QC=<=!J-> M&#O)3 6JN0"=#)2S 78ZD,_')"Q4,XX@Y&UP\)6VN,%$U3EUH2)F"?=QD@G( MR5."'[80"N(^E8;A+C-9^Z9Z(5?#PKRO/J$D'QZGM>8?T9K]B![S;.P43S&6 MKZ97 '%,UEVYW_Z[(.F3U6?::V;KR;!6?"&&/>?:F>6":J$?.4(7Z4M/,>V=/T%DM@#;>*=ONI M8!M-V1>(RE=#J![??$=SS/MLO\B4;KX]RL_T\<3#8PI_/N!7O)[%^GU/!D/1 M7%8?;!,0(?H(RN: MG?MK-857,V@)ENS@3W,A\$_KN,U28S&II4F6-("+2E< M?_,4/[]%7=[B$D/XAS?X!P8?C>&L11R?SBQ*+\J;$,.7"XN#B.%8R-PUM+9Q ML:/<%\[.:[01]2C;^K@VG6Q"*E0"SS4UU!K@YJYESY7,*0B:"VQY-N#!IE$6 M9,>;((2BX)'6,&@,:1L!IP2(GN^\M:-1Q^+C[9QU3Y M) KI%2[TGB"-U>\/%O)97*!$2I$<-+6N9]02"]!E/Q\ X!$<>7%;RK6.+#5+ MN@#MZI DZ,RB5J@@>L(3'#B6(4.$"8:WF'&@HD4.JKP/*#L!VLO]B2077!U" MDI4;WCX*:"*VDRABB'0=+Y^FQ^V).[P3\/!I4>U(91^LO7H%FMR#1RZXT_U' MN/).X,$J4W*%MK.G.#GVJMY6H]IZ %@POUK!1<=3WM;5U48BC*:*6U]96V=X M-=9T!Y,GM!%]2.(OV18;UKRH/PSP1[=JU) 0(@=%T070/B#OY%H%E@JLCA/Q MHHV,(OF@+Z3T3X!U('J_[@\MS:'M;QM-(A0P>0%5A]Q*XL0:1((H(+9H"IJVSK4 FD@($PL69W6/+X6Y"CU/GR%S\9#S+ MGWYM'VH%25*=^-/YZS0Z)^I@8><.@I!K9\L$A($,3(F0;:0#$+4(:0N+C MH[[43A:I*S1HXH6SR(&EX)S-8KQU:GU]T@WUXF*X>G*>N95"J54A, %-E\+JJPR @2;29Y%Y"4?9P&ANO(L(8CU9*-\^5G$8XVCY/C MAR3F*1K=\7,R@_73ICZ_ "!E([?%I_G28)' 64V'X^8^@7LO\*:6GMFL- 0F=:1T4G-4@2_B$(ND)(.U*,ZIB\G#=.C?&>F08EZ=6"V&SB-/E M2J?7%NN3# @]R6RVE1\Q*5U1!MZ@@XZ^]+3'3R*YW=34 FZ\$R;FBKG>=)_@ MC,?L>!_BAU4B?_KS(=AC&R$Z2H?9Y"3SN=";9 2)GX8E70C28-'^#$3068!B M&W'6MS'%ZHU5J)-W-[$U:!N'/A('GD-41+@?D&G/[> XU:5-@+W;V>1R=CM; MS:8/8#*_!@^KQ=5?OE_<7D^7#__^;[][=_'M'\#U]&9V-5NYW=_:RI]%92L> MF9ZPS"06+ N2V6R?L&)2%#8&!GM.#0UJR0G -(S)X=X[XKLG0BKZ37* ?G/& M(2T0.M.[-$AHT*>R3^SI$.2\]>@@I;KG^L0U0 '/AJ'+)>/SN#D1O;&XA:R" MAG'@5DYD%_ *KR2C +(>0.1HUN"=,:3)V/,X@\5\0]^0>7-9M]R)*!'@D+0L M0.C4O*L25^.^*UID!]/>51P]H_M.@&W%=H"CF-'%"U)2BH0%3LM.(&(A-8IK MKYY8ZP5,E4PPO5A68Q\'Q)1T/A>8DA$DP%3>!82X#]*TTFV<9 #-M'-@3F>MB+ZJN $(' MA ,0&HB>Q61;U@Q1NGX8=4T\G;WD!0UJ- O1K]D^(RTYS]?/Y"LW+!HYO.^! MXV&P"ADM+X*.U\ !1M2> 8']W]CY"3<0[5'4Q3#8"4EQI]PX!8PO>7YP!S#;2Z!JN(7GBB_[VXKLS=&"F>TA*J(1NSTL)5D[B M0KAL[@VEZ)1=)*28E4]&OX<)B;(?'KC"F=VX[75(TT5X"6WE@]?.D:>2OQB, M4B89ZV?U.6C"QZ3<#(9'96-&-R%R$HIT0=C821U?4_4D*\8;EP]]GWO/,'F, MNTJ']U)I0SR57$;SUN00$CKO=RN@#]G8V@;RV6Q'5(A):?GM4X7)<3BL0H8J M.#$+[Q*6V!Q8FDY_C3EL M0^F4 (GM*([$M[YWY])K'[JNO?_=^[-OO_M/D&KS#J@SK1,GMI(L+91KW_S<@JS-K4^7-:;^[49^_[#7/=ET;BSR M FJT\":[Y+F%F,[U0;7ZG@\VCS:XN$,6U[M7+Y+R_[WRXNYQH*A>6 M10$M;;[NDVN<(_N-0GY2#)U>XGK!S\ 7.%5-(/=(4E_?N'#BW=W&@BG%Y4VK M%I!9/+OODT+(7GCO!?XLNO+V0>:%0P!+-)63Z'0^+:(@]+(U(#FRZ(!;TPZ. M;$$%_ZB41@F(Z6:\/NP,)8[F&FV =#!(;H#&K=;^P MFB9Q@D/1$/BTI5M=5E^F++PTU]^E>E$U(@EKK[V&BM\HVI$W4>%K?7 MCN&A%EW]2B-=KSF"'F 8XM=_8 03+\29P/XNB,C;F-CA490:&O*9\W84V$9: M._)$H:_3V]O9_,,9^#"=3Y>36U)%8W)]-YO/'E;+R6KV:>K2^&<&@MJ3Z>VY M9([9)4PA=MRA::[11AK&I'A,/LW)PDY(L4B[T-\G'[5R_7M24.2 M]8-3M?0!E#HMG41!%U]1XF-!;K]6'O1>OC6" CE56M^I9PE>9 4:BV0T!&-:5M\"CH$< H[T5+$=7Z M-7'E %2:-JA8NX>I)W:3"*Z@2[5RK[Z=+,)M? M+>ZFX*OI7^^G\X?IUT[+!VI+M9[OKK/^;J6LZ+A#8(H=WDE!9SJW""/$4]/P MS;@J45470Z,J%;,4\YWE)DY@\!31"@GK(WG7&8$(J>4?O"#"KIM+N$%M!O(' MMIG>2;47??I$Q5_H"'D)<*0X9=48((S=O)W40?JU>C MN=/A&0P,=31,OM== MHM-V,TQHA&@J%^@3T"(R BP7GV8/L\4OTP;&.KI!>_?T,\8J[ MQ/^=^J0+?_20^I/.M&X2%E1D254H!*O[Y?1[I#[-/DW![>+!-;Q:B/SN!,(MXTT>6!_"OTR+_\?Q[2+"^!3\BZCQ/RARQ+@L=#ABL>K>)[;]!* MH]86X*9\J:WEM5(.Z/CH8EQ,, )=U#:0&]JN54EU"+(KPO>*#*=!2SR)YK)? M[$E B:@6\'1%3@YP3P^4.Z2T/'P_64X='R4JX=4J0,F6W". +KTT6&/W61 > MLF&R7E13VKZI*^@1@(JTHGY3VFZ$F92:PI7AC,>,_M5(#?^V!F$\#S?:@\F] METADG:>9X/YGX/%_K03/N^P8G]$IN$4#39#0O">2SW<=I&LD M@$,"9QG<#?J4<4^4.;@E]4.Y8*?Z/)U]^'XUO0:33]/EY,,4S#_>7:*3<'%3 M.PP?P.+CZF$UF5_/YA^*&/;UCH>N7E%ZCI"TS600H1 ME3AK M T?MR'L*"/IK)DT=;&)T02@G&5K(GFWP4_E)H8_U*(R MU_]B278H>RF8BRVDX6;_$5%@/5:V%7E=MA^!#CLF#"M@H0%B&=^<6*3:T\DU M4!'E7+HGC:5"DPO1=C)5K>!N'R=>C M S1W 0>+:6.N=03>21BW,2QJ<=UF##/% 1H'X1.ZP;S(58A^EZVZ%^XP!!^#IRK MN1)JA,_T5CUH%AG39R2Y\AHBK;_9*V>"H7+*CK/87,/'#/M0XT.4W2=P%QQV M@^S:RDF=^&=45(F*N;'8BC? 1SV!GWR?OWQ"NON>75A$I=*K63[%BS8\:@O/0.Y21H?X M9R])/*1F,B;417(5>L%NF!VN%0$.K *M"-2H3#XZ?Z$1!&J;7&L.F5H FMMI M>;W)8R>&O->WF-W^?JA/G/1,3D\NVFD*\\?0F0/9:06"]AB0'\A2-IGNJLU9 M<#Y0.95UK5$\O:,<85WZI%4/1JTC*B6N@*64(SW>929K)ZZJ0/V--.X U(:#_\<%IV=)_A;H($.6K5?#+<406N MAEF$U7?7?BP9%>/Q8TFHU/1CS>:?I@^OP8^E 0L-/Y:*83W[9&^""&G1KK$L MHV(\6)90J8GEF]E\,K]Z!5C6@(4&EE4,,\4RFF<-H9_>H*5B#03L]VOBQ M#7:@P!+A=/;U! DUXJ*WI ? H@?KJ@^(X@R6JH+;5Z:5$CV)4Y'RP#P^J1QV MCEF3:Q1#@ZHVEW6KNH@2+31A!#4 Y$BY5(E/A*#&HMV409>1Q N_%7_6V._F M]%3I2Q)=:IZS&P2M7@+] 9\<5,SH)B)10I'6UUV[.H(P]B+WX8L:+5(L**T"3R\7]P6.VS%PX5F]UJ?ON5;EI0)P C M'0)[SV ^"$C0*&"=6XWCB,1JN86D"0IJ12_:\JF+R_:PWX=P1RI[XZ%OPOC+ M+-K$R8Y&TPSY4I'FU-9QJDF8Z)$ IC>HBBY@S.+! !X-,,.Y3=)K)_Z:$[@% MESH =):'!>'49'2I',827)_"A7>W3H+(>(#Q0QX!QE[;(F#*K=>6+YZZ>;:Y MM@Z>5UKD%"N%P2"51$ZG<(*&&@E::,AP:_>V?)YTN%5JF:69@J'8=>:(,O1C M92>-?(Z=J=J*!ZU&50,/O?95^T2P&WLG]MO@7^E.VI>G, M5?YZS;J"<(YDY/@NS!.M(&/YPL0J^IBDFW^P<R52VA3Z*%Z1NG$?2<:.4CCIC*IP!?T!P:-GZK MB!T"21CIO0N@0X0+U7H'?-#J=(H>-=7O*- C^(29I'-SD;]:-1,F=[B\M$@> MI>(MJS?5K,[=E>[E4/'^J83'KX?)!C5\R#=/PT9G$0ZQIV\:DCI!. U'F2,C M.'Q:#MG7&:/^] RHTTN H:]:MLB#L7UBF$FY/!@,>&9/@36DD+<3=!3KKUZJ MY_6CLJ?(U25<0S3?0-$!6O/:VX/:D*4*3$W*EHY-F?J2U0L_/6%!GZ##9H,( M=; 6',U..) BU YG#$%"I9.V.+H.0]$2GQQ2IZOMY%$Y'?P^@=B.? TW,$F@ M7[R*&?DD^G]"DF_LH$R+DE' 3X=2840%Z5J^UTMN\3%)):$EQK(\X6EDVV$; MF,C1K,T\ YCG)@"S.S\BX6.$]*/P&$1/1?J@IJFJSQG[4SLUKQ.]DJ^;B4*J MCZS7"-0!H&*M4WQSN< :@L8OBW^N?#T$"[Q.<;9D=[Y'$L-$, MAYCL=P,]C]=B=IL?0GOR1!L$FJ+-CI\V=KG?0G88='1<S?5]2$N:];)SJN5W. N7,/.""&FA^5MCPX%* M,)/]/8=/B%AM.^P.U!&.-/9@'3@M=2P7%XL:R2I-MZ&*%:*750?8/ MGP1/48#V=*RYT^LY?L@@#M$N#],5?,DN4?^?!HD3TYO9!;#T2!,%/GZ\NYLL M?\#@>IA]F,]N9E>3^0I,KJX6'^>D:L']XG9V-9LZ1UP[V=<"R?099([,]1;Z MAU#DQYMDV-]'/'TK\@CYH%@UI<7Z,SV&A(JPG ^'#1D;&C6);A.,TQCLH(># M4WW@94P13;VEJ#,/LSGC?&.6F*UJN*^V/"='/UL MF_()K1M1I.2T@=T;\"7OY?H(UQ(INZ&I>>"FU(&2+EZ<4_%WWLGSJQ"&<;4# MSF8RCZD%;;+#^MH0G[MZ4A?*O)(JP9>_BNN64B?/(&A*L?X8@LYZS:)L/\2X M0"DF/(D$"K= %^'WM*I\<$D0"/_# E_4KA;SJ^ER[F)/4;.[5!S$ZS+6%(H, M"IIY-NC52C25FZV"2XO((;>8?YHN5[/+VRF8+U;3!W _^6&"_N5ZTY#*KKY5 MB-?;7ATI]/VN(K!C &.=>0! ,G5YOH6A6D07%$0/UW%;$J8S+%MJV0L+I@-)D1#4".(F&3@"@F6O(8F 4KTIIBH,' M!5$>8K<,N5YSXU19<5:W"UW"^GX1RF7.E'&VE$[V6Q\XRTT:/8",,Y+###TA M42W1E5L3QY>-IY2?#%8"MG0I75)Z8ZH7J/)HU GBH4^"#1?T02U,!"U$AC;3 M'?V=34=A+Q0Z<7[WN@2=NT3M6VBZ#:$&/ZUL.\C$.3O18WAOL<4TB/UC>!!P# M&([PF<(!H*A^\;!OMO=\K])PNUE9%\]U5^()E^]U7#7K5PNH<^/2BH.0]RD. MT3#8(?6J=OP3LNV7(QY^4:)JVWEC\%RV_A5^JGQ8#OZQV>N>^821)K_0M@_2GFP3"PJKY*LX!+M&O7//GK4EP"."F8(/:5K;T M$YWM]7^N,EP.]K$*9=#E2WU4$_?89B=9P60W3)G@X:AU4+%]N-4(L\$C4@WZ MX(4 4;=+P5=!!([02]*O1Z"C#0K#QA[ZM2ZVM,'68UX3\]='V^+YF"/VY.]_3H. M0_1A@CU,0(KG'<,^/R@T![PFG0K#U3X_V(KX^WP[4/T+5IV%8!:JWY%EUI];%%E)E]R?=Y9OZ>8IB M)+L@HS7=!H^04$VX"9G15]( MNR%,NZ,\*TH*+N'."W"QR\7F!B'="W] =U$;*&Q!C8N8+'-R14;=HBW #'*_ M,W8"A@S!+3EE?%%?TI?"[O&S82ND/:;>FNB$ED[O-M.[ ' +^D2(G=Y.5M-K M<#]9KGX J^5D_C"Y:A1NB@%16)>:_/BNU=1,F&1+(.G[= 8-B;&@<_8E%8-K;<(R/;H6Z7.']GH M#!)![+4!XXS29D(O3DTG6:P MFO/7B50!=O/!0'S(TLR+?/+L< 8>X5,0X6&<5HSJ1?I5,DYG]AFF&/+F32=/ M3PDINK^H.#]#3Q!RP-17V=LY7//L5"6Z M"I3V@!;M&=R?P[JD:@-M'$AK*V,Y$%LQR>YIVP-:6\TRBNVO#<6O:XP>NSVB13G#Z(_=]D ;%])T9=SI MV&W@U.*QVP-:6\TRBNVO#<6O:XP?78?)-VV43K .(PK.37BI%;\ MU]%M@S41J':Y:H']V3R4>V=GD&B-;S=,L0.ENO@:"\#:2+?C*5N'I]5#MB-( M6\PQCLU.G^!7M1^VEW4/A^L0NZJFV^7=X"Z\=R.XP^B2VLZ%!\E/(P-P6[GW MXKQ[U_.])LV*O3W?\G$\J#%2^:,Y1R67+ 4"8=5RK B4RDZ*-C%#AD#6";1K MND6_J-.=R;T&VIKF;G =B8YJC E--+?A99]ZJ^;F_7YP%>"]^\U6F]37OP&W MEGLO*L#[WD(MN:F1;-'121[YYZ:L;DNJW+W$:4JR1@QF3/KS0C!'4A'7##JJ M*K@&?#3/QS1.$#JQI*\IA]X,LKTD MU!N(I?=X^B&K-K1?'Z^$ Q]W37W^7Z ;3"@]^E6_H["+8#82R%T((7=6:-RZ MU4/^A<#!9-11ES&I7I%VDL^@>)D'L?TCB=) 7Y(<@\S7>5CCKD"<&D?.9#)F^[D-9 K0^ M#V 1@U_C'4.P%MY]8G[8/2+EC=J14O D \_KO%:XQ<_YD(:GM!5-HS,^]4C^ M"*NQ][_8.TU6?;LQA,0FZ[JH:YH'NM!6";)JM^1\N+T_\^K;LE M'4&O=&2ZD(3]6ML"%0#]Z]K+8#W(\#5@VEB5]K<[QJ.U3SP.J0N+ M.>_.*YLGL.+G90M"Q_AI\LA\C?8+SCI46=:B2^@K_!(E8.OSNQ,Q>;@34:5= M[;#="L;XBEFO*]0O/C/. MB]P@@.U5-VPO#E,WAVK1/<8ON8=U:1V737URC)]RC^CLTTBC M+05WG^T^2$B?45M&>62^1LLH9QWR0AV_FL@N"=#Z_>#X#'9G%>50] KUWG9K M>(56T99+U"X'-("[.H>4FJ86:V70ERD%5H'(I.]=+AD=.; M45-:]LIZ>%O[S >]0ADNZ'+RI=E=8ZL,H1$4FG$(S]["X$S%U/)S[OF*BXLP MT/R"<=X?3XE\;0%NC17(/TUNQ9S1N#^&@MP IIL3AKN+86/H&=W]L2?27Z=% M1VMM!E_KK^0+M9U&@T XS6 ;3U&'Q+"FSKO>W($WPV5XN[N]GJ;CI? M/8#)_!I<+>:KV?S#='XUFSZXSEDV@P +>@,>&58L74)TM!CY^JGT5(Q,'N)H@\1) 7/A3]1>]N"PPTP\QLVP0S MR"H$H%].'U:3U12CWN'S$H,BIK29#,=7(R-G4862(2N5U3T5&24UQK%N1%33 MI%&*=%^*""1P'RR MWNDT2>+D*DX2N":*##H(T#TE3JCG:^+_\Y!FLFVW[]*[!O2XT.P[T-L.Y@)T MEZ"@!7IA[K$$7H0;[M 6]0K>(8 G>*IVPB.'K#&K]5KR'OCF*?#8PI_/J ! MI\_#?Q'"R5S 742,",L?+Q^F__,1:1!@^@EKSVX!J));#5W2I9I"Y\8+$N(' MG47[0Y;>PF<87MS!H=P6LNGLQ\A(J!%E%J$>@'0Y [33&2#=P 7XD?;\NUNS MA89 652I6&!XC/.&?6<75N]&!:MWAK!Z-V)8O6L'JW?#P.J]75B]'Q6LWAO" MZOV(8?6^':S>F\,J3;)_W'DOP>ZPTP81ZL, "/WK%#S-02WJ18W)!)ZLLYB :071(7B=QO==V9_*YN?<7?<+'('I:YC;PR2X^ M1%FIME7.N^&^RK8DV/]F6U(H^*(G*2@&X$#.A=O73/8UOZ\!9TS\694%EH=# M@?.JTBL:[/'Z,@I_1(0+3=1+L MAP22WL2]*QXR4&F1)( 8[@NJSH#I=8HT!RAK)646<_HL,;16XPEF49HE!Q*4 M.2#83F:QO&$U*9 !J6HYDFU*+*93M' 6:;PYE7%:PR-$-)5EF C($/DNBM;C M XQ"=#6'A63-'7(MT.4(1VIC3*Y0AZ& PY^H9QU9!ADN :+0#MSV#=*X=P"W M/@.X/09H>'66R8A(&AT,*?R"):N 2( NAQL83'&$>G M/4/ ]"&!:NR_%]D6)B#;>A&H=QH%M*329:$E9DY[:&&'S2K(<*3;+/*#Y\ _ M>*$FK+3\:OS!+9U70@($4")M<;1CU;J)#)&&"N\2AOC:?^\E MV7&%@)9ZZR&O6;+IK%ZN)(2(4AEH#T"Z *;/.'85#4&R>XMJ_29A&>@@?/*> MX&V,AEM$2^B%4V)48NYG=$N[3W"4<7;L<_\QG-W"66=.G1"):+NBW7.5">UD M13^'U_ON("A#"\S9U24@._ #+SD^>'B+)5ZVP;1TX63]!Z1(E741'2*%W:/' M)FDWDJN=4G"G$=GB!;?%#K&=GVIIJR9H!*X,?D^K_@PN"2*E">\TBPVC:0.B MD;IS5DE97SHWQ<OL[?(\;,O=U@M_C:^%;U(G9F 0YP$X#;.%699:)@O_C& M@DRSW.JY'(/:< 1363;^"<@0'0UE:T":+22X)E8'RI[ MXC)(!U,MI/-9]S*(:1'Z&XHN$B.R$X^#6HQUWX-BZ<: FOY\"++C'5 9R E0X& C.567S/#A3@(0(MQ?<%XD01/0>2%^+BPV%_.2 =O4D^ 7ZJ_@25HV'>W_/F"#KI6N[4"NZ\A K6%*V WLZ MZAF(R+C84I;OO%XY-,AB\ B97K[;>@9]P*J1G=")T89EP:YPA1ZT?6#;\&*# MRY'%$2&&SJEED5.-8=4VIR!&Y"5G>F$ KDD_D.*.I2(PCK<'-"56&O)T&-+S M_EH67!S=1MN:,E>/GW:FO/7NFQ03&.[#H]F&3=&GWH^-9&#J6N-$BM-;**E_ MAVZ@N:Z^2/!_JV+E!57TKT-\6CU1YN#3ZH=R58*"5XU^!B"UD 3Y!/EM$FGS MY"<\15/Q<:S(]XL\1?:#*?^-/RLO#=+%9K)>X^L%?CHY#H/UD?[OH/7$-&=V M<4G5(TV$>]P9@[?J?@9H5_!C_E\\!B"#./=\MP- #;WZ7#)+[D^OO'1[OJW:*7F-E<\YD>D MG%J RNDT;_]D^;SB$"'!"3@434\QXN@(DHCJ%"6\578H&(1]5Q'Z\W$.!T%' M;7S[!2?8Z06 *)NXW"AX8F EWUB'<6+F/H'K@-A^AG&Y,./;%S<[O="-4C4! M\ 6_*^+6#)$@??>"WB$$=P$V1CL">8BK\6AM>.* MH>[ GV4)\?*"D.HF5UN<&#"+II&WSJ"?M[$'4RUJ7-A2SYR*#4% M1@090C;^M]N0M.X@40-;FVMF]M;/Q)<#A<(:@D:-Z^XK25O05=[ MQZ*$"D7E\SQ0D+QI1+JC'VG_;QSY&36$46) LF0#O8L&Q-#8UP![%^,,IO?> M$7L:F219O:@G]3#6[A":! D/F+(CB'!/L*==S]!&479V"19]D55A3WK<, V; MJX^.4!JAS6D?@!JC&$W;$Y.C"BI$34CK3B&=<<8$8E$!!#NBLWCX@Y[ M-!(.JR<'%TP2Z-^7P43,^^?]9D"J)G6A#RNI$F&KBE!#C4 "UQ"IAV[CS72E M6L^/U%F_84F U9IB_&F4!=G14EJK_N2V(TFT*1.%M!&[(2G*.;H\UM8B9P^C=HPQ M#T;)RX'B!P[PL8VGS,>^]]+L^@ 'R0#4F-6Z6T=-D^C(.V1IYD4^MML4+VGS MS=CN*L-JR)=3)%;%BPX.E7KQ8D;%7R&:I78&4EF]T.FQ(3*J)5>[+XQMC!IQ%6TS#IHIB=79Q=G6%YO\[3$M MA5%S*)L(;4&7V=F.#:5?Z #N-,MV,BRUS!9\,8[ZV,4(Q[_D7O%R0[_"H3&3 MR"\N.8/XJ[7G=A!JI$N;+-N_N-6ZSO]I*^-:6$4;/IB"L-1>:1@39AX-W,"! M3@P!0X!0>VX'(-2E377-SON?Y?7ERS$ .XC;^-EV *C'UK9@DE%M2UQ_E1^" M+SAG:QTL^Q39N06XH$T:)G[;AR*/K>71UUB&J7>0<1 M-G-$4J6ZW2-:@C3% M8=GQ::B+0++ZHUFUP&F3)3RNJH>1D+X4Q=$;9@B<4YZ/0?R)+KU"K<59(JH= MCSI4.MS':9#=!MYC$)(8Q,EZG1QP92:Z3PUS)U5-ZN;6J:!*%-U*6Y4YULYO MDYH2/0G[UUB[H9>HLB3E#ELOO*06)3U?D:2_Y=-*0HJ&&6U?="D,:@Y?E]00 M2N5'4JS:]*PKDNOOO/46Y^5KH:'1R>K)=3J[0.KSLJ+"+F_HS%4H8G(I7>Z2 MC,^3#UX0W<9INHAPK7:.L!\\F$XBIF7 MM-!N<'5($CC0URN>S7KM:B$I(C/+ >*">TG^AMJ>]G%4V=L>NJ?$EQU^IC'\@6Y!Y)%I?[S(4HX M$F3248B>ZU?CD%1YAY?K'@%27M/ZXJSI95TP_Y)$SQSQ')U 71O'=L$P#9H4 M[TONR?N26=47%S1%0-SGW=VY+5K(386U!C]:GL!D[#OH!VL7*&^.=L;;&>X--G&"]SE\KR>['#."PQVN MG11+8+7@C)'K\QK"'?1;U ZO=;!\5K)S"QU=N E; /RT)H83GU:3R8S;ZF11 M':(I25@:K;EZ?<#IE_X!Q^(7\9YBTWK8GM%Z70HDL )=+HM+9\ M\W$9=^\9Z JZ42=;BR&F#PCR)Z#X=H'!TYF=I-1ID:9TC7" .((MSDSR&J#D ML<<\P1,/-EPF9S6ZBP<(RME%CPC@!GD,-_,H!HZBI4>E<^PTI%/#1WU]QF]? MXV$N<9U_7"D*70))V%CU8FYV>:R:Y&K[Y(N7Y$ L@W!=S;:]$F-3%.O'*3CH[S$)"N*K@Z[ /@ .&Y],WS*P_N&1__D$4UP0 M<1D\;8<)4^^3O-?TN37)UXL>+#ZG9]H5GR+HM';[OE?_".OE:Q*PV.F'1)6K M0?(Y>Z7/^MMY/1(ONE(*OAB'2E?/:.K]JV$9:AY^8$S*]&4?T *-UP-52^R+ MM%?SN=3I%CNO\D; 9RLGOJ;/A(^=7KX0#@\[?AR/:BH>3ZE84$4 ?ZDX[IE^ MJC=>D!!STG GS!"T.C$+#;084=C]TU,"GW!!P0UJ"IX+^V:NSXW!!# @"AO? MW5",[_8V)YWA'@ENP,K_@ID<;A$B?PJ1H'<73$'*!-2R<_'6:N(3+=RV9 M<=//01A>PCPC\O0A26%L@<9 5O,%="@2AA84#Z*F#%)2\ 7UQH^@>D5_E[[ M-J)CP@LTF6*6;W071]DV/"Y)R3ONMB.*)^!UM!V+PB-"%"I FY)($R]L[B$. MP@(DK*^" $0K--D['K8(,(BCNUN(3C<]I_]I']LB/IE?Z.5 K=[@9B D[5P* M5L#F4J:$1FZ7&]AFD*8OR00/9$!A<61^U$@5%/:OHPJZ!'%VY->9Z#L!TA' M7$:!4T79@8*A*5E6T]#AA/E5L3YNBG>D?#\:Z'TZ^836$SJDY C5DB@KCIHS ML&..(-<&0"UIUI*"E,OO$KQD:@Q9H5T49[.-SB=;(\PZ5GLA6U3K&?T+X-/+ M;6Y#KY#IQ3#7X%V'#^**A/L0E3]_4H,Z9W' >O),?+,WA^R0P%GNZQX"_.V) ML/^X;%L2=0,*DGP $E"P(4-4<04C"28P!DGMX5HC#O;PGD>],$N'%SW$ [EZ ME4%(D<:C'B?U>$3/>CA\L4$I.-ZS#7*6F-DN&.A.7V"R#KCO-0@!).AL^R$8 M/AE"I#!AH##OH!?=9Q\QQ5=(\V M<75K$/&TDN'),CJ4V&*SF(N"2OCMN(>,I%D-6B6_Q>PN7M#6)4Y5,_+D0<(1 MI+;K"%J<[*[DA?&3[.PL=UZ&7YX]8K?[P#8VO8E=0U! E_"-.]H:X.:C,;.U M$K$8@3)6&((/*4]I' 8^N7[>HY_6QQ5\R2Y1KY^&N>U)YG,1(B$C2/7&68JO M_KO>'EQ^BWW[G__+M\],/Q^CC M]>'+AV^3[[[]R[M_?EP=T_#;Y_4OY^&?L[?9 _SS+]^^_^GE8GV;G?_MYN;= MPU_>/K]<7OUP_NP_)#_,?W?UX?VU/_^OF[?_\>[NXW/P[KN_G!^SB\TOX6_O MOOW.>_Q\_=W\?!V_^^W[=T]7\.F[MQ^?CD^KF3?];?0N3O[CA[OU]H=OO9\> M_R/>_-?'G^ZSO\(OWUT\[CY=_,\_T[_])WWWF__7CQ MF/QPEX3G?PDW[Q_#U>'VN]_>_OGV[G=_BSZ$+X>++]Z'PY\7M_O?^H<_G[][ MB_;8]>*P^I__S++KE]]MOU]\"U\^':^_G4S?_?-^-W_P__8_X=\6L^O]]"J9 M_2WU[K9_^_Z__G+Y=W#UL'SSQM@10G3=R,?_F?Y\")Z]$.?XV]BAM2:VKQ5H MT26]W40^(#\PW9UJ!:U$7-NUM5EAJ!7,HF!-.)?U#5U$B?"BDS=W MZZ)0R:I>Z5ZRP@Z.A/LDWL,D.V*O38:0B5%)BMQ8P(_VW XRIW1I$RJ:M/L9 M*#N27>P:[A.X#IP_NM!6["P46['&-)T)7Y\L0) WC9-2D)JG(>,(("]A@_PI M;.=ETH72.KT3][Q_74/RJ'SP#&UH6)+9K!<@%)(BS-0L.H#*+N&Z *%2>G7X M2)=L'KJTA.AP/< E7,=/46#)GJ*>U(5114F5,)*)] -,1Z<:NK9(68#I+=[8 ML,*O)IA'2=&9A@&:>EH'&I8&64*L,94JF;Z %&9T;:=I(>4Z]O388?S8GT\T MA[1XP,W"#J>:TO:1J:!'%#J."^(3J-UYR4\0ASBZAIBF+&MO^6FLO>\<:IJ, M@@ ]B["S#9W;^,J0#K?3F9 QCMQH*8VRG+, E?.
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

Stockholders' Deficit (Details) - Schedule of warrant activity - Warrant [Member]	3 Months Ended
	Mar. 31, 2020 USD ($) $ / shares shares
Class of Warrant or Right [Line Items]
Warrant outstanding at beginning \| shares	502,250
Warrant outstanding at beginning \| $ / shares	$ 0.57
Warrant outstanding at beginning	3 years 357 days
Warrant outstanding at beginning \| $
Granted \| $
Forfeited \| shares
Forfeited \| $ / shares
Forfeited \| $
Exercised \| shares
Exercised \| $ / shares
Exercised \| $
Expired \| shares
Expired \| $ / shares
Expired \| $
Warrant outstanding at ending \| shares	502,250
Warrant outstanding at ending \| $ / shares	$ 0.57
Warrant outstanding at ending	3 years 266 days
Warrant exercisable at ending \| shares	502,250
Warrant exercisable at ending \| $ / shares	$ 0.57
Warrant exercisable at ending	3 years 266 days